The online abstract site will be operational by mid-December 2010. Meeting information will be posted at www.pharmacoepi.org
### Wednesday, August 18, 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>7:00am</th>
<th>8:00am</th>
<th>9:00am</th>
<th>10:00am</th>
<th>11:00am</th>
<th>12:00pm</th>
<th>1:00pm</th>
<th>2:00pm</th>
<th>3:00pm</th>
<th>4:00pm</th>
<th>5:00pm</th>
<th>6:00pm</th>
<th>7:00pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am-8:00am</td>
<td>Registration Open</td>
<td>Office Lounge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30am-9:30am</td>
<td>Educational Sessions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacogenetics 2</td>
<td>Dukes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulatory Pharmacoequity/Public Health Decision Making</td>
<td>Ambassador</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Introduction to Drug Utilization Research</td>
<td>Buckingham</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate Pharmacoequity: Concepts, Data and Methods</td>
<td>Clearance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medications in Pregnancy</td>
<td>Balmoral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparative Effectiveness Research</td>
<td>Hall 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>11:00am</th>
<th>12:00pm</th>
<th>1:00pm</th>
<th>2:00pm</th>
<th>3:00pm</th>
<th>4:00pm</th>
<th>5:00pm</th>
<th>6:00pm</th>
<th>7:00pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00am-12:00pm</td>
<td>11:00am-12:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00pm-1:00pm</td>
<td>12:00pm-1:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00pm-2:00pm</td>
<td>1:00pm-2:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00pm-3:00pm</td>
<td>2:00pm-3:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00pm-4:00pm</td>
<td>3:00pm-4:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00pm-5:00pm</td>
<td>4:00pm-5:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00pm-6:00pm</td>
<td>5:00pm-6:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00pm-7:00pm</td>
<td>6:00pm-7:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Thursday, August 19, 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>7:00am</th>
<th>8:00am</th>
<th>9:00am</th>
<th>10:00am</th>
<th>11:00am</th>
<th>12:00pm</th>
<th>1:00pm</th>
<th>2:00pm</th>
<th>3:00pm</th>
<th>4:00pm</th>
<th>5:00pm</th>
<th>6:00pm</th>
<th>7:00pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am-8:00am</td>
<td>Registration Open</td>
<td>Office Lounge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30am-9:30am</td>
<td>Educational Sessions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacogenetics 2</td>
<td>Dukes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulatory Pharmacoequity/Public Health Decision Making</td>
<td>Ambassador</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Introduction to Drug Utilization Research</td>
<td>Buckingham</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intermediate Pharmacoequity: Concepts, Data and Methods</td>
<td>Clearance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medications in Pregnancy</td>
<td>Balmoral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comparative Effectiveness Research</td>
<td>Hall 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>11:00am</th>
<th>12:00pm</th>
<th>1:00pm</th>
<th>2:00pm</th>
<th>3:00pm</th>
<th>4:00pm</th>
<th>5:00pm</th>
<th>6:00pm</th>
<th>7:00pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00am-12:00pm</td>
<td>11:00am-12:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00pm-1:00pm</td>
<td>12:00pm-1:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00pm-2:00pm</td>
<td>1:00pm-2:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00pm-3:00pm</td>
<td>2:00pm-3:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00pm-4:00pm</td>
<td>3:00pm-4:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00pm-5:00pm</td>
<td>4:00pm-5:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00pm-6:00pm</td>
<td>5:00pm-6:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00pm-7:00pm</td>
<td>6:00pm-7:00pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Friday, August 20, 2010

<table>
<thead>
<tr>
<th>Time</th>
<th>7:00am</th>
<th>8:00am</th>
<th>9:00am</th>
<th>10:00am</th>
<th>11:00am</th>
<th>12:00pm</th>
<th>1:00pm</th>
<th>2:00pm</th>
<th>3:00pm</th>
<th>4:00pm</th>
<th>5:00pm</th>
<th>6:00pm</th>
<th>7:00pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am-8:00am</td>
<td>Exhibitors/Posters</td>
<td>Durham 5, Hall 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00am-9:00am</td>
<td>Opening Session</td>
<td>Oxford</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00am-10:30am</td>
<td>Educational Sessions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>Clarence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection: Down with Resistance</td>
<td>Dukes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods: Exposure and Outcome Assessment</td>
<td>Hall 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Siddy</td>
<td>Buckingham</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Brighter Side of Cancer</td>
<td>Balmoral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccines in the HINI Era</td>
<td>Cambridge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00am-12:00pm</td>
<td>Keynote Session A: Exhibits</td>
<td>Durham 5, Hall 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00pm-1:00pm</td>
<td>Lunch/Poster Session A: Exhibits</td>
<td>Durham 5, Hall 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00pm-2:00pm</td>
<td>Educational Sessions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodological Challenges of Drug Utilization</td>
<td>Balmoral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodological Controversies from Comparative Effectiveness</td>
<td>Cambridge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologics</td>
<td>Dukes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guidance Regarding Electronic Healthcare Databases</td>
<td>Hall 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identifying the Genetic Basis of Serious Adverse Events</td>
<td>Buckingham</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Birth Defects</td>
<td>Clarence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Public Health Burden of Acetaminophen Poisonings</td>
<td>Ambassador</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>3:30pm</th>
<th>4:00pm</th>
<th>5:00pm</th>
<th>6:00pm</th>
<th>7:00pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30pm-4:00pm</td>
<td>Symposium &amp; Workshops</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodological Challenges of Drug Utilization</td>
<td>Balmoral</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodological Controversies from Comparative Effectiveness</td>
<td>Cambridge</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologics</td>
<td>Dukes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guidance Regarding Electronic Healthcare Databases</td>
<td>Hall 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>5:00pm-6:00pm</th>
<th>6:00pm-7:00pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00pm-6:00pm</td>
<td>ISPE Council Meetings</td>
<td>Academic Hall 4</td>
</tr>
<tr>
<td>6:00pm-7:00pm</td>
<td>ISPE Council Meetings</td>
<td>Academic Hall 4</td>
</tr>
</tbody>
</table>

### Committees
- **Education**
- **Finance**
- **Finance**
- **Finance**
ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs. Their contributions helped to enhance the scientific program content and increase attendance at the ICPE 2010.

**Thank you**

### Serious Fun!

#### Exhibitors
- i3 Drug Safety
- Bayer Schering Pharma AG
- DrugLogic
- Erasmus MC
- GPRD
- HealthCore
- IMS Health
- Kantar Health
- Kendle
- LA-SER
- Outcome
- ParagonRx
- Phase Forward
- Pope Woodhead & Associates, Ltd.
- Premier healthcare alliance
- ProSanos
- REGISTRAT-MAPI
- RTI Health Solutions
- The Degge Group, LTD
- Thomson Reuters
- United BioSource Corporation
- WHO Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre
- WHO Collaborating Centre for Drug Statistics Methodology
- Wiley-Blackwell

#### Academic Supporters
- Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital & Harvard Medical School
- Drug Safety Research Unit, Associated Department of the School of Pharmacy and Biomedical Sciences, Portsmouth University
- Eu2P Programme in Pharmacovigilance and Pharmacoepidemiology, Université Victor Segalen
- London School of Hygiene & Tropical Medicine
- McGill Pharmacoepidemiology Research Unit, McGill University
- Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- Program in Pharmacoepidemiology, Harvard School of Public Health
- Slone Epidemiology Center at Boston University
- University of Texas at Austin, College of Pharmacy

#### ICPE Sponsors

<table>
<thead>
<tr>
<th>Corporate Benefactor</th>
<th>Joint Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca R &amp; D</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>

**Joint Sponsors**
- European Association for Clinical Pharmacology and Therapeutics
- International Society for Pharmacovigilance

#### Annual Meeting Sponsors

<table>
<thead>
<tr>
<th>Platinum</th>
<th>Gold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>REGISTRAT-MAPI</td>
</tr>
<tr>
<td>Wiley-Blackwell</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gold</th>
</tr>
</thead>
<tbody>
<tr>
<td>i3 Drug Safety</td>
</tr>
<tr>
<td>Amgen</td>
</tr>
<tr>
<td>Bayer Schering Pharma AG</td>
</tr>
<tr>
<td>Boehringer Ingelheim GmbH</td>
</tr>
<tr>
<td>Celgene</td>
</tr>
<tr>
<td>Eli Lilly &amp; Company</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>HealthCore</td>
</tr>
<tr>
<td>Hoffmann-La Roche</td>
</tr>
<tr>
<td>IMS Health</td>
</tr>
<tr>
<td>Kantar Health</td>
</tr>
<tr>
<td>LA-SER</td>
</tr>
<tr>
<td>Outcome</td>
</tr>
<tr>
<td>ParagonRx</td>
</tr>
<tr>
<td>Phase Forward</td>
</tr>
<tr>
<td>Pope Woodhead &amp; Associates Ltd</td>
</tr>
<tr>
<td>ProSanos</td>
</tr>
<tr>
<td>RTI Health Solutions</td>
</tr>
<tr>
<td>The Degge Group, LTD</td>
</tr>
<tr>
<td>United BioSource Corporation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Silver</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cephalon</td>
</tr>
<tr>
<td>Genzyme Corporation</td>
</tr>
<tr>
<td>Novartis</td>
</tr>
<tr>
<td>PPD</td>
</tr>
<tr>
<td>Sanofi Pasteur</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bronze</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston Collaborative Drug Surveillance Program, Boston University School of Medicine</td>
</tr>
<tr>
<td>CSD-EPIC</td>
</tr>
<tr>
<td>EpiSource</td>
</tr>
<tr>
<td>PharmIdeas</td>
</tr>
<tr>
<td>WHISCON</td>
</tr>
<tr>
<td>Program in Pharmacoepidemiology, Harvard School of Public Health</td>
</tr>
<tr>
<td>Slone Epidemiology Center at Boston University</td>
</tr>
<tr>
<td>University of Texas at Austin, College of Pharmacy</td>
</tr>
</tbody>
</table>
Organizational & Institutional Members

Corporate Benefactors

- AstraZeneca R & D
- Pfizer

Members

Pharmaceuticals

- Sanofi-Aventis
- F. Hoffmann-LaRoche AG

Service Providers

- RTI Health Solutions

Government/Regulatory Agency

- Department of Health, Pharmaceutical Services, Hong Kong Special Administrative Region, People’s Republic of China
- Drug Safety and Effectiveness Network, Canadian Institute of Health Research

Academic Programs

- Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- Center for Drug Safety, School of Pharmacy, University of Maryland
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- Drug Safety Research Unit, Associated Department of the School of Pharmacy and Biomedical Sciences, Portsmouth University
- Harvard School of Public Health
- London School of Hygiene and Tropical Medicine
- McGill Pharmacoepidemiology Research Unit, McGill University
- Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- Program in Pharmacoepidemiology and Pharmacoeconomics, College of Pharmacy, University of Rhode Island
- Slone Epidemiology Center at Boston University
- University of Texas at Austin, College of Pharmacy

IN THIS PROGRAM

26th ICPE Posters
Poster Guidelines 42
Poster Session A 43
Poster Session B 52
Poster Session C 60

Indexes
Abstract Index 70
Advertisers Index 78

Annual Campaign
As of July 29, 2010

The Society expresses its sincere appreciation to those supporters listed below for their contribution in honor of the 26th Annual Meeting (ICPE).

Edward Adams
Michael Adena
Obehi Akoria
Anna Birna Almardottir
Keith Altman
Pierre Anhoury
Kwame Appenteng
Ivar Aursnes
Keith Beard, FISPE
Alison Bourke, FISPE
David Bradford
Miles Braun, FISPE
Emily Brouwer
James Buchanan
Claudia Cabrera-Moksnes
Javier Cid Ruzafa
Alexander Cole
Lyn Colvin
Suellen Curkendall
Marie-Christyne Cyr
Hassy Dattani
Josta de Jong
Lolkje de Jong-van den Berg
Juergen Dinger
Thomas Einarson, FISPE
Cheryl Enger
Kimberly Farrand
Genevieve Gabb
David Gagnon
Anna Greenacre
Jeff Guo
Eelko Hak
Marte Handal
Klaas Heinemann
Deborah Hennessey
Marlene Hovhanchian
Zhiping Huang
Helen Huang
Jacqueline Hugtenburg
Betsey Jackson
Sara Johansson
Jeffrey Johnson
Yea-Huei Kao Yang
Oystein Karlstad
Junichi Kawakami
Judy Kempf
Farhad Ali Khan
Maarit Korhonen
Tzuyung Kou
Kiyoishi Kubota, FISPE
Sarah Landis
Linda Levesque
Michael A. Lewis, FISPE
Marina Maggini
Milada Mahic
Frank May, FISPE
Carl Metzdorff
Montserrat Miret
Ditte Molgaard-Nielsen
Nancy E. Morden
Yola Moride, FISPE
Mette Norgaard
Susan Oliveria, FISPE
Cynthia Phillips
Paola Primatetua
Elham Rahme
Joe Reilly
Adriano Reis
Susan Roberts
Jamie Robinson
Motonobu Sakaguchi
Ida Schnabel
Markus Schuerch
Barbara Schwierin
Prasanthi Shah
Hee-Young Shin
Rosemary Sift-Carter
Herik Toft Sorensen
Montse Soriano Garbro
Patrick Souverein
Miriam Sturkenboom, FISPE
Bharat Thakrar
Sengwee Toh
Toshihiko Tokimoto
Gianluca Trifiro
Ilse Truter
Marianne Ulcikas Yood
Carla M. Van Bennekomo
Mari-Ann Wallander, FISPE
Alex Ward
Mark Waring
Made Wente
Jean-Frederic Westphal
Almut Winterstein
Zhong Yuan
Xiaofeng Zhou
HealthCore

Safety & Epidemiology Research
Prospective Effectiveness Research
Health Economics & Outcomes Research

We Provide Clarity that Empowers Decision-Makers to Act with Precision to Improve Quality, Safety and Affordability in Healthcare.

A comprehensive, proven and innovative research environment:
• Rich data assets – the HealthCore Integrated Research Database (HIRDSM)
• Deep scientific expertise and data capabilities provide unparalleled insights
• Strategic collaborations with delivery systems, academia, government and managed care

800 Delaware Ave., Fifth Floor • Wilmington, DE 19801 • P 302.230.2156 • F 302.230.2046
info@healthcore.com • www.healthcore.com • For more information, contact Michael Chance at 610.613.2979
Wednesday, August 18

8:30am-5:00pm
ISPE Board of Directors Meeting (Buckingham)
(Open to ISPE members; notify ISPE staff if you would like to attend.)

11:00am-5:00pm
Registration (Sussex Lounge)

11:00am-5:00pm
Speaker Ready Room (Office 1)

NOTE:
Topics in Day 1 and Day 2 are complementary.
Individuals registered for either day may attend both sessions. On Day 1, there will be a focus on didactic teaching. On Day 2 there will be small group workshop that will use real pharmacogenetic case studies catering to both novice and advanced participants, focused on methodology.

Pre-Conference Educational Sessions* (Registration required)

8:30am-5:00pm
ISPE Board of Directors Meeting (Buckingham)
(Open to ISPE members; notify ISPE staff if you would like to attend.)

11:00am-5:00pm
Registration (Sussex Lounge)

11:00am-5:00pm
Speaker Ready Room (Office 1)

Pre-Conference Educational Sessions* (Registration required)

1:00-5:00pm
Introduction to Pharmacoepidemiology (Balmoral)
Chair: Andrew McAfee
Harry Seifert, GSK, Spontaneous Reporting
Soko Setoguchi, Duke University, Cohort Studies
Andrew McAfee, Brigham & Women’s Hospital, Case-Control Studies
Anita McGrogan, University of Bath, Confounding and Bias

1:00-5:00pm
Introduction to Pharmacogenetics Part I: Didactic Approach Infused with Practical Examples (Dukes)

Educational Objectives
This year’s course will focus more on methodologic approaches in pharmacogenetics in Day 1 and in Day 2.

• Understand the genetic and pharmacogenetic terminology and how cellular and molecular biology informs pharmacogenetic studies at analysis
• Know the study design and methodologic approaches, their strengths and weakness used in pharmacogenetic epidemiology
• Understand statistical approaches used in Pharmacogenetics
• Understand how pharmacogenetics relates to current focus of Personalized Medicine
• Have an overview of clinical utility of pharmacogenetics and associated regulatory issues.

Faculty
Geoffrey Liu, Introduction to Pharmacogenetic and Biospecimen Terminology, and Approach Overview
Anke-Hilse Maitland-van der Zee/Efrosini Setakis, Advanced Pharmacogenetic Methods for Epidemiologists
Andrew Freedman, Application of Methods: From Discovery to Confirmation to Clinical Utility
Steven Kimmel, FISPE, Application of Methods: Warfarin as a Prototype Pharmacogenetic Example
Amalia Issa, Methodology to Investigate Policy-Relevant Aspects of Pharmacogenomics: Tools of the Trade (Methodology)

1:00-5:00pm
STUDENTS ONLY
Student Skills Workshop (Ambassador)
–Organized by ISPE Student Council

Introduction
Presentation Clinic
Careers Panel
Stella Blackburn, FISPE, EMA, Drug Regulation
Robert Reynolds, Pfizer, Pharmaceutical Industry
Kenneth J. Rothman, FISPE, RTI Health Solutions, Contract Research Organization
Sean Hennessy, FISPE, Academic

5:30-?
Student Meet and Greet
– Open to all students.
– Organized by the ISPE Student Council
– Assemble at ICPE Registration Desk, then walk to Revolution.

* Included as part of full meeting registration; registration required
Pre-Conference Educational Sessions* (Registration required)

**Thursday, August 19**

**7:00am-6:00pm**
Registration
(Sussex Lounge)

**7:00am-5:00pm**
Speaker Ready Room (Office 1)

**8:30-Noon**

**Pharmacogenetics 2 - Practicum/Small Group Case-based Projects (Dukes)**

**Educational Objectives**
- This year’s course will focus more on methodologic approaches in pharmacogenetics in Day 1 and in Day 2.
- Understand the genetic and pharmacogenetic terminology and how cellular and molecular biology informs pharmacogenetic studies at analysis
- Know the study design and methodologic approaches, their strengths and weakness used in pharmacogenetic epidemiology
- Understand statistical approaches used in Pharmacogenetics
- Understand how pharmacogenetics relates to current focus of Personalized Medicine
- Have an overview of clinical utility of pharmacogenetics and associated regulatory issues.

**Faculty**
Andrew Freedman
Anke-Hilse Maitland van der Zee
Efrosini Setakis
Amalia Issa
Steven Kimmel
Geoffrey Liu

**8:30-Noon**

**Introduction to Drug Utilization Research (Buckingham)**

**Educational Objectives**
- To explain the definition and scope of the eclectic discipline of Drug Utilization Research within the context of Pharmacoepidemiology.
- To motivate researchers providing international cross-national comparisons of national drug utilization data to cooperate on the collection of a minimal dataset of reliable and comparable drug utilization data in their country, in terms of volume, expenditures and quality of drug use.
- To explain the process of developing and validating prescribing quality indicators.
- To give an applied overview of methods useful for drug policy research (time series analysis)

**Faculty**
Robert Vander Stichele, Course Objectives, Definitions of Research Fields and Methodological Framework
Hanne Strom, The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose: Classifying and Quantifying Drug Use for Cross-National Comparison
Julie Zito, Overview of Drug Utilization Research in the US
Monique Elseviers, Using DUR – Data for Descriptive Cross National Comparisons
Flora Haaijer-Ruskamp, Using DUR – Data to Create Valid Prescribing Quality Indicators
Colin Dormuth, Testing Interventions on Drug Utilization (time series analysis and other methods)
8:30-Noon
Intermediate Pharmacoepidemiology: Concepts, Data and Methods (Clarence)

Course Description
• This course is for the general epidemiologist who wishes to review topics that are particular to pharmacoepidemiology. Concepts: drugs, devices and biologics as "exposures"; time-courses of their risks; confounding by indication; clinical and epidemiologic inference. Data: use of insurance claims and electronic medical records. Analysis: propensity, instruments, time-varying exposures and confounders.

Faculty
Alec Walker, FISPE, World Health Information Science Consultants, Harvard School of Public Health

8:30-Noon
Medications in Pregnancy (Balmoral)

Educational Objectives
• Recognize the unique methodological challenges of discovering unintended drug effects in pregnant women in pre-marketing and post-marketing studies.
• Understand the circumstances around the discovery and management of known drug safety crises affecting pregnant women and their offspring. This includes the critical evaluation of the available scientific evidence.
• Evaluate and design pharmacoepidemiologic studies for pregnant populations.

Faculty
Carol Louik, Assistant Professor, Slone Epidemiology Center at Boston University
Sonia Hernandez-Diaz, FISPE, Associate Professor, Department of Epidemiology, Director of Pharmacoepidemiology Program, Harvard School of Public Health

8:30-Noon
Comparative Effectiveness Research (Hall 4)

Educational Objectives
• Appreciate the differences between comparative effectiveness and efficacy research and implications for improving routine care
• Understand the basic study design issues for non-randomized data recorded in routine care settings
• Recognize the advantages and limitations of a variety of data sources for comparative effectiveness research and how to combine sources
• Understand methodologic challenges and proposed solutions in non-randomized effectiveness research
• Learn how to generate and synthesize evidence with the decision maker in mind

Faculty
Eric S Johnson, Course Chair, Kaiser Permanente’s Center for Effectiveness and Safety Research, Introduction to Comparative Effectiveness Research via Pragmatic Cohort Studies
David J Magid, Kaiser Permanente’s Institute for Health Research, Combining Electronic Health Record and Registry Data Sources for Comparative Effectiveness
Sebastian Schneeweiss, FISPE, Harvard Medical School, Methodological Challenges in Non-Randomized Studies of Comparative Effectiveness
Kenneth R Paterson, Scottish Medicines Consortium, Generating and Synthesizing Evidence with the Decision Maker in Mind

Noon-1:30pm
Lunch On Your Own

Noon-1:30pm
New Member Luncheon
(Windsor Restaurant)
–By Invitation
Pre-Conference Educational Sessions* (Registration required)

1:30-6:00pm
Advanced Topics in Pharmacoepidemiology
(Hall 4)

This course is a series of four lectures covering new and advanced methods for pharmacoepidemiology research.

Chair: Jim Lewis, FISPE

Paddy Farrington, Methods for Use of Self-Controlled Designs
Byrony Dean Franklin, Methods to Study the Risk, Consequences, and Prevention of Medication Errors
Til Stürmer, FISPE, Update on Propensity Scoring
Reed Johnson, Methods of Quantitative Risk Benefit Analysis

1:30-6:00pm
Introduction to Risk Management (Balmoral)

Educational Objectives

• To provide basic overview/framework for biopharmaceutical risk management -- both EU-based risk minimization plans (RMP) and US-based risk evaluation & mitigation strategies (REMS) -- including the regulatory context and perspective
• To describe the use of surveys in planning and evaluating the effectiveness of RMP/REMS
• To present key concepts in the design and conduct of survey research
• To illustrate key concepts of survey research with examples of RMP/REMS assessment surveys
• To provide an opportunity for interactive session in developing and evaluating RMP/REMS assessment surveys

Faculty

Elizabeth Andrews, FISPE, Course Objectives and Introductions; Overview of Risk Management the Role of Evaluation, with Focus on Survey Research
Stella Blackburn, FISPE, Implementation and Experiences in Risk Management in the EU
Carla van Bennekom, Selected Topics and Examples - Survey Design and Analysis
Judith Jones, FISPE, Workshop for Participants to Develop/Review an Assessment Survey

1:30-6:00pm
Advanced Drug Utilization Research: Using Drug Data to Guide Planning and Evaluation of Quality Use of Medicines Interventions (Ambassador)

Educational Objectives

• To gain an advanced understanding of planning, implementation and evaluation requirements for an effective quality use of medicines intervention.
• To develop a sophisticated understanding of the importance of behavioral and project planning processes to the effectiveness of interventions.
• To develop a sophisticated appreciation of the significance of this work to knowledge transfer at the patient care practice and policy change levels of the health system.

Faculty

Andrew Gilbert, Introductions, Workshop Objectives, and Plan
Libby Roughead, Theoretical Methods Underpinning Intervention Planning
Jerry Avorn, FISPE, Expert Commentary

6:00-7:30pm
Welcome Reception (Hilton Metropole Beach, weather permitting)

– Admission by badge or ticket. Cash Bar

Welcome

Corinne S. de Vries, FISPE, Chair, 2010 Scientific Program Committee
Sebastian Schneeweiss, FISPE, ISPE President
The Epidemiology Group at Pfizer pursues excellence in developing and executing pharmacoepidemiology safety strategies to inform benefit-risk decisions about our medicines.

Pfizer, Inc. discovers, develops, manufactures, and markets leading prescription medicines for humans and animals. Our diversified global health care portfolio includes biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products.

With 2009 actual spending of $7.8 billion in research & development (R&D), Pfizer has the industry’s largest pharmaceutical R&D organization. Our search for new treatments spans hundreds of research projects across 58 major disease groups in 10 therapeutic areas.

We build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues.

Every year we help 150 million patients, utilize the skills of medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses – adding both years to life, and life to years.

We are proud to support the 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management and welcome the opportunity for the open exchange of scientific ideas and research findings in order to advance the fields of pharmacoepidemiology and risk management.
**AGENDA  
Friday, August 20**

**7:00am-6:00pm**

**Registration** (Sussex Lounge)

**7:00am-5:00pm**

**Speaker Ready Room** (Office 1)

**7:00-8:00am**

**ISPE Committee Meetings**
- Open to all participants.
  - Education Committee (Lancaster)
  - Finance Committee (Hilton 3)

**7:00-8:00am**

**Poster Session A Set-up**
(Durham & Hall 7)

**7:30am-6:00pm**

**Exhibits/Posters** (Durham & Hall 7)

**8:00-9:00am**

**Opening Session** (Oxford)
- Welcome
  Corinne S. de Vries, FISPE, Chair, 2010 Scientific Program Committee
- Presidential Address
  Sebastian Schneeweiss, FISPE, ISPE President

---

**9:00am - 10:30am**

**Concurrent Sessions: Contributed Papers**

**Diabetes** (Clarence)

**Moderators:** Bert Leufkens, FISPE, & Jurgen Dinger

**9:00 am**
- Clinical and Demographic Characteristics of Newly Diagnosed Diabetes Patients Prescribed Oral Hypoglycemics [1]
  S L West, E S Brouwer, M N Kluckman, A L Masica, E Ewen, R Kudyakov. (United States)

**9:15 am**
- Improved Glycemic Control and Cancer Risk in Type 2 Diabetes: A Meta-Analysis of Major Trials [2]
  Jeffrey A Johnson, Samantha L Bowker. (Canada)

**9:30 am**
- A Retrospective Cohort Study To Assess the Relative Risk of Acute Pancreatitis among Initiators of Exenatide Compared to Initiators of Other Anti-Diabetic Medication: A Follow-Up Study [6]
  Made Wenten, Julia Gaebleer, Elise Pelletier, Dan Smith, Prafulla Girase, Rebecca Noel, Daniel Braun, Gary Bloomgren, Mohamed Hussein. (United States)

**9:45 am**
- Comparative Cardiovascular Morbidity and Mortality of Metformin in Older Adults with Diabetes: A Population-Based Cohort Study [4]
  Linda E Levesque, James M Brophy, Sophie Dell’Aniello, Samy Suissa. (Canada)

**10:00 am**
- Risk of Acute Pancreatitis in Association with Type 2 Diabetes Mellitus [5]
  Antonio González-Pérez, Raymond G Schlienger, Luis A Garcia Rodriguez. (Switzerland)

**10:15 am**
- Hypoglycemic Agents and the Risk of Cancer [3]
  Hui Zhang, Hammad A Tarek, David C Christiani, Edward Giovannucci. (United States)

---

**Infection: Down with Resistance** (Dukes)

**Moderators:** Kay Johannes & Mari-Ann Wallander, FISPE

**9:00 am**
- Time-Varying Antibiotic Exposure and Risk of Clostridium Difficile Infection (CDI) [7]
  Vanessa Stevens, Ghinwa Dumyati, Susan Fisher, Lynn Fine, Edwin van Wijngaarden. (United States)

**9:15 am**
  Nkuchia M M’ikanatha, A Russell Localio, Collette Fitzgerald, Irving Nachamkin. (United States)
**AGENDA**  
**Friday, August 20**

9:30 am  
*Antibiotic-Induced Liver Injury Among Hospitalized Patients [9]*  
Marie L De Bruin, Yang Yu, Hanneke J den Breeijen, Wouter W van Solinge, Anke Hilse Maitland-van der Zee. (Netherlands)

9:45 am  
*The Risk of Infections among Patients Treated with TNFi: Population-Based Continuous ADRs Monitoring Using the Maximized Sequential Probability Ratio Testing [10]*  
Yan Chen, Indiana Strombom, Dale Marmaduke, Olivier Benichou, Illya Lipkovich. (United States)

10:00 am  
*Hepatitis C Treatment Adherence over Time and Virologic Response [11]*  
V Lo Re, V Teal, R Localio, V Amorosa, R Gross. (United States)

10:15 am  
*Tuberculosis Risk Awareness and Screening Practices among Prescribers of Anti-Tumor Necrosis Factor (TNF) Agents in the European Union [12]*  
Meredith Y Smith, Brian Attig, Thomas Eagle. (United States)

---

**Powerful solutions at every phase.**

The Phase Forward™ Integrated Clinical Research Suite

eClinical Solutions  •  Safety Solutions  •  Clinical Development Center

[Phase Forward](http://www.phaseforward.com)

Copyright © 2010 Phase Forward Incorporated. All rights reserved. Phase Forward and the Phase Forward logo are trademarks or registered trademarks of Phase Forward Incorporated in the U.S. Patent and Trademark Office and other jurisdictions. Other marks may be trademarks or registered trademarks of their respective owners.
Methods: Exposure and Outcome Assessment (Hall 4)

Moderators: Yola Moride, FISPE & Michele Johnson Funk

9:00 am
  Robert A Greevy, Mary M Huizinga, Christianne L Roumie, Carlos G Grijalva, Harvey Murff, Xulei Liu, Kristen Kotter, Marie R Griffin. (United States)

9:15 am
- Variability in Measurement of Medication Exposure in Pharmacoepidemiologic Studies of COPD [14]
  Caitlyn T Wilke, Fang-Ju Lin, Todd A Lee, Bruce L Lambert, Min J Joo, A Simon Pickard. (United States)

9:30 am
  Jodi B Segal, Suzanne West, Marie R Griffin, Elizabeth Selvin, Patrick O’Conner, Eric B Bass. (United States)

9:45 am
- Identification of Novel Post-Vaccine Syndromes Using Information Theory [16]
  Alexander M Walker, Gregory W Daniel, Karen Smoyer-Tomic, Tosmai Puenpatom, Tao Gu, Hector Izurieta. (United States)

10:00 am
- Benefit-Risk Assessment Based on Ordered Clinical Outcomes [17]
  Ola Caster, G Niklas Norén, Love Ekenberg, I Ralph Edwards. (Sweden)

10:15 am
- Impact of Medicare Claim Resubmissions on Drug and Health Identifiers [18]
  Abraham G Hartzema, Thomas E Macurdy, Jonathan M Gibbs, Judith A Racoosin, Chris Worrall, Jeffrey A Kelman. (United States)

Sundry (Buckingham)

Moderators: Michael Peng & Kiyoshi Kubota, FISPE

9:00 am
- Trends of Oseltamivir Usage in the United States During the 2009 Influenza A (H1N1) Pandemic [19]
  John K Iskander, Craig Hales, Charbel El Bcheraoui, Robert T Chen. (United States)

9:15 am
- Prescribing of Anti-Osteoporotic Therapies Following the Use of Proton Pump Inhibitors in General Practice [20]
  Bernie McGowan, Kath Bennett, Michael Barry. (Ireland)

9:30 am
- Vaccine Safety: Background Rates of Events of Specific Interest [21]
  J Dieleman, A Hviid, T Kilpi, J Storsaeter, S Mannino, H Heijbel, F de Abajo, C de Vries, G Mazzaglia, K Johansen, P Kramarz, D Weibel, J Bonhoffe, M Sturkenboom. (Netherlands)

9:45 am
- Tiotropium Use and the Risk of Cerebrovascular Events [22]
  Mendel Haag, Katia Verhamme, Ana Afonso, Charlotte Van Noord, Peter Koudstaal, Miriam Sturkenboom. (Netherlands)

10:00 am
- Prevalence of Co-Morbidities and Drug Exposure in Patients with Alzheimer’s Disease around the Time of Diagnosis [557]
  Patrick Imfeld, Yolanda B Brauchli, Markus Schuerch, Christoph R Meier. (Switzerland)

10:15 am
- Impact of Regulatory Risk Communication in the Netherlands; 30 Time Series Analyses [24]
  S Piening, K Reber, J Wieringa, S Straus, P de Graeff, F Haaijer-Ruskamp, P Mol. (Netherlands)
The Brighter Side of Cancer (Balmoral)
Moderators: Marieke Schoonen & Jim Kaye

9:00 am
✦ Validation of Cancer Diagnoses Recorded in the General Practice Research Database [25]
Hui Zhang, Tarek A Hammad, Edward Giovannucci, Elizabeth Kang, David C Christiani. (United States)

9:15 am
✦ Liver Function Test Abnormalities in Patients Treated with Small Molecule Tyrosine Kinase Inhibitors [26]
Beth L Nordstrom, Kathy H Fraeman, Weixiu Luo, Sumitra Shantakumar, Sarah H Landis. (United States)

9:30 am
✦ High-Ceiling Diuretics Are Associated with an Increased Risk of Basal Cell Carcinoma in a Population-Based Follow-Up Study [345]
Rikje Ruiter, Loes Visser, Mark Eijgelsheim, Eline Rodenburg, Albert Hofman, Jan-Willem Coebergh, Tamar Nijsten, Bruno Stricker. (Netherlands)

9:45 am
✦ Lymphoma among Patients with Atopic Dermatitis Treated with Topical Corticosteroids (TCS) and/or Topical Calcineurin Inhibitors (TCIs) [28]
Alejandro Arana, Charles W Wentworth, Elena Rivero, Estel Plana, Eulogio Conde. (Spain)

10:00 am
✦ Use of Cyclosporine and Risk of Squamous Cell Carcinoma in the Skin: A Population Based Cohort Study in Denmark [29]
Julie Lavole, Annette Østergaard Jensen, Malene Cramer Engebjerg, Bente Jespersen, Knud Kragballe, Henrik Toft Sørensen. (France)

10:15 am
James Lewis, Assiamira Ferrara, Tiffany Peng, Monique Hederson, Warren Bilker, Charles Quesenberry, Lisa Nessel, Brian Strom. (United States)
**AGENDA**

**Friday, August 20**

**Vaccines in the H1N1 Era** (Cambridge)

Moderators: Patricia Saddier & Montserrat Soriano

9:00 am

- Factors Predictive of H1N1 Influenza Vaccine Uptake among ‘At-Risk’ Patients in the UK General Practice Research Database [31]
  Cormac Sammon, Anita McGrogan, Julia Snowball, Corinne de Vries. (United Kingdom)

9:15 am

- Background Incidence of Disease for Assessment of Pandemic A/H1N1 Vaccine Safety in Taiwan [32]
  Wan-Ting Huang, Chia-Luen Tsai, Jen-Hsiang Chuang, Cheng-Hua Lee, Shou-Hsia Cheng, Hsu-Sung Kuo. (Taiwan)

9:45 am

- H1N1 Influenza Vaccine Surveillance Project [33]
  Cheryl Enger, Bruce Turnbull, Robert Gately, Jeanne Loughlin, K Arnold Chan. (United States)

10:00 am

- Confounding in Studies of Influenza Vaccination and Mortality in the Elderly [35]
  Amanda R Patrick, M Alan Brookhart. (United States)

10:30-11:00 am

**Break/Posters/Exhibits** (Durham & Hall 7)

**SPONSORED BY: CSD - EPIC**

11:00-12:00 pm

**Keynote Address** (Oxford)

Moderator: Stephen J.W. Evans, FISPE, ISPE President-Elect

**Thomas Lööngren**, Executive Director, European Medicines Agency

- The Future of Medicines Regulation: Where Does Pharmacoepidemiology Fit into Risk Management and Comparative Effectiveness Measurement?

Thomas Lööngren has been the Executive Director of the European Medicines Agency since 1 January 2001. He is currently serving a second five-year term, which expires at the end of 2010. Mr Lööngren qualified as a pharmacist from the University of Uppsala, Sweden, in 1976 and holds an MSc in social and regulatory pharmacy. From 1976-78 he was a lecturer at the same university. He served with the Swedish National Board of Health and Welfare from 1978-90, where his responsibilities included herbal medicines, cosmetics, medical devices, narcotics and contraceptives. From 1982-94, he acted as senior pharmaceutical consultant for the Swedish International Development Agency’s health cooperation programme in Vietnam. In 1990 he was appointed Director of Operations of the Swedish Medical Products Agency (MPA), of which he later became the Deputy Director-General. He became an Honorary Member of the Royal Pharmaceutical Society of Great Britain in 2003 and was made an Honorary Fellow of the Royal College of Physicians in 2004. He was granted an Honorary Doctorate from the University of Uppsala in January 2008, and received the Drug Information Association’s Distinguished Career Award in March 2008.

12:00pm-1:30pm

**Lunch/Poster Session A/Exhibits**

(Durham, Durham Gallery, Hall 7 & 8)

**SPONSORED BY ACADEMIC SUPPORTERS** (listed on page 6)

**ISPE Committee/Council Meetings**

–Open to all participants.

- Development Committee (Lancaster)
- Fellowship & Awards Committee (Hilton 3)
- Public Policy Comm. (Buckingham)
- Student Council (Ambassador)

1:30-3:00pm

**EMA Scientific Debate** (Oxford)

**CO-SPONSORED BY ISPE & EMA**

**Motion:** Results from epidemiology and pharmacoepidemiology studies mislead the public because of a failure to adjust for multiple comparisons. Journals should not publish studies that do not account for multiplicity.

- **For the motion:**
  Stan Young, National Institutes of Statistical Sciences, USA
  Stuart Pocock, London School of Hygiene and Tropical Medicine, UK

- **Against the motion:**
  Sonia Hernández-Díaz, FISPE, Harvard School of Public Health, USA
  Kenneth J. Rothman, FISPE, RTI Health Solutions, USA
Friday, August 20

3:00-3:30pm
Break/Posters/Exhibits (Durham & Hall 7)

3:30-5:00pm
Concurrent Sessions: Symposia And Workshops

Methodological Challenges in Cross-National Comparisons of Drug Utilization [37] (Balmoral)
- Sponsored by the Drug Utilization/Health Services Research SIG
- Björn Wettermark, Monique Elseviers, Brian Godman, Marit Rönning, Lesley Tilson, Vera Vlahovic Palcevski. (Sweden)

Methodological Controversies from Comparative Effectiveness (CE) Studies Using Claims vs. Electronic Health Record (EHR) Data [38] (Cambridge)
- Soko Setoguchi, Nirav Shah, Jason Roy, Wolfgang Winkelmayer, Robert Glynn. (United States)

Ascertaining the Use of Biologics [39] (Dukes)
- Sponsored by the Biologics SIG
- Thijs Giezen, Judith Jones, Will Dixon, Michael Taylor, Bert Leufkens, Earl Goehring. (Netherlands)

Guidance Regarding the Identification, Development, Validation and Translation of Coding Algorithms in Electronic Healthcare (EH) Databases [40] (Hall 4)
- Sponsored by the Database SIG
- Vinay Mehta, Robert J Locasale, Matthew W Reynolds, Rhonda L Bohn, Gianluca Trifiro, Tami L Mark. (United States)

Identifying the Genetic Basis of Serious Adverse Events: Will High-Profile Genome-Wide Association (GWA) Studies Improve Drug Safety in the Next Decade? [41] (Buckingham)
- Jointly sponsored by the MepPharmacogenomics SIG & ISAEC
- Anke-Hilse Maitland-van der Zee, Andrew Freedman, Ann K Daly, Arthur Holden. (Netherlands)

Identification and Classification of Birth Defects in Pharma-coepidemiology: A Comparison of Approaches [42] (Clarence)
- Sponsored by the Medications in Pregnancy SIG

The Public Health Burden of Acetaminophen Poisonings: Risk Management Efforts To Mitigate It [575] (Ambassador)
- Syed Rizwanuddin Ahmad, June Raine, Keith Hawton, Gerald Dal Pan. (United States)

5:00-6:00pm
ISPE Council Meetings
- Open to all interested participants
  - Academic Council (Hall 4)
  - Government/Regulatory Council (Hilton 3)
  - Industry/Service Providers Council (Lancaster)

6:00pm-7:00pm
General Assembly/European Chapter of Drug Utilization/Health Services Research SIG (Ambassador)

7:00-9:00pm
PDS Editorial Board
- By Invitation

7:00pm-?
Student Social Event A Night Out in Brighton
- Open to all students.
- Organized by the ISPE Student Council
- Assemble at ICPE Registration Desk, then walk to Al Duomo.

3:00-3:30pm
Break/Posters/Exhibits (Durham & Hall 7)
AGENDA Saturday, August 21

7:00am-6:00pm Registration
(Sussex Lounge)

7:00am-5:00pm Speaker Ready Room (Office 1)

7:00-8:00am Poster Session B Set-up
(Durham & Hall 7)

8:00am-6:00pm Exhibits/Posters
(Durham & Hall 7)

8:30-10:00am Concurrent Sessions: Contributed Papers

CNS: The Brain and the Heart (Balmoral)
Moderators: Nadia Foskett & Cristina Varas-Lorenzo

8:30 am
✔ Risk of Heart Failure with Dopamine Aganist Use in Parkinson’s Disease [237]
G Trifirò, M Mokhles, J Dieleman, E van Soest, G Mazzaglia, R Herings, C de Luise, D Ross, G Brusselle, A Colao, W Haeverkamp, R Schade, G van Camp, R Zanettini, M Sturkenboom. (Netherlands)

9:15 am
✔ Use of Serotonergic Medications and Cardiac Valvulopathy: A Nested Case-Control Study in the Health Improvement Network (Thin) Database [240]
Annalisa Rubino, Francesco Lapi, Federica Nicotra, Antonella Zambon, Lorenza Scotti, Mary Thompson, Alfredo Vannacci, Giovanni Corrao, Alessandro Mugelli. (Italy)

9:30 am
✔ Antipsychotics and the Risk of Sudden Cardiac Death and Ventricular Arrhythmia [241]
Charles E Leonard, Warren B Bilker, Craig Newcomb, Stephen E Kimmel, Brian L Strom, Sean Hennessy. (United States)

9:45 am
✔ Risk of Death and Major Medical Events Associated with Psychotropic Medications in Patients Newly Admitted to Nursing Homes [242]
Krista Huybrechts, Kenneth J Rothman, Rebeca Silliman, M Alan Brookhart, Sebastian Schneeweiss. (United States)

8:30 am
✔ Validating Pneumonia Hospitalizations in the THIN Database [243]
Sharon B Meropol, Joshua P Metlay. (United States)

8:45 am
✔ Validity of Claims-Based Definitions of Impaired Left Ventricular Systolic Function in Medicare Patients [244]
Qian Li, Robert J Glynn, Nancy A Dreyer, Jun Liu, Helen Mogun, Soko Setoguchi. (United States)

9:00 am
✔ The Effect of Antidepressants on Cardiovascular Morbidity and Mortality in Older Adults: A Population-Based Cohort Study [239]
Gregory L Kennedy, Kristan Aronson, Linda E Levesque. (Canada)

9:15 am
✔ Validation of the Health Improvement Network (THIN) Database for Epidemiologic Studies of Chronic Kidney Disease [246]
Michelle R Denburg, Kevin Haynes, Justine Shults, James Lewis, Mary B Leonard. (United States)

9:30 am
✔ Automated Classification of Free Text Electronic Health Records for Epidemiological Studies [247]
Martijn J Schuemie, Emine Sen, Eva M van Soest, Miriam C Sturkenboom, Jan A Kors. (Netherlands)

9:45 am
✔ Comparing Bias of Two Different Instrumental Variable (IV) Approaches with Logistic Regression [190]
Bing Cai, Dylan S Small, Sean Hennessy, Thomas R Ten Have. (United States)
Celgene Corporation is proud to sponsor the 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Committed to improving the lives of patients worldwide®

Celgene shares ISPE’s dedication to enhancing public health through the creation of critical and innovative safety and risk management programs in areas of great medical need

www.celgene.com
AGENDA  
Saturday, August 21

Miscellaneous (Buckingham)
Moderators: Susan Olivera, FISPE & John Logie

8:30 am
▶ A Propensity Score Adjusted Cohort Study To Measure the Impact of Statin Therapy on Short-Term Mortality Following a Pneumonia Episode [464]
Ian J Douglas, Liam Smeeth, Stephen J Evans. (United Kingdom)

8:45 am
▶ Assessment of the Cost-Effectiveness of Pharmacogenomic Diagnostics for Breast Cancer [250]
Mo Yang, Amalia Issa. (United States)

9:00 am
▶ The Epidemiology of HIV-1 Co-Receptor Tropism in Patients Infected with Non-Clade B HIV from India, Uganda and South Africa [251]
Anna Greenacre, Quazi Ataher, Simon Portsmouth, Randy Tressler, Sybil Eng. (United States)

9:15 am
▶ Cohort Studies in Chronic Diseases Using Routinely Collected Databases When a Prescription Is Used as Surrogate Outcome [252]
Sara Lodi, James Carpenter, Stephen Evans. (United Kingdom)

9:30 am
▶ Methodological Challenges When Applying ICD-10 Codes to Research Data: Findings from the Post-Hoc Endpoint Readjudication of Sudden Death for the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) Large Simple Trial [253]
Jamie Geier, Onur Karayal, Michael Lewis, John Camm, Martin Keane, Charlotte Kremer, Sheela Kolluri, Robert Reynolds, Brian L Strom. (United States)

9:45 am
▶ Potential Ascertainment Bias in Assessment of Obesity and Smoking History and Its Impact on Type 2 Diabetes Disease in the General Practice Research Database [254]
Tzuyung D Kou, Kimberly G Brodovicz, Charles Alexander, Leonid Katz, Cynthia J Girman. (United States)

Signal Detection and Evaluation in any Observational Database

» Standardized Approach
» Robust and Transparent Analytic Methodology
» Interactive Workflow
» Familiar Vocabulary
» Saves Time and Money

For more information, please visit us today at www.prosanos.com
AGENDA  Saturday, August 21

NSAIDs and Associated Treatments  (Dukes)
Moderators: Jordi Castellsague & Tobias Gerhard

8:30 am
★ Concordance of Nonsteroidal Anti-Inflammatory Drug Prescriptions with Recent Clinical Practice Guidelines in Quebec, Canada [255]
Elham Rahme, Jean-Philip LaFrance, Jean-Pascal Roussy, Suzanne Morin. (Canada)

8:45 am
★ Adherence to Proton Pump Inhibitors and the Risk of Upper Gastrointestinal Complications in Cooxib Users [256]
V Valkhoff, E van Soest, G Mazzaglia, R Schade, M Molokhia, J Dieleman, M Sturkenboom. (Netherlands)

9:00 am
★ Factors Associated with Proton Pump Inhibitor Discontinuation in Nursing Homes [257]
Amy Linsky, John A Hermos, James L Rudolph, Elizabeth V Lawler. (United States)

9:15 am
★ Cyclooxygenase (COX)-2 Selective and Non-elective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Risk of Hyperkalemia [258]
Jean-Philippe Lafrance, Donald R Miller. (Canada)

9:30 am
★ Nonsteroidal Anti-Inflammatory Drug Use and Risk of Atrial Fibrillation or Flutter: A Population-Based Case-Control Study [259]
Morten Schmidt, Christian F Christiansen, Frank Mehnert, Kenneth J Rothman, Henrik Toft Sørensen. (Denmark)

9:45 am
★ Pain Relief Medication Following Cessation of Co-Proxamol Use: An Analysis Using the GPRD [260]
David Irvine, Jakob Petersen, Lesley Wise. (United Kingdom)

P4M: Pharmacogenomics, Predictors, Prognosis, and Personalised Medicine  (Clarence)
Moderators: Geoff Liu & Joanna Haas

8:30 am
★ Single Nucleotide Polymorphisms (SNPs) in the Matrix Metalloproteinase (MMP) Gene Family, Gastroesophageal Reflux Disease (GERD), and Risk of Esophageal Adenocarcinoma (EAC) [261]
Winson Y Cheung, Rihong Zhai, Matthew Kulke, Rebecca Heist, Kofi Asomaning, Clement Ma, Zhaoxi Wang, Li Su, Geoffrey Liu, David Christiani. (Canada)

8:45 am
★ Analysis of Proteomic Biomarkers for Acute Interstitial Lung Disease (ILD) in Gefitinib-Treated Japanese Non-Small Cell Lung Cancer (NSCLC) Patients [262]
Fredrik Nyberg, Atsushi Ogiwara, Chris G Harbron, Takao Kawakami, Yasuhiko Komatsu, Toshihide Nishimura, György Marko-Varga. (Sweden)

9:00 am
★ Integrating Pharmacogenetics into Clinical Trials: Implications for Sample Size to Test Gene-Drug Interactions [263]
Kimberly A Lowe. (United States)

9:15 am
★ Results of the First European Genome-Wide Association Study of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [264]
Emmanuelle Genin, Peggy Sekula, Diana Zelenika, Mark Lathrop, Martin Schumacher, Jean-Claude Roujeau, Maja Mockenhaupt, Regiscar Group. (Germany)

9:30 am
★ Pharmacogenetic-Based Warfarin Dosing: Simplified Pharmacogenetic Tables vs. Pharmacogenetic Algorithms [265]
Brian S Finkelman, Brian F Gage, Julie A Johnson, Colleen M Brensinger, Stephen E Kimmel. (United States)

9:45 am
★ The PCSK9 E670G Polymorphism Modifies the Effectiveness of Statins in Reducing the Risk of Myocardial Infarction [266]
B JM Peters, H Pett, A de Boer, O H Klungel, A H Maitland-van der Zee. (Netherlands)
We Innovate Healthcare

Roche and Genentech have successfully teamed up. It is our shared ambition to change the practice of medicine with novel approaches. Together, we provide millions of patients with the best results of our cooperation: Innovative medicines that help fight severe diseases and improve patients' lives.

ICPE 2010  August 19-22, 2010  Brighton, UK

AGENDA  Saturday, August 21

Risk Management: Are We Taking the Bull by the Horn? (Oxford)
Moderator: Klaas Heinemann & June Raine

8:30 am

* Additional Safety Risk to Exceptionally Approved Drugs in EU? [267]
  (Netherlands)

8:45 am

* One Year after: The EU Strategy for Epidemiological Monitoring of Pandemic H1N1 Vaccines [268]
  X Kurz, A Hidalgo-Simon, K Johansen, B Ciancio, A Nicoll, P Arlett.
  (United Kingdom)

9:00 am

* Not-in-Trial Simulation: Predicting Cardiovascular Risk from Clinical Trial Data [269]
  Anne Chain, Jeanne Dieleman, Meindert Danhof, Bruno Stricker,
  Jacqueline Witteeman, Oscar Della Pasqua, Miriam Sturkenboom.
  (Netherlands)

9:15 am

* Increasing the Benefit of EU Risk Management Plans (EU-RMPs)
  – Is There Room for Improvement? [270]
  Steve Mayall, Carol Walton, Aruna Jeans, Mazhar Thakur, Simon Ingate,
  Swapu Banerjee. (United Kingdom)

9:30 am

* Charting a New Course in Long-Term Safety: The Critical Role of Cancer Registries [271]
  (United States)

9:45 am

* Assessing the Effectiveness of an IT-Based Pharmacist-Led Intervention Aimed at Reducing Proportions of Patients at Risk of Medication Errors in Family Practice: The PINCER Trial [272]
  Anthony J Avery, Sarah Rodgers, Judith A Cantrill, Sarah Armstrong, Martin Eden,
  Denise Kendrick, Aziz Sheikh. (United Kingdom)

10:00-10:30am
Break/Posters/Exhibits (Durham & Hall 7)

Our Swiss-American story of success
We Innovate Healthcare

Roche and Genentech have successfully teamed up. It is our shared ambition to change the practice of medicine with novel approaches. Together, we provide millions of patients with the best results of our cooperation: Innovative medicines that help fight severe diseases and improve patients’ lives.

The Only Global CRO Dedicated Exclusively to Late Phase Research
Pharmaco-epidemiology, Risk Management and Drug Safety

Visit REGISTRAT-MAPI at Booth #18

- Global Reach
- Unique Solutions
- Flexible Technology
- Customized Services
- Scientific Expertise
AGENDA
Saturday, August 21

10:30am-12:00pm
Concurrent Sessions: Contributed Papers

Clinically Important Public Health Issues and New Insights in Rare Diseases (Dukes)
Moderators: Judith Jones, FISPE & Michael Taylor

10:30 am
Jennifer B Christian, Nancy E Bourgeois, Rose G Snipes. (United States)

10:45 am
❖ Frequency and Risk Factors of Gout Flares in a Large Population-Based Cohort of Incident Gout [274]
Dietrich Rothenbacher, Paola Primastesa, Alberto Ferreira, Lucia Cea Soriano, Luis A Garcia Rodriguez. (Switzerland)

11:00 am
❖ Avascular Osteonecrosis in Untreated Patients with Type 1 Gaucher Disease [275]
Pramod K Mistry, Patrick Deegan, Ashok Vellodi, J Alexander Cole, Michael Yeh, Neal J Weinreb. (United States)

11:15 am
❖ Catheter-Related Complications in Patients with Central Venous or Hemodialysis Catheters [276]
Pavel Napalkov, Diana Felici, Laura Chu, Joan Jacobs, Susan M Begelman. (United States)

11:30 am
❖ The Incidence of Ischemic and Hemorrhagic Stroke in Pediatric Patients [277]
Pavel Napalkov, Diana Felici, Laura Chu. (United States)

11:45 am
❖ Hemoglobinuria, Hemoglobinemia, and Renal Impairment in ITP Patients [278]
Fei Xue, Chuck Wentworth, Vanitha Ganesh, Victor Gastanaga, Gail Hughes, Scott Stryker, Steven Cha, Sean Zhao. (United States)

CNS: Potpourri (Oxford)
Moderators: Suellen Curkendall & Jessica Jalbert

10:30 am
❖ Switching of Antiepileptic Drugs and Seizure-Related Events after Refill Adjustment [279]
Joshua J Gagne, Jerry Avorn, William H Shrank, Sebastian Schneeweiss. (United States)
STUDENT AWARD RECIPIENT – THIRD BEST ABSTRACT

10:45 am
❖ Anticonvulsant Medications and the Risk of Suicide, Attempted Suicide, and Injury or Accident Related Death [280]
Elisabetta Patorno, Rhonda Bohn, Peter Wahl, Jerry Avorn, Amanda Patrick, Jun Liu, Sebastian Schneeweiss. (United States)

11:00 am
❖ Risk of Cataract in Patients with Multiple Sclerosis: A Population-Based Cohort Study [612]
S Müller-Schotte, M Bazelier, T P van Staa, HGM Leufkens, F de Vries. (Netherlands)
STUDENT PRIZE RECIPIENT – SECOND BEST ABSTRACT

11:15 am
❖ Use of Antidepressant Drugs and Risk of Osteoporotic and Non-Osteoporotic Fractures: Focus on the Affinity for the Serotonin Receptor [282]
Bertha Maria Verdel, Patrick C Souverein, Toine CG Egberts, Tjeerd P van Staa, Hubert GM Leufkens, Frank de Vries. (Netherlands)

11:30 am
❖ Risk of Bleeding with Combined SSRI and Antiplatelet Therapy in Patients Following Myocardial Infarction [283]
Christopher Labos, Kaberi Dasgupta, Elham Rahme. (Canada)

11:45 am
❖ Comparative Effectiveness of Antipsychotic Medications for the Treatment of Behavioral and Psychological Symptoms of Dementia [284]
Tobias Gerhard, Edmond S Malka, Judith Lucas, Krista Huybrechts, Sebastian Schneeweiss, Stephen Crystal. (United States)
Methods in Pregnancy Studies: Practical Applications
(Cambridge)
Moderators: Deborah Covington & Alicia Gilsenan

10:30 am
¢ Recording of Pregnancy Losses on the General Practice Research Database [285]
  Rachel Charlton, Julia Snowball, John Weil, Marianne Cunnington, Corinne de Vries. (United Kingdom)

10:45 am
¢ Drug Certainty-Response in Interview-Based Studies [286]
  Kuei-Yu Lin, Wai-Ping Yau, Allen A Mitchell, Sonia Hernández-Díaz. (United States)

11:00 am
¢ Maternal Use of Macrolide Antibiotics and the Risk of Congenital Heart Defects [287]
  Kuei-Yu Lin, Allen A Mitchell, Wai-Ping Yau, Sonia Hernández-Díaz. (United States)

11:15 am
¢ Validity of an Algorithm for the Identification of Premature Infants Using Medicaid Administrative Data [288]
  Efe Odia, Christian Hampp, Almut G Winterstein. (United States)

11:30 am
  Carl deMoor, Deborah Covington, Amanda Golembesky. (United States)

11:45 am
¢ Comparative Safety of Topiramate During Pregnancy [290]
  Sonia Hernandez-Diaz, Robert Mittendorf, Lewis B Holmes. (United States)

Answers

Wouldn’t it be wonderful if you always had the best information to help you take care of yourself?

If you could count on having reliable answers for those times when your health is a concern?

If you could be assured breakthrough medicines would continue to be sought?

We think that would be wonderful, too. And we’re working to make it happen.

Your good health is our passion.

lilly.com
AGENDA Saturday, August 21

Pharmacovigilance - Needles in Haystacks? (Balmoral)
Moderators: Andrzej Czarnecki, FISPE, & Marieke de Bruin

10:30 am
- Vaccine Signal Detection: A Pilot To Determine Effects of Varying Data Mining Strategies on VAERS [291]
  Steven R Bailey, Robert Azadian, Peter Huber. (United States)

10:45 am
  A Bauer-Mehren, E van Mulligen, P Avillach, P Coloma, R Garcia-Serna, R Herings, M Sturkenboom, S Boyer, F Sanz, J Mestres, J Kors, L Furlong. (Spain)

11:00 am
- Ongoing Monitoring in Active Surveillance: A Case Study in Performance of Observational Screening over Time [293]
  Patrick B Ryan, Gregory E Powell, Ed N Pattishall. (United States)

11:15 am
- Polyethylene Glycol and Acute Renal Failure in Elderly: Data-Mining Study Using National Health Insurance Claims Database [294]
  Nam-Kyong Choi, Yu-Kyong Choi, Sun-Young Jung, Yoosoo Chang, Ju-Young Kim, Hong-Ji Song, Joongyub Lee, Byung-Joo Park. (Republic of Korea)

Potpourri (Buckingham)
Moderators: Susana Perez Gutthann, FISPE, & Usha Gungabissoon

10:30 am
- Genetic Polymorphisms and the Development of Secondary Primary Cancers (SPC) in Patients with Head and Neck Cancer (HNC) [297]

10:45 am
- Race, Oxaliplatin Use, and Treatment Outcomes for Stage III Colon Cancer among Elderly Medicare Patients [298]
  Christina D Mack, William Carpenter, Til Stürmer. (United States)

11:00 am
- Can Tricyclic Antidepressant Use Explain the Observed Associations between Baseline Depressive Symptoms and Incident Hypertension? [299]
  Joseph AC Delaney, Bruce E Oddson, Holly Kramer, Steven Shea, Bruce M Psaty, Robyn L McClelland. (United States)

11:30 am
- Evaluation of a Proposed Classification System for Adverse Drug Reactions for Biologics Using The WHO-ADR Database VigiBase [295]
  Thijs Giezen, Aukje Mantel-Teeuwisse, Sabine Straus, Bert Leufkens, Toine Egberts. (Netherlands)

11:45 am
- The Contribution of Patient Reporting To Signal Detection in the Netherlands [296]
  Florence van Hunsel, Eugene van Puijenbroek, Kees van Grootheest. (Netherlands)

11:15 am
- Safety Profile of Thiazolidinediones on the Basis of the FDA-AERS Database: Cardiovascular and Bone Fracture Risks for Rosiglitazone and Pioglitazone [300]
  Domenico Motola, Elisabetta Poluzzi, Anna Marra, Chiara Biagi, Carlo Piccinni, Nicola Montanaro. (Italy)

11:30 am
- Risk of Fracture in Patients with Multiple Sclerosis: The General Practice Research Database [301]
  Marloes Bazelier, Tjeerd van Staa, Hubert Leufkens, Peter Vestergaard, Frank de Vries. (Netherlands)

11:45 am
- Patterns of Antipsychotic (APM) Initiation in US Nursing Homes [302]
  Judith A Lucas, Sujoy Chakravarty, John R Bowblis, Tobias Gerhard, Michele Siegel, Ece Kalay, Stephen Crystal. (United States)
Prescribing Problems in Older Persons (Clarence)
Moderators: Keith Beard, FISPE, & Kevin Haynes

10:30 am
* Drug Related Problems among Elderly Patients Using Five or More Chronic Drugs Who Are Discharged from the Hospital [303]
  Abeer Ahmad, Jacqueline Hugtenburg, Ruth Mast, Laura MC Welschen, Jacqueline M Dekker, Giel Nijpels. (Netherlands)

10:45 am
* Adverse Outcomes Associated with Potential Prescribing Cascades [304]
  Gillian Caughey, Elizabeth Roughhead, Nicole Pratt, Sepehr Shakib, Agnes Vitry, Andrew Gilbert. (Australia)

11:00 am
* Treatment with Cholinesterase Inhibitors May Increase the Risk of Urinary Incontinence [305]
  Edeltraut Kröger, Rob van Marum, Patrick Souverein, Pierre-Hugues Carmichael, Toine Egberts. (Netherlands)

11:15 am
* Use of Opioids or Benzodiazepines and Risk of Pneumonia in Older Adults [306]
  Sascha Dublin, Rod L Walker, Michael L Jackson, Jennifer C Nelson, Noel S Weiss, Michael Von Korff, Lisa A Jackson. (United States)

11:30 am
  Agnes I Vitry, Elizabeth E Roughead, Emmaye N Ramsay, Adrian K Preiss, Gillian E Caughey, Andrew L Gilbert, Philip Ryan. (Australia)

11:45 am
* A Randomized Trial of a Warfarin Management Protocol To Enhance Communication between Nursing Home Staff and Physicians: The SBAR Approach [308]
  Terry S Field, Jennifer Tjia, Kathleen M Mazor, Jennifer L Donovan, Abir O Kanaan, Leslie R Harrold, Peter Doherty, Ann Spenard, Jerry H Gurwitz, George Reed. (United States)

12:00-1:30pm
Lunch/Poster Session B/Exhibits
(Durham, Durham Gallery, Hall 7 & 8)

ISPE Committee Meetings
– Open to all participants.
– Lunches will be available in meeting rooms
  ◆ Bylaws and Policies Committee (Sandringham)
  ◆ External Communications Committee (Hilton 3)
  ◆ Global Development Committee (Lancaster)
  ◆ Membership Committee (Osborne)
  ◆ Publications Committee (Surrey 1)

12:45-1:30pm
Poster Walks (Durham/Hall 7)
◆ Biologic SIG
◆ Comparative Effectiveness Research SIG
◆ Database SIG
◆ Drug Utilization SIG
◆ Medicines in Pregnancy SIG
◆ Molecular Epidemiology - Biomarkers - Pharmacogenetics SIG

1:30-2:30pm
Plenary Session
Moderator: Bert Leufkens, FISPE, Chairman of the Dutch Medicines Evaluation Board & Professor of Pharmacoeconomics, University of Utrecht

Professor Jan P. Vandenbroucke, University of Leiden, The Netherlands (Oxford)
◆ Benefits and Risks of Drug Treatments: How to Combine the Best Evidence on Benefits with the Best Evidence on Harms?
AGENDA
Saturday, August 21

2:30-3:30pm
Annual Meeting of ISPE Members, Awards Ceremony (Oxford)

Annual Meeting of ISPE Members

※ Sebastian Schneeweiss, FISPE, ISPE President
※ Nancy Dreyer, FISPE, ISPE Vice President Finance

Awards Ceremony

ICPE 2010
Student Awards
※ Presented by Corinne S. de Vries, FISPE, Chair, 2010 Scientific Program Committee
Best Drug Utilization Abstract: Krista Huybrechts
Third Best Abstract: Joshua Gagne
Second Best Abstract: Sigrid Müeller-Schotte
Edlavitch Award (Best Student Abstract) & Oral Presentation:
Caitlyn T. Wilke, Sensitivity of Hazard Estimates to Exposure Definition: A Simulation Study (309)

Induction of ISPE Fellows (FISPE)

※ Sebastian Schneeweiss, FISPE, ISPE President
Inductees:
Corinne S. de Vries, FISPE  Susan Ann Oliveria, FISPE
Stephen JW Evans, FISPE  Miriam CJM Sturkenboom, FISPE
Kiyoshi Kubota, FISPE  Douglas J. Watson, FISPE
※ Miriam Sturkenboom, FISPE, Chair, Fellowship & Awards Committee
Honorary Lifetime Fellow
Ronald D. Mann, FISPE

Pharmacoepidemiology & Drug Safety
ISPE-PDS Prizes for Best Papers published in PDS Volume 18 (2009)
Brian Strom, FISPE, Editor-in-Chief
Joerg Hasford, Regional Editor for Europe
Richard Hughes, Managing Editor, Pharmacoepidemiology & Drug Safety (PDS)
Ronald Mann, FISPE, Founding Editor
Sean Hennessy, FISPE, Regional Editor for the Americas
B J Park, FISPE, Regional Editor for Asia, Africa, Oceania

Installation of New President

※ Stephen JW Evans, FISPE

3:30-4:00pm
Break/Posters/Exhibits (Durham & Hall 7)

4:00-5:30pm
Concurrent Sessions: Symposia And Workshops

Optimizing Global Vaccine Safety Monitoring: Lessons Learned from HINI [310] (Hall 4)
※ Jan Bonhoeffer, Miriam Sturkenboom, Xavier Kurz, Piotr Kramarz, Patrick Zuber, Hector Izurieta. (Switzerland)

Matching on Propensity Scores: Good Practices and New Directions [311] (Balmoral)
※ Jeremy A Rassen, Robert J Glynn, Mark Lunt, Kenneth Rothman. (United States)

Regulatory Risk Communication Are We Getting Ahead? [312] (Oxford)
※ P Mol, P Bahri, J Avorn, P Benkimoun, A Arias, E Morrat, G del Pan, F Haaijer-Ruskamp, S Straus. (Netherlands)

Role of Meta-Analysis in Drug Safety: Methodological Considerations and Regulatory Implications [313] (Buckingham)
※ Tarek Hammad, Simone P Pinheiro, David Irvine, Steven Kesten. (United States)

※ Yola Moride, Antoine Pariente, Anne Fourrier, Thierry Ducruet, Patrick Farrington. (Canada)

How Can Better Scientific Methods Result in Better Drug Regulation Two Recent Case Studies [315] (Clarence)
※ Marie L De Bruin, Stella Blackburn, Ingemar Persson, Jeremy Rassen, Lamiae Grimaldi. (Netherlands)

Evaluating Adverse Pregnancy Outcomes A Workshop To Develop an Inventory of Methodological Issues Related to Different Approaches [780] (Ambassador)
※ L de Jong-van den Berg, H Dolk, E Andrews, S Hernandez-Diaz, A Mitchell, C de Vries. (Netherlands)
Safety & Risk Management

UBC understands that the greatest risk is the unknown. We help clients assess, identify and plan for risk by developing and implementing Risk Evaluation and Mitigation Strategies (REMS), Risk Management Plans, epidemiology studies, registries and large simple safety studies globally. All of our solutions are designed and executed by industry-leading experts to assess and demonstrate product safety, mitigate risk and meet regulatory requirements.

UBC is a global scientific and medical affairs organization that partners with life science companies to develop and commercialize their products. We bring together scientific experts, research professionals and new technologies to generate authoritative, real-world evidence of product effectiveness, safety and value.
5:30-6:30pm
Special Interest Group (SIG) Meetings
–Open to all participants.

• Biologics SIG (Ambassador)
• Comparative Effectiveness Research SIG (Balmoral)
• Database SIG (Buckingham)
• Drug Utilization/Health Services Research SIG (Cambridge)
• Medications in Pregnancy SIG (Clarence)
• Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG (Dukes)

7:30-Midnight
Evening at the Corn Exchange/Brighton Dome

Early in their career, ABBA was looking for what every pop group is looking for: that one magic moment that would give them the boost needed to catapult them to rock stardom. They found it at the Brighton Dome during the Eurovision Song Contest (1974). As the final notes of their song "Waterloo" echoed through the packed auditorium, the Swedish group had officially arrived. They ultimately won the Eurovision Song Contest, achieving a stunning upset against favorite contender Olivia Newton-John. ABBA went on to become Sweden's most successful pop rock group, and continues to charm music lovers to this day. Join your colleagues to relive those golden moments with Abba's Angels – one of the UK's premier tribute bands!

–Admission is by badge or ticket. Cash bar

Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that bring population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:

- Analyzing the occurrence and distribution of diseases, including underlying disease process
- Determining the burden of illness and unmet medical need
- Exploring traditional and new risk factors for diseases
- Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug uses and adverse events
- Detecting opportunities for possible new drug uses and new paths of drug development

Please visit our website at http://epidemiology.gsk.com/organization.html to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

Developing talent through equality of opportunity
BAYER SCHERING PHARMA AG

Expanding it’s Epidemiology Organization around the World

Bayer Schering Pharma AG, division of Bayer HealthCare, is one of the ten largest specialty pharmaceutical companies in the world. We market our products in more than 100 countries, and generated total net sales of about € 10.5 billion in 2009.

More than 36,000 employees – with more than 5,800 of them in research and development – work for Bayer Schering Pharma around the world.

We aim to improve people’s quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches in four core areas: General Medicine, including oncology and cardiovascular diseases, Specialty Medicine, Women’s Healthcare and Diagnostic Imaging. In addition, our clinical development drives the introduction of new products as well as the further development of marketed products across all business areas. Our top 10 products are:

- YAZ® / Yasmin® / Yasminelle® (hormonal contraceptive)
- Betaferon®/Betaseron® (multiple sclerosis)
- Kogenate® (hemophilia)
- Adalat® (high blood pressure)
- Nexavar® (kidney and liver cancer)
- Mirena® (hormonal intrauterine delivery system for contraception)
- Avalox®/Avelox® (respiratory tract infections)
- Levitra® (erectile disfunction)
- Cipro®/Ciprobay (infectious diseases, especially of the urinary tract)
- Glucobay® (diabetes)

Our Global Epidemiology organization is currently expanding its team around the world. Opportunities for Global Epidemiology Directors and Professionals exist in Berlin, Beijing, and New Jersey. To learn more, visit at our booth no 26.

You can also contact: Melanie Wolff at +49 171 6222507 (melanie.wolff@bayerhealthcare.com) or Montse Soriano-Gabarro (montse.soriano-gabarro@bayerhealthcare.com)


Bayer is an equal opportunity employer, embracing diversity throughout our global workforce.
AGENDA
Sunday, August 22

7:30am-4:30pm
Registration
(Sussex Lounge)

7:30am-3:30pm
Speaker Ready Room (Office 1)

7:00-8:00am
Poster Session C Set-up
(Durham & Hall 7)

8:00am-1:45pm
Exhibits/Posters
(Durham & Hall 7)

8:30-10:00am
Concurrent Sessions: Contributed Papers

Bias and Confounding: Methods for Control Freaks
(Oxford)

8:30 am

Conceptualizing Confounding by Measured and Unmeasured Covariates in Pharmacoepidemiology with Directed Acyclic Graphs (DAGs) [500]
Aisling Raffrey, Kerry L Laplante, Brian J Quilliam. (United States)

8:45 am

Impact of Collider-Stratification Bias (M-bias) in Pharmacoepidemiologic Studies: A Simulation Study [501]
Wei Liu, M Alan Brookhart, Soko Setoguchi. (United States)

9:00 am

Simulating the Application of Propensity Scores Estimated in a Full Cohort To Adjust for Confounding in Subgroup Analyses [502]
Jeremy A Rassen, Robert J Glynn, Sebastian Schneeweiss. (United States)

Clotting or Bleeding
(Buckingham)

8:30 am

Risk of Venous Thromboembolism in Patients with Chronic Immune Thrombocytopenic Purpura (cITP) [506]
Marianne Tang Severinsen, Malene Cramer Engebjer, Mette Nørgaard, Sean Zhao, Henrik Toft Sørensen. (Denmark)

8:45 am

The Risk of Venous Thromboembolism in OC Users: Time Patterns after Initiation of Treatment [507]
Juergen Dinger, Thai Do Minh, Sabine Moehner. (Germany)

9:00 am

Use of NSAID, Aspirin, Acetaminophen, Statins and Risk of VTE in Women [508]
Annica Bergendal, Anders Sundström, Shahram Bahnmayar, Ingemar Persson, Helle Kieler. (Sweden)

9:15 am

Effect of Weight Trimming on IPW Estimates and Standard Errors: An Applied Analysis [503]
Michele Jonsson Funk, Jennifer S Fusco, Til Sturmer, Stephen R Cole. (United States)

9:30 am

New Method for Stabilizing the Variance of Instrumental Variable Physician Preference-Based Estimates of Treatment Effect [504]
Michal Abrahamowicz, Marie-Eve Beau-champ, Raluca Ionescu-Ifitu, Joseph AC Delaney. (Canada)

9:45 am

Modifying the High-Dimensional Propensity Score (hd-PS) Algorithm To Improve Small Sample Performance [456]
Jeremy A Rassen, Robert J Glynn, Sebastian Schneeweiss. (United States)

9:15 am

Drug Interactions with Phenprocoumon and the Risk of Serious Hemorrhage: A Nested Case-Control Study in a Large Population-Based German Database [509]
Kathrin Jobski, Sigrid Behr, Edeltraut Garbe. (Germany)

9:30 am

Diuretic Use and the Risk of Gastrointestinal Bleeding in the United Kingdom General Population [510]
Joseph AC Delaney, Alain Bitton, Samy Suissa. (United States)

9:45 am

Antiplatelet Medicine Prescribing and Subsequent Events Following Intracerebral Haemorrhage [511]
Robert W Flynn, Thomas M MacDonald, Gordon D Murray, Ronald S MacWalter, Alexander S Doney. (United Kingdom)
Compliance & Utilization I (Balmoral)
Moderators: Miriam Sturkenboom, FISPE & Deborah Layton

8:30 am
★ Appropriateness of Care after Myocardial Infarction in Cancer Survivors [512]
Winson Y Cheung, Mary McBride, Raisa Levin, Soko Setoguchi. (Canada)

8:45 am
★ Cost-Effective Proton Pump Inhibitor Prescribing: Potential Strategies for More Rational Prescribing [513]
Caitriona Cahir, Tom Fahey, Conor Teljeur, Lesley Tilson, Kathleen Bennett. (Ireland)

9:00 am
★ Antiplatelet Agents’ Effectiveness for Secondary Prevention of Ischemic Stroke [514]
Mi-Sook Kim, Ye-Jee Kim, Jong-Mi Seong, Nam-Kyong Choi, Byung-Joo Park. (Korea)

9:15 am
★ Placebo Adherence, Clinical Outcomes and Mortality in the Women’s Health Initiative Randomized Hormone Therapy Trials [515]
J R Curtis, J Larson, E Delzell, MA Brookhart, S Cadarette, R Chlebowski, S Judd, M Safford, D Solomon, A LaCroix. (United States)

9:30 am
★ Adherence to Gastroprotective Agents and the Risk of Upper Gastrointestinal Complications in NSAID Users [516]
E van Soest, V Valkhoff, G Mazzaglia, R Schade, M Molokhia, J Dieleman, M Sturkenboom. (Netherlands)

9:45 am
★ Low Income Workers Face the Largest Cost Burden for Prescription Medicines in Australia [517]
Anna Kemp, Elizabeth E Roughead, David B Preen, John Glover, James Semmens. (Australia)

Outcomes After Prenatal Exposure: Causes Versus Biases
(Cambridge)
Moderators: Susan Roberts & Elizabeth Andrews, FISPE

8:30 am
★ Systemic Immunosuppressive Drug Use During Pregnancy May Be Associated with Preeclampsia [518]
Kristin Palmsten, Sonia Hernández-Díaz, Daniel H Solomon, Soko Setoguchi. (United States)

8:45 am
★ Maternal Use of Antibiotics and the Risk of Oral Facial Clefts: A Nationwide Danish Cohort Study [519]
Ditte Mølgaard-Nielsen, Anders Hviid. (Denmark)

9:00 am
★ Maternal Exposure to Amoxicillin and the Risk of Oral Clefts [520]
Kuei-Yu Lin, Allen A Mitchell, Wai-Ping Yau, Sonia Hernández-Díaz. (United States)

9:15 am
★ Prenatal Exposure to Decongestants and the Risk of Pyloric Stenosis [521]
Wai-Ping Yau, Allen A Mitchell, Kuei-Yu Lin, Sonia Hernández-Díaz. (United States)

9:30 am
★ Phthalates in Drugs and Male Genital Malformations [522]
Sonia Hernandez-Diaz, Russ Hauser, Allen A Mitchell. (United States)

9:45 am
★ The Impact of Methadone Maintenance Treatment During Pregnancy on Perinatal Outcomes [523]
Brian J Cleary, Jean Donnelly, Judith Strawbridge, Paul J Gallagher, Tom Fahey, Deirdre J Murphy. (Ireland)
Pharmacovigilance - Real or Fool's Gold
(Clarence)
Moderators: Suzie Seabroke & Anita Assmann

8:30 am
✦ Postlicensure Safety Monitoring of Pandemic A/H1N1 Vaccine — Taiwan, November 1, 2009–January 7, 2010 [524]
  Wan-Ting Huang, Wen-Wen Chen, Chia-Ping Su, Huai-Te Tsai, Angela S Huang, Yu-San Chien, Yen-Nan Chao, Jen-Hsiang Chung. (Taiwan)

8:45 am
✦ Adverse Drug Reactions to Antiretroviral Therapy (ART) Identified by Intensive Monitoring at an ART Centre in India [525]
  Pathasarathi Gurumurthy, Retty R Modayil, Anand Harugeri, Madhan Ramesh, S Rajendra Prasad. (India)

9:00 am
✦ Delays in the Detection of Signals of Serious Adverse Events Due to the Inclusion of Non-Serious Adverse Event Reports in Analyses [526]
  Keith L. Altman. (United States)

9:15 am
✦ Pharmacovigilance Data Mining with False Discovery Rate Based Methods: A Comparative Simulation Study [527]
  Ismail Ahmed, Frantz Thiessard, Ghada Miremont-Salamé, Bernard Bégaud, Pascale Tubert-Bitter. (United Kingdom)

9:30 am
✦ Impact of Drug Product Litigation on Safety Signal Detection in AERS [528]
  G Gipson, R Schaaf, W DuMouchel, R Valentino, A Wisniewski. (United States)

9:45 am
✦ Early Indicators of Drug Dependence [529]
  Ola Caster, Anna Kindlundh-Högberg, Johan Hopstadius, G Niklas Norén. (Sweden)

Stimulating Findings from Medicine Use in Children (Dukes)
Moderators: Jesper Hallas & Tamar Lasky

8:30 am
✦ Use of Antipsychotic Medications in US Youth, 2001-2007 [530]
  Stephen Crystal, Tobias Gerhard, Cecilia Huang, Mark Olfson. (United States)

8:45 am
✦ Payer Source & Atypical Antipsychotic (AP) Use in Pediatric Inpatients [531]
  Shirley Wang, Tamar Lasky, Frank R Ernst, Jay Greenspan, Liliana Gonzalez. (United States)

9:00 am
✦ Methylphenidate Treatment in Germany – Are Co-Morbidities Taken into Account? [532]
  Christina Lindemann, Kraut Angela, Langner Ingo, Mikolajczyk Rafael, Garbe Edeltraut. (Germany)

9:15 am
✦ Incidence of Epilepsy and Anti-Epileptic Drug (AED) Prescribing in Children in the UK [533]
  W H Meeraus, R Gilbert, R F Chin, I Petersen. (United Kingdom)

9:30 am
✦ Stimulant Prescription and Risk of Injury among Children with Attention Deficit Hyperactivity Disorder (ADHD) in the United Kingdom (UK): Preliminary Results [534]
  Sudha R Raman, Stephen W Marshall, Til Stürmer. (United States)

9:45 am
✦ Use of Stimulants Following the Public Discussion and Regulatory Actions on ADHD Drug’s Cardiovascular Safety [116]
  CY Chen, Almut Winterstein. (United States)

10:00-10:30 am
Break/Posters/Exhibits (Durham & Hall 7)
AGENDA  Sunday, August 22

10:30-Noon

Concurrent Sessions: Contributed Papers

Analysis Methods - The Details that Bedevil Us (Oxford)

Moderators: John Seeger & Alec Walker, FISPE

10:30 am
- Using Inverse Probability Weighting To Estimate Warfarin Adverse Effects: Concerns with Large and Variable Inverse Probability Weights [536]
  Joseph AC Delaney, Robert W Platt, Samy Suissa. (United States)

10:45 am
- Evaluating a Hybrid Self Controlled Analysis Method [537]
  Shirley Wang, Crystal Linkletter, David Dore, Malcolm Maclure, Vincent Mor, Stephen Buka. (United States)

11:00 am
- A Comparison of Statistical Approaches for Clustered Pharma-coepidemiology Data with Survival Outcomes [538]
  Margaret R Stedman, David R Gagnon, Robert A Lew, Elena Losina, Daniel H Solomon, M Alan Brookhart. (United States)

11:15 am
- Treatment Effects in Frail Patients: A Simulation Study of Treatment Contrary to Prediction [539]
  Til Stürmer, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)

11:30 am
- Self-Controlled Case Series and Prescription Event Symmetry Analysis: How Different Are They Really? [540]
  Nicole L Pratt, Libby E Roughead, Robert Peck, Gilbert Andrew. (Australia)

11:45 am
- Effects of Cox-2 Selectivity NSAID Groupings in UGIB and MI ADR Substantiation Using Bayesian Hierarchical Modeling: Comparison of IPCI and PHARMO Databases: EU-ADR Project [541]
  D Prieto, M Molokhia, S Evans, M Schuemie, R Herings, J van der Lei, M Sturkenboom. (United Kingdom)
Atypical Prescribing in Older People (Balmoral)
Moderators: Jerry Gurwitz & Jamie Robinson

10:30 am
Psychotropic Drug Use in the Elderly across Europe: A Perspective from the EU-ADR Project [542]
Preciosa Coloma, Gianluca Trifirò, Martijn Schuemie, Rosa Gini, Ron Herings, Julia Hippisley-Cox, Giampiero Mazzaglia, Giovanni Corrao, Lars Pedersen, Johan van der Lei, Miriam Sturkenboom. (Netherlands)

10:45 am
Explained Variation in Antipsychotic Medication Prescribing in Patients Admitted to Nursing Homes [543]
Krista Huybrechts, Kenneth J Rothman, M Alan Brookhart, Rebecca Silliman, Stephen Crystal, Sebastian Schneeweiss. (United States)

11:00 am
Student Award Recipient: Best Methods Abstract
Antipsychotic Use and the Risk of Diabetes in Older Adults with Dementia [544]
Jessica J Jalbert, Lori A Daiello, Charles B Eaton, Susan C Miller, Kate L Lapan. (United States)

11:15 am
Suicidality Assessment in Placebo-Controlled Studies of Ziprasidone [104]
Onur N Karayal, Susan D Anway, Evan Batzar, Douglas G Vanderburg. (United Kingdom)

11:30 am
Comparison of Different Approaches to Confounding Adjustment in a Study on the Effect of Antipsychotic Medication on Mortality in Elderly Nursing Home Patients [448]
Krista Huybrechts, M Alan Brookhart, Kenneth J Rothman, Rebecca Silliman, Tobias Gerhard, Sebastian Schneeweiss. (United States)

11:45 am
Did the US FDA Black Box Advisory Reduce Use of Antipsychotics for Dementia? [547]
Tami L Mark, Suellen Curkendall. (United States)

Cardiovascular (Cambridge)
Moderators: Tom MacDonald, FISPE & Klaas Heinemann

10:30 am
Long-Term Active Surveillance Study for Oral Contraceptives (LASS): Impact of Oral Contraceptive Treatment on the Start of Antihypertensive Treatment [548]
Juergen Dinger, Anita Assmann, Sabine Moehner. (Germany)

10:45 am
Lipid Lowering Agents and Non-Traumatic Tendon Rupture [549]
Elizabeth V Lawler, Jennifer R Fonda, Soe Soe Thwin, J Michael Gaziano, Mary T Brophy, David R Gagnon. (United States)

11:00 am
The Cost-Effectiveness of Using Statins To Treat Patients with Elevated C-Reactive Protein and Normal Cholesterol Levels [550]
Niteesh K Choudhry, Amanda R Patrick, Robert J Glynn, Jerry Avorn. (United States)

11:15 am
Impact of Allopurinol Use on Urate Concentration and Cardiovascular Outcome [551]
Li Wei, Isla S Mackenzie, Yang Chen, Allan D Struthers, Thomas M MacDonald. (United Kingdom)

11:30 am
Comparative Effectiveness of Angiotensin Receptor II Blockers (ARBs) vs. Angiotensin-Converting Enzyme Inhibitors (ACEIs) in Hypertensive Elderly Patients with Cardiovascular Comorbidities [552]
Soko Setoguchi, William H Shrank, Jun Liu, Helen Mogun, Wolfgang C Winkelmayr, Nancy A Dreyer. (United States)

11:45 am
Associations between Anti-Retroviral Drug Use and HIV-Specific Risk Factors with Carotid Intima-Media Thickness: The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) [553]
Joseph AC Delaney, Rebecca Scherzer, Mary L Biggs, Michael G Shlipak, Joseph F Polak, Judith S Currier, Daniel O’Leary, Phyllis Tien, Christine Wanke, Richard A Kronmal, Peter Bacchetti, Carl Grunfeld. (United States)
**Compliance & Utilization II (Buckingham)**
Moderators: Frank May, FISPE & Amanda Golembesky

10:30 am
- Magnitude and Determinants of Off-Label Prescribing in Primary Care [554]
  Tewodros Eguale, Andrea Benedetti, James A Hanley, David L Buckeridge, Robyn Tamblyn. (Canada)

10:45 am
- Adherence Rates and Predictors of Early Termination to Niacinamide [555]
  Jennifer B Christian, Vincent Rabatin. (United States)

11:00 am
- Adherence to Cardiovascular Medications after Myocardial Infarction in Cancer Survivors [556]
  Winson Y Cheung, Mary McBride, Raisa Levin, Soko Setoguchi. (Canada)

11:15 am
- The Prevalence and Cost of Unapproved Uses of Orphan Drugs [23]
  Aaron Kesselheim, Daniel Solomon, Wolfgang Winkelmann, Raisa Levin, Jerry Avorn. (United States)

11:30 am
  Jose Guerreiro, Carla Torre, Suzete Costa. (Portugal)

11:45 am
- Incidence of Statin Use before and after Restricting Reimbursement in Iceland [559]
  Gudrun Thengilsdóttir, Ingunn Björnsdóttir, Anna B Almarsdóttir. (Iceland)

**Pediatric Potpourri (Dukes)**
Moderators: Allen Mitchell, FISPE & Kourtney Davis

10:30 am
- Rates of Spontaneous Reports of Adverse Drug Reactions in Children [560]
  Susanna M Wallerstedt, Gertrud Brunlöf, Anders Sundström. (Sweden)

10:45 am
- Comparing the Mortality Risk of Exposure in Children to Different Opioids [561]
  Paul M Coplan, J David Haddox. (United States)

11:00 am
- Determinants of Uncontrolled Asthma at Age 8: The Importance of Parental Perception towards Medication Use [562]
  Ellen S Koster, Gerard Koppelman, Alet Wijga, Dirkje Postma, Maarten Hoekstra, Johan de Jongste, Henriette Smit, Jan Raaijmakers, Anke-Hilse Maitland-van der Zee. (Netherlands)

11:15 am
- Anti-Inflammatory Asthma Therapy Adherence in Paediatric Patients: The PACMAN Cohort Study [563]
  Ellen S Koster, Jan A Raaijmakers, Anke-Hilse Maitland-van der Zee. (Netherlands)

11:30 am
- Claims Algorithms To Quantify Use of Live Attenuated Influenza Vaccine among Non-Recommended Children [564]
  Pat Tennis, Elizabeth Andrews, Seth Toback, Chris Ambrose, Lisa McQuay, Matthew Rous culp. (United States)

11:45 am
- Antibacterial Drugs and the Risk of Community-Associated Methicillin Resistant Staphylococcus Aureus (C-MRSA) in Children [565]
  Verena Schneider-Lindner, Caroline Quach, James A Hanley, Samy Suissa. (Canada)
AGENDA  Sunday, August 22

Random Women (Clarence)
Moderators: Lolkje de Jong-van den Berg & Maureen Cronin

10:30 am
Maternal Use of Proton Pump Inhibitors (PPI) during Pregnancy Is Associated with an Increased Risk for Cardiac Birth Defects: Analysis of 208,951 Pregnancies from the THIN Database [566]
Andrew D Rhim, Kevin Haynes, Janet R Hardy, Jeffery M Testani, Yu-Xiao Yang. (United States)

10:45 am
Clomiphene Citrate and Birth Defects, National Birth Defects Prevention Study 1997-2005 [567]
Jennita Reefhuis, Margaret A Honein, Laura A Schieve, Sonja A Rasmussen. (United States)

11:00 am
Utilisation of Endocrine Therapy in Women with Breast Cancer in Australia [568]
Agnes I Vitry, Loc Thai, Christine Lu. (Australia)

11:15 am
Differences in Drug Utilization of Oral Contraceptives in the US and Europe [569]
Kristina Bardenheuer, Juergen Dinger, Thai Do Minh, Christian Franke, Janko Leddin. (Germany)

11:30 am
Adolescent and Young Adult Women’s Use of Emergency Contraception [570]
Sharon Hensley Alford, Rachel E Lappin, Karen E Wells, Amanda R Barone, Marianne Ulcickas Yood, Vanessa K Dalton. (United States)

11:45 am
Unintended Pregnancies in Women Using Intrauterine Devices: Results from the EURAS-IUD Study [571]
Juergen Dinger, Clare Barnett, Sabine Moehner, Anita Assmann. (Germany)

Noon-1:30pm
Lunch/Poster Session C/Exhibits
(Durham, Durham Gallery, Hall 7 & 8)

Roundtable Discussions - TBA

ISPE Board of Directors Luncheon
(Ambassador)
(Meeting open to all members; check with staff if you wish to attend)

1:30-3:00pm

Concurrent Sessions: Symposia And Workshops

Lessons Learned from Collaboration among EU Biologics Registries in Rheumatology [572] (Hall 4)
William G Dixon, Margaret Richards, Johan Askling, Hans Petri, Syed R Ahmad. (United States)

The Industry-Academic Nexus: Experiences, Perspectives, and Suggestions for Enhancing Research Relationships [573] (Cambridge)
Jerry L Avorn, Sara A Ephross, Allen A Mitchell, Walter L Straus. (United States)

The Alternate Life of Regulators [574] (Oxford)
Stella CF Blackburn, Peter Arlett, Xavier Kurz, Henry Fitt. (United Kingdom)

Rare Diseases: Unmet Medical Needs, Epidemiology and Regulatory Considerations [576] (Dukes)
Wei Dong, Judith Jones, Joanna Haas, Michael Taylor, Pavel Napalkov. (United States)

Linking Administrative and Electronic Medical Record Databases Using Hybrid Probabilistic and Deterministic Techniques [577] (Balmoral)
Erica Danielson, Stella Chang, Daniel Huse. (United States)

Challenges and Opportunities in Shaping Medical Device Epidemiology [781] (Buckingham)
Danica Marinac-Dabic, Art Sedrakyan, Mary E Ritchey, Sharon-Lise Normand, Frederic Resnic. (United States)

Observed vs Expected Methodologies in Vaccine Safety Surveillance [782] (Clarence)
June Raine, Martin Kulldorff, Stephen Evans, Suzie Seabroke, Vincent Bauchau. (United Kingdom)
Even after more than a century of experience, we remain intensely curious.
For the sake of future generations.

Boehringer Ingelheim has always remained true to its character as an independent family-owned company. Our vision drives us forward. It helps to foster value through innovation in our company and to look to the future with constantly renewed commitment and ambition. Today, we operate globally with 142 affiliated companies in 50 countries. With more than 41,500 employees worldwide and a track record built up in nearly 125 years, we are continuously dedicated to improving the outlook for a healthier life.

Global epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real life settings. Would you like to join our epidemiological research group? Please send a fax to us indicating your interest. Fax: +49 (6132) 72-93367
www.boehringer-ingelheim.com
Overview

Poster sessions are designed to give presenters an opportunity to informally discuss their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

Poster Session

Posters will be displayed in the Durham Room of the Hilton Metropole, August 20-22. Each day will have a separate poster session. All posters for a specific day’s session must be removed that day.

- **Friday, August 20** .................Poster Session A
- **Saturday, August 21** ...............Poster Session B
- **Sunday, August 22** .................Poster Session C

1. **Set Up:**
   - 7:00am-8:00am; all posters must be in place by 8:00am. The poster sessions will be held in the Durham Room and Exhibit Hall 7.

2. **Hours:**
   - Posters will be displayed from 7:30am-6:00pm on Friday; 8:00am-6:00pm on Saturday, and 8:00am-1:45pm on Sunday.

3. **Discussion Time:**
   - **General:** Presenters should be at their posters between 12:15-1:15pm.
   - **Poster Walks:** organized by the ISPE Special Interest Groups (SIG).
     - **Saturday, August 21, 12:45-1:30pm.** Poster walks offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience.

   **There will be poster walks for:**
   - Biologics
   - Drug Utilization/Health Services Research
   - Comparative Effectiveness Research
   - Databases
   - Medicines in Pregnancy
   - Molecular Epidemiology/Biomarkers/Pharmacogenetics

**Poster walk presenter:**

Be at your poster 12:45-1:30pm
When the poster walk chair and audience stop at your poster, please give a brief, 3-minute presentation and be prepared to answer questions about your research.

**Poster Prizes:**

A group of judges will select the best posters of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The best posters will be announced and prizes awarded during The Final Session at 4:30pm, August 22.

4. **Take Down:**

All posters must be taken down by 6:30pm on Friday and Saturday, and by 5:00pm on Sunday.

Numbering System

- Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the **Final Program**, which will be available at the ISPE Registration Desk (Sussex Lounge). The poster number is the first number listed. Please note the number may differ from that shown in the preliminary program. The abstract number is for use locating abstracts in the **Final Program** and the special issue of Pharmacoepidemiology and Drug Safety, is in brackets [ ] after the title of the abstract.

Poster Specifications

1. Posters must be designed to fit a free-standing poster board 3 feet WIDE x 5 feet HIGH (90 cm wide x 150 cm high) PORTRAIT. Posters may be mounted using Velcro tape; please bring your own supplies.
   - Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board.

2. Posters may be attached to the boards using Velcro. All poster presenters are encouraged to bring their own supplies.

3. **Disclosure Statement**

A disclosure statement must accompany each abstract submission and each presentation. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before ICPE 2010. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed. Potential conflicts must be listed on the poster in a type size consistent with the rest of the poster.
Antimicrobial Use: Main Indications and Characteristics [45]  
Veronika J Wirtz, Jonneke Verdijk, Katja Doro, Gyongyver Soos. (Hungary)

Utilization of Antithrombotic Agents after Major Orthopedic Surgeries in Southern Taiwan [56]  
Li-Chia Chen, Yu-Ying Yu, Hsu-Wei Er Chan, Jin-Song Wu. (Taiwan)

Risk of Subarachnoid Hemorrhage Associated with Outpatient Anticoagulant Use [54]  
Sigrid Behr, Edeltraut Garbe. (Germany)

Analysis of Aranesp Patient Exposure for Cancer Indications Using 2 Existing Databases [55]  
Fei Xue, David Quach, Greg Hess, Daniel Blaney, Julie Moloney, Victor Gastanaga, Jason Yuan, Scott Stryker, Gail Hughes, Cristina Damatarca, Sean Zhao. (United States)

Cardiovascular Drug Use in Patients Hospitalized with a First-Time Myocardial Infarction in Sweden [53]  
Andreas Leimanni, Michael Fored, Niklas Hammar, Helena Schröder, Björn Wettermark. (Sweden)

Risk of Osteoporosis and Esophageal Cancer among Diabetes and Immune Thrombocytopenic Purpura (cITP) [53]  
Mette Nørgaard, Annette Østergaard Jensen, Malene Cramer Engebjerg, Sean Zhao, Henrik Toft Sørensen. (Denmark)

Effectiveness and Safety of Bevacizumab (BV)+FOLFIRI as 1st-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study [64]  
A Fourrier-Reglat, M Rayer, J Benichou, A Balestra, M A Bernard, A Grelaud, D Smith, A Ravault, N Moore, and the ETNA Group. (France)

Cardiototoxicity and Other Adverse Events Associated with Mitoxantrone Treatment for Multiple Sclerosis [65]  
Elaine Kingwell, Markus Koch, Bonnie Leung, Saul Isserow, Jane Geddes, Peter Rieckmann, Helen Tremlett. (Canada)

Utilization of Antithrombotic Agents in Hip Replacement: ETNA Cohort Study [65]  
Mette Nørgaard, Annette Østergaard Jensen, Malene Cramer Engebjerg, Sean Zhao, Henrik Toft Sørensen. (Denmark)

Utilization of Non-Steroidal Anti-Inflammatory Drugs and Risk of Re-Operation Due to Bleeding after Breast Cancer Surgery: A Danish Population Based Cohort Study [50]  
Deirdre Cronin-Fenton, Timothy L Lash, Heidi Hundborg, Henrik T Sørensen. (Denmark)

Intestinal Perforation (GIP), Fistula, and Abscess among Ovarian Cancer Patients [57]  
Michael Taylor, Wei Dong, Laura Chu. (United States)

Use of Non-Steroidal Anti-Inflammatory Drugs and Risk of Re-Operation Due to Bleeding after Breast Cancer Surgery: A Danish Population Based Cohort Study [50]  
Deirdre Cronin-Fenton, Timothy L Lash, Heidi Hundborg, Henrik T Sørensen. (Denmark)

Risk of Lung Cancer in Users of Estradiol/Dydrogesterone or Other HRT Preparations [60]  
Carmela Schneider, Susan S Jick, Christoph R Meier. (Switzerland)

Phenprocoumon Exposure and Risk of Intracerebral Bleeding [51]  
Sigrid Behr, Frank Andersohn, Edeltraut Garbe. (Germany)

Adverse Drug Reactions Induced by Antineoplastic Agents in Hospitalized Patients [59]  
Kheirollah Gholami, Mahdieh Fazlolahi, Sanambar Sadighi, Gloria Shalviri. (Islamic Republic of Iran)

Risk of Subarachnoid Hemorrhage Associated with Outpatient Anticoagulant Use [54]  
Sigrid Behr, Edeltraut Garbe. (Germany)

Aranesp Patient Exposure for Cancer Indications Using 2 Existing Databases [55]  
Fei Xue, David Quach, Greg Hess, Daniel Blaney, Julie Moloney, Victor Gastanaga, Jason Yuan, Scott Stryker, Gail Hughes, Cristina Damatarca, Sean Zhao. (United States)

Risk of Osteoporosis and Esophageal Cancer among Diabetes and Immune Thrombocytopenic Purpura (cITP) [53]  
Mette Nørgaard, Annette Østergaard Jensen, Malene Cramer Engebjerg, Sean Zhao, Henrik Toft Sørensen. (Denmark)

Effectiveness and Safety of Bevacizumab (BV)+FOLFIRI as 1st-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study [64]  
A Fourrier-Reglat, M Rayer, J Benichou, A Balestra, M A Bernard, A Grelaud, D Smith, A Ravault, N Moore, and the ETNA Group. (France)

Cardiototoxicity and Other Adverse Events Associated with Mitoxantrone Treatment for Multiple Sclerosis [65]  
Elaine Kingwell, Markus Koch, Bonnie Leung, Saul Isserow, Jane Geddes, Peter Rieckmann, Helen Tremlett. (Canada)
<table>
<thead>
<tr>
<th>Poster Session A</th>
<th>Friday, August 20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>29</strong></td>
<td>Risk Profile and OC Utilization Patterns of Women Enrolled in INASCORE [71]</td>
</tr>
<tr>
<td>Kristina Bardenheuer, Clare A Barnett, Juergen Dinger, Christian Franke. (Germany)</td>
<td></td>
</tr>
<tr>
<td><strong>30</strong></td>
<td>Compliance with Antihypertensive Agents and the Onset of End-Stage Renal Disease [72]</td>
</tr>
<tr>
<td>Miriam Lessard, Louise Roy, Alice Dragomir, Sylvie Perreault. (Canada)</td>
<td></td>
</tr>
<tr>
<td><strong>31</strong></td>
<td>The Safety of Oral Hormone Replacement Therapy: Interim Results from the EURAS-HRT Study [73]</td>
</tr>
<tr>
<td>Anita Assmann, Klaas Heinemann, Juergen Dinger. (Germany)</td>
<td></td>
</tr>
<tr>
<td><strong>32</strong></td>
<td>Trends in Statin Prescription in the UK 2002-2008 – Demographics and Determinants of Non-Adherence [74]</td>
</tr>
<tr>
<td>Jakob Petersen, David Irvine, Lesley Wise. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td><strong>33</strong></td>
<td>Abstract Withdrawn by Author [75]</td>
</tr>
<tr>
<td><strong>34</strong></td>
<td>Prescription Trends for Dopamine Agonists in UK Primary Care – The Influence of Safety Alerts Concerning Valvular Heart Disease [76]</td>
</tr>
<tr>
<td>René Schode, Jeanne P Dieleman, Miriam C Sturkenboom. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td><strong>35</strong></td>
<td>Aspirin Use in Elderly with Type 2 Diabetes: Effects on Myocardial Infarction and Gastro-Intestinal Bleeding [77]</td>
</tr>
<tr>
<td>Caroline Siros, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)</td>
<td></td>
</tr>
<tr>
<td><strong>36</strong></td>
<td>Cohort Description of the Drug-Induced Arrhythmia Risk Evaluation (DARE) Study [78]</td>
</tr>
<tr>
<td>Vanessa Marshall, Elijah Behr, Victoria Cornelius, Saad Shakir, John Camm. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td><strong>37</strong></td>
<td>Prescribing Patterns of Antihypertensive Drugs in 78000 Incident Users [79]</td>
</tr>
<tr>
<td>Randi Selmer, Hege S Blix, Knud Landmark, Aasmund Reikvam. (Norway)</td>
<td></td>
</tr>
<tr>
<td><strong>38</strong></td>
<td>Discontinuation Rates of Statins Vary If Different Calculation Methods Are Used [80]</td>
</tr>
<tr>
<td>Harm CJ Geers, Marcel L Bouvy, Rob Heerdink. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td><strong>39</strong></td>
<td>Comparison of Cardiovascular Risk Factors and Survival in Patients with Ischemic or Hemorrhagic Stroke [81]</td>
</tr>
<tr>
<td>Karin M Henriksson, Bahman Frahmand, Signild Åsberg, Nils Edvardsson, Andreas Terén. (Sweden)</td>
<td></td>
</tr>
<tr>
<td><strong>40</strong></td>
<td>Comparison of Discontinuation of Pioglitazone Versus Rosiglitazone Utilization after Discordant Safety Concerns [82]</td>
</tr>
<tr>
<td>Cat N Bui, Paul Godley, James Wilson, Karen Rascati. (United States)</td>
<td></td>
</tr>
<tr>
<td><strong>41</strong></td>
<td>A Randomized Controlled Trial of the Effect of a Pharmaceutical Care Program on Improving Adherence to Statin Therapy: The Statin Intervention Research Project (STIPT) [83]</td>
</tr>
<tr>
<td>Simone Eussen, Menno van der Elst, Olaf Klungel, Cathy Rompelberg, Johan Garssen, Marco Oosterveld, Anthonius de Boer, Johan de Gier, Marcel Bouvy. (Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>

**Information on the LA-SER booth:**

- PGRx systematic case-control information system
- Multipurpose cohort studies for relative benefit/risk assessment
- Patient Reported Outcomes and Use of Drugs capabilities

**ALSO IN POSTER AND ORAL PRESENTATIONS DURING THE MEETING**

www.la-ser.com
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Location/Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>42</td>
<td>Regional Variation in Use of Secondary Prevention Medications among Medicare Part D Enrollees after an Acute Myocardial Infarction [84]</td>
<td>Nancy E. Morden, Gregory A. Roth, Weiping Zhou, Jonathan A. Skinner.</td>
<td>(United States)</td>
</tr>
<tr>
<td>43</td>
<td>Abstract Withdrawn by Author [85]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Medication Non-Adherence Affects Treatment Intensification for Hyperglycaemia but not for Hypertension [86]</td>
<td>Petra Denig, Jago Voorham, Bruce HR Wolfenbuttel, Ronald P. Stolk, Flora M Haoijer-Ruskamp.   (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Abstract Withdrawn by Author [87]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Recruitment Strategy for Genetic Data Collection: The UK General Practice Research Database [88]</td>
<td>Efrasini Setakis, Frank de Vries, Munir Pirmohamed, Tjierd-Pieter van Staas.</td>
<td>(United Kingdom)</td>
</tr>
<tr>
<td>47</td>
<td>Using Laboratory Data To Supplement Claims Data To Improve Control of Confounding in Studies of Treatment Effects [89]</td>
<td>S Schneeweiss, JA Rassen, J Avorn, DH Solomon, SY Kim, G Daniel, RJ Rothman, J Liu, RJ Gynn.</td>
<td>(United States)</td>
</tr>
<tr>
<td>48</td>
<td>Risk of Circulatory Disorders among Patients with Asthma in a Large Integrated Health Care Delivery System [90]</td>
<td>Carla Isbrarson, Irina Tolstykh, Mary K Miller, Mark D Eisner.</td>
<td>(United States)</td>
</tr>
<tr>
<td>49</td>
<td>Statistical Models for the Comparison of the Average Per-Patient Cost of Lower Limb Osteoarthritis with or without Spa Therapy [91]</td>
<td>P Blin, C Toussaint, R Lassalle, S Lignot, F Hamoud, A Abouelfath , J Benichou, JL Demeaux, C Garreau, C Ohayon-Courtes, T Schaeverbeke, M Vray, N Moore. (France)</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Drugs Inducing DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): The RegiSCAR Experience [92]</td>
<td>Sylvia H Kardaun, Peggy Sekula, Majo Mockenhaupt, Jean-Claude Roujeau.</td>
<td>(Netherlands)</td>
</tr>
<tr>
<td>52</td>
<td>Lymphoma Case Ascertainment in the US Pharmetrics Database [94]</td>
<td>Eulogio Conde, Charles W Wentworth, Elena Rivero, Alejandro Arana.</td>
<td>(Spain)</td>
</tr>
<tr>
<td>53</td>
<td>Serum Sodium Concentration Monitoring and Hyponatraemia in Thiazide-Treated Patients [95]</td>
<td>Sarah E McDowell, Jamie J Coleman, Stephen JW Evans, Rabin E Ferner. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Generic Substitution in a Cohort of Swedish Patients with Heart Failure [96]</td>
<td>Chamlin Nouri, Bjorn Wettermark, Morten Andersen, Anders Sundström, Karin Söderberg, Ulf Bergman.</td>
<td>(Sweden)</td>
</tr>
<tr>
<td>57</td>
<td>Drug-Drug Interactions: Theoretical or Clinically Relevant? [99]</td>
<td>Gabriella Martha, Peter Doro, Ria Benko, Ilona Higyisan, Maria Matuz, Gyongyver Soos. (Hungary)</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Comprehensive Survival Analysis of a Cohort of Patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [100]</td>
<td>Peggy Sekula, Yvonne Liss, Sylvia H Kardaun, Jean-Claude Roujeau, for the RegiSCAR-Study Group. (Germany)</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>Risk of Hepatotoxicity-Related Hospitalizations among Patients Treated with Opioid/Acetaminophen Combination Prescription Pain Medications [101]</td>
<td>Mei-Sheng Duh, Francis Vekeman, Caroline Korves, Patrick Lefebvre, Ellison Dial, Dominick Latremouille-Viav, Robert S Wei, Bruce E Stangle, Marie-Helene Lafeuille, Edward Michna, Paul E Greenberg.</td>
<td>(United States)</td>
</tr>
<tr>
<td>60</td>
<td>High Degree of Co-Medication of Benzodiazepines in Norway [102]</td>
<td>Marte Handal, Svetlana Skurtveit, Jørgen Marland (Norway)</td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>A Comparison of Opioid Use Patterns in Medicare, Medicaid, and a National Prescription Tracker Service [103]</td>
<td>Fatmatta Kuyateh, Hina Mehta, Rita Ouellet-Hellstrom, Farzana Ali, Emily Singer, Thomas E MaCurdy, David J Graham. (United States)</td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>Patterns and Predictors of Pharmacotherapy after Hospitalization for Major Depression [105]</td>
<td>Jennifer Lund, Stacie Dusetzina, Bradley Goynes, Richard Hansen, Michele Jonason Funk. (United States)</td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>Patients’ Value of Benefits and Harms of Migraine Treatments [106]</td>
<td>Paul M Coplan, Brett A Hauber, Ateessa Mohamed, Reed F Johnson, Bennett Levitan. (United States)</td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>Antiepileptic Drug Use during Pregnancy: Perinatal Outcomes with Monotherapy, Polytherapy, or Discontinuation of Treatment [107]</td>
<td>Sophie Kulaga, Odile Sheehy, Amir Zargarzadeh, Anick Bérard. (Canada)</td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>Can Pharmacoethnicity Be Studied in Spontaneous Reports? The Example of Vincristine Neurotoxicity [109]</td>
<td>M Hauben, M Younus, A Bate. (United States)</td>
<td></td>
</tr>
</tbody>
</table>
68 Prescribed Antipsychotic Drugs and Risk of Re-Hospitalization among Incident Patients with Schizophrenia-Related Diagnosis [111]
Olaf Stephansson, Johan Rautsors, Lena Brandt, Helle Kieler. (Sweden)

69 Co-Prescribing of Medications with Anticholinergic Properties to Those Using Cholinesterase Inhibitors for Dementia [112]
Katherine Bloomfield, Nick John, Anita McGrogan, Ray Jones, Corinne de Vries. (United Kingdom)

70 Overdose Deaths in Relation to Filled Prescriptions with Methadone, Subutex and Suboxone [113]
Helle Kieler, Lena Brandt, Henrik Druid, Johan Franck, Olof Stephansson. (Sweden)

71 The Impact of Regulatory Action on ECG Monitoring in Patients with Dopamine Agonists in Japan: Analysis of Claims Database [114]
Nobuhiro Ooba, Takahiro Yamaguchi, Kiyoshi Kubota. (Japan)

Sarah-Gabrielle Beland, Anne-Marie Cloutier, Camille Craig, Michel Previle, Yola Moride. (Canada)

73 Factors Associated with Adherence and Persistency to Antidepressants in Korea [117]
Sun-Young Jung, Hyunjin Song, Sangjin Shin, Eunhee Shin, Joo-Yeon Park, Jeonghoon Ahn. (Republic of Korea)

74 Heterogeneity in Drug Utilization in Three European Countries: A Study of Dopamine Agonists [658]
Cynthia de Luise, Gianluca Trifirò, Sun-Young Jung, HyunJin Song, Robert Bourrel, Jean Louis Montastruc. (France)

75 Factors Associated with Adherence to Antidepressants in the United States [118]
Sarah Gabrielle Beland, Anne-Marie Cloutier, Camille Craig, Michel Previle, Yola Moride. (Canada)

76 Hormone Replacement Therapy Prescription in France [119]
Florence Gass, Christine Damase-Michel, Caroline Hurault, Robert Bourrel, Jean Louis Montastruc. (France)

77 Medication Use and Prominent Predictors of High Level Polypharmacy in Hospitalized Indian Elderly: A Study from Two Tertiary Care Hospitals [120]
Gurumurthy Parthasarathi, Anand Harugeri, Madhan Ramesh, Shoba Guido. (India)

78 Utilization, Price and Expenditure Trends for Both Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Medicaid Program [121]
Boyang Bian, Jeff Guo, Chris Kelton, Patricia Wigle. (United States)

79 Abstract Withdrawn by Author [122]

80 Antiepileptic Drug Utilization and Medicaid Reimbursement Trends from 1991 to 2008 [123]
Namita Tundia, Jeff J Guo, Patricia R Wigle, Pamela C Heaton. (United States)

81 The Epidemiology, Treatment and Care Patterns, and Medical Resource Utilization Following Hospitalization for Heart Failure [124]
Caroline Korves, Joshua McHale, Marie-Helene Lafuillée, Rinat Ariely, Mei Sheng Duh. (United States)

82 Changes in Insulin Dose in Response to Severe Hypoglycemia in the Diabetes and Complication Trial [125]
Zhiwen Liu, Timothy S Carey, TIl Stürmer. (United States)

83 Utilization, Price, and Expenditure Trends for Anti-Migraine Drugs in the U.S. Medicaid Program from 1991 through 2008 [126]
Chien-Hsiang Chiu, Jeff J Guo, Patricia R Wigle, Alex C Lin. (United States)

84 Racial and Ethnic Disparities in Quality of Health Care among Adults with Diabetes in the United States in 2005-2006 [127]
Yan-Jun Zhang, Monic Holiday-Goodman, Aliaksandr Amialchuk, Jing-Bo Wang, Rose Jung. (United States)

85 Evaluation of Guideline-Conformity of Initiation of Oral Hypoglycemic Treatment for Incident Diabetes Mellitus Type 2 in Austria [128]
Wolfgang C Winkelmayer, Margaret R Stedman, Michaela Pogantsch, Peter Wieneringer, Anna Bucsis, Alan Brookhart. (United States)

86 Knowledge and Attitudes towards Complementary and Alternative Medicine by Pharmacy Students [129]
Ilse Truter. (South Africa)

87 Health Care Resource Utilization among Hispanic and Non-Hispanic White Adults in the United States [130]
Margaret McDonald, Michael B Lustik. (United States)

88 Drug Utilization Study on the Prescribing Indications of Oral Contraceptives in Croatia [131]
Kristina Bardenheuer, Juergen Dinger, Anita Assmann, Klaas Heinemann, Janko Leddin. (Germany)

89 News Reports of Medicines in Relation to Decisions of the Australian Pharmaceutical Benefits Advisory Committee [132]
Jane Robertson, Marc D Bevan, Emily J Walken, David A Newby. (Australia)

90 Use of Cytochrome P450 Inducers and Inhibitors in Patients with Osteoarthritis Compared to the General Population [133]
Stephen P Motsko, John Roberts, Dharam Singh, Jill Chappell. (United States)

91 Descriptive Analysis of Antipsychotic Prescriptions in Primary Care [134]
P Prah, I Petersen, I Nazareth, K Walters, D Osborn. (United Kingdom)

92 Drug Burden as a Predictor of Adherence to a Newly Prescribed Statin [135]
Jennifer Polinski, Elisabetta Patorno, Amrita Desai, Wei Liu, Siyog Kamatkar, Kristin Palmen, Joy Lee, Joshua Gagne. (United States)

93 The Challenge of Drug Regimen Surveillance When Changing Level of Care [136]
Kirsten K Viktil, Hege S Blix, AnneKEek, TronA Mager, Aasmund Reikvam. (Norway)
Gut

94 Validation of ICD-9-CM Codes To Identify Gastrointestinal Perforation (GIP) Cases in Administrative Claims Data in Rheumatoid Arthritis (RA) Patients [137]
Jeffrey R Curtis, Shih-yin Chen, Winifred Werther, Ani John, David Johnson. (United States)

95 Long-Term Statin Use Reduces the Risk of Gallstone Disease – A Population-Based Case-Control Study [138]
Rune Eriksen, Trine Fraslev, Lars Pedersen, Henrik T Sørensen. (Denmark)

Carlo Torre, José Guerreiro, Suzette Costa. (Portugal)

97 Tysabri TOUCH Prescriber Program Risk Management Program (Risk-MAP) Surveys [140]
Kelly Hollis, Brian Calingaert, Mark Price, Elizabeth Andrews, Liam Mey, Mariska Kooymans, Lynda Cristiano, Carmen Bozic. (United States)

98 Antibacterial Use and Risk of Acute Pancreatitis: A Case-Control Study Using the National Veterans Affairs Database [141]
Thahir M Alshammari, Aisling R. Caffrey, Kerry L LaPlante, Brian J Quilliam, Robert Laforge, E Paul Larrat. (United States)

99 Potential Diagnostic/Ascertainment Bias Associated with Endoscopic Findings among Bisphosphonates Users [142]
Robert N Lubwama, Tzuyung D Koo, Julie Chandler. (United States)

100 Stable Incidence of Type 1 Diabetes in Children Observed in the Norwegian Prescription Database (NorPD) in the Period 2005-2009 [143]
Hanne Strøm, Christian Berg, Randi Selmer. (Norway)

101 Clinical Outcomes in Familial Adenomatous Polyposis (FAP) Patients with a Long-Term Treatment of Celecoxib: A Matched Cohort Study [144]
Kui Huang, Lia P Gutierrez, Steffen Bulow, Steven Gallinger, Antoni Castells, Craig J Eagle, James M Church. (United States)

102 Temporal Trends in Compliance with the Alosetron Risk Management Program (RMP) [145]
Kelly Hollis, Pat Tennis, Jean Paul Nicandro, Paul Shin, Carolyn Sweeney, Lee Bennett, Elizabeth Andrews. (United States)

103 Influenza and the Incidence of Acute Pancreatitis in a UK Population [146]
William A Blumentals, Alan Nevitt, Leping Huang, Michael M Peng, M Connie Abelardo. (United States)

104 Adherence to Inhaled Corticosteroids among Adult Patients Privately Insured [147]
Marie-Christyne Cyr, Amélie Forget, Lucie Blais. (Canada)

105 Characterization of Salmeterol Utilization and Concurrent Asthma Therapy [148]
Sigal Kaplan, Yulan Ding. (United States)

106 Utilization of Cough/Cold Preparations among Pediatrics in Taiwan [149]
Ching-Lan Cheng, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)

107 Risk of Serious Asthma Exacerbations Associated with Long-Acting-Beta-Agonists among Medicaid Patients with Asthma: A Retrospective Cohort Study [150]
Jeff J Guo, Katherine Tsai, Christine ML Kelton, Boyang Bian, Patricia R Wigle. (United States)

108 Evaluating Safety of Long-Acting Beta-Agonists (LABAs) in Patients with Asthma [151]
Boyang Bian, Jeff Guo, Chris Kelton, Patricia Wigle. (United States)

109 Drug-Induced ECG Abnormalities in Patients with COPD [152]
Miriam J Warner, Marie L de Bruin, Frans H Rutten, Arno W Hoes, Ton de Boer. (Netherlands)

Fatma Karapinar, Sander D Borgsteede, Jan Zoor, Marijo JA Janssen, Antoine CG Egberts, Patricia MLA van den Bemt, Maurits van Tulder. (Netherlands)

111 Off Label Prescribing of Inhaled Corticosteroids to Children with Asthma in Primary Care [154]
Hajer Elkout, Peter J Helms, Colin R Simpson, James S McIay. (United Kingdom)

Lungs

112 Pregnancy Outcomes Associated with Substitution Treatment for Opioid Dependency: A Pilot Study Using Danish Population Registries [155]
Zhiping Huang, Helen Huang, Anne-Mette Bay Bjørn, Vera Elvenstein. (United States)

113 Treatment of Diabetes before and during Pregnancy [156]
Anita McGrogan, Julia Snowball, Corinne de Vries. (United Kingdom)

114 Increased Risk for Spontaneous Abortion and Preterm Birth Associated with Antidepressant Use in Pregnancy: A Comparison between Continuers and Discontinuers [157]
Adrienne Einarson, Jacqueline Choi, Pina Baggio, Gideon Koren, Thomas Einarson. (Canada)

115 Fluoxetine and Infantile Hypertrophic Pylorus Stenosis: A Signal from a Birth Defects – Drug Exposure Surveillance Study [158]
Marian K Bakker, Hermien EK De Walle, Bob Wilffert, Lolkje TW De Jong-van den Berg. (Netherlands)

116 Antidepressant Use during Pregnancy and Congenital Malformations: Systematic Review of Study Methods, Confounders and Limitations [159]
Deborah A Kennedy, Adrienne Einarson, Marcio Machado, Sachi Sagakuchi, Irene Lara, Amy Sharma, Hisaki Fuji, Alexandra Balma-Mena, Hiroaki Aki, Elena Reydam, Thomas R Einarson. (Canada)

Susan S Roberts, Jessica D Albano. (United States)

118 Trends in Prescriptions for Folic Acid among French Pregnant Women: Assessment of Accordance with Recommendations [161]
Reginald River, Caroline Hurault, Robert Bourrel, Jean Louis Monatastruc, Christine Damase-Michel, Isabelle Lacroix. (France)

119 Medication Use during Pregnancy in Out-Patient Setting of an Indian Tertiary Care Hospital [162]
Gurumurthy Parthasarathi, Nidudi R Veda, Madhan Ramesh, Anand Harugeri. (India)

120 Population-Based Antiepileptic Drug Utilization Study in Europe among Pregnant Women [163]
Janneke Jentink, Christine Damase-Michel, Lolkje TW De Jong-van den Berg. (Netherlands)
121 Evaluation of the Representativeness of a Dutch Non-Malformed Control Group with the General Pregnant Population, Are They Useful as Controls for EUROCAT? [164]
Janneke Jentink, Lakhwinder Jit Duggal van den Berg. (Netherlands)

122 Prevalence of Antidepressant and/or Benzodiazepine Polytherapy during Pregnancy [165]
Odile Sheehy, Melanie Soumaire, Martin St-Andre, Berard Anick. (Canada)

123 Socio-Demographic and Lifestyle Predictors of Folic Acid and Multivitamin Supplementation in Danish Pregnancy Planners [166]
Heidi T Cueto, Anders Riis, Lauren A Wise, Elizabeth E Hatch, Kenneth J Rothman, Henrik T Sørensen, Ellen M Mikkelsen. (Denmark)

124 Improving Accuracy in Enrollment Targets for Pregnancy Registries [167]
Deborah Covington, Hadley Mates, Paige Churchill, Amanda Golensbksy, Laura McKain. (United States)

125 A Combined Comorbidity Score for Predicting 1-Year Mortality in Elderly Patients Using Healthcare Claims Data [168]
Joshua Gagne, Robert Glynn, Jerry Avorn, Raisa Levin, Sebastian Schneeweiss. (United States)

126 National Estimates of Pediatric Inpatient Medication Use in the US in 2008 [169]
Tamar Lasky, Shirley V Wang, Frank R Ernst, Jay Greenspan, M Liliana Gonzalez. (United States)

127 Qualitative Evaluation of Medication Use in Two Different Geriatric Inpatient Populations of a University-Affiliated Hospital [170]
Jean Frederic Westphal, Cathy Nonnenmacher. (France)

128 Assessing the Effectiveness of Counter Matching as a Tool for Improving the Efficiency of the Nested Case Control Design in Pharmacoepidemiological Studies [171]
Victor A Kiri, Gilbert MacKenzie. (United Kingdom)

129 Room for Improvements in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs [172]
Grace Wangge, Olaf H Klungel, Kit CB Roos, Anthonia de Boer, Arno W Hoes, Mirjam J Kool. (Netherlands)

130 Validation of Claims-Based Diagnostic Codes for Severe Hypoglycemic Events (SHES) in a Commercially-Insured Population [173]
Debra F Eisenberg, Gregory W Daniel, Usha Subramanian, Tracy Breen, Rhonda L Bahn, Peter M Wahl, William H Herman. (United States)

131 Accuracy of Identifying Outpatient Neutropenia Diagnoses in Claims Data [174]
Seo Young Kim, Daniel H Solomon, Jun Liu, Gina Chang, Gregory W Daniel, Sebastian Schneeweiss. (United States)

132 Extracting Meaningful, Searchable and Discrete Data from Unstructured Medical Text [176]
Aaron WC Kamaus, Gerasimos Petratos, Anthony Amey, Peter Bechtel, Daniel Dine. (United States)

133 Comparison of Two Penalized Regression Methods for Signal Detection [177]
Marietta Rottenkolber. (Germany)

134 A Combined Statistical and Non-Statistical Approach to Assessing Whether Adverse Events Associated with Different Lots of Identical Drug Are Clinically and Statistically Relevant [178]
Dorian Villegas, Wendy Ye, Fred Schneeweiss, Mark Von Tress, Sam Yaran. (United States)

135 The Effect of Reimbursement System Versus Global Financial System on Drug Cost, Precentage of Branded Drug and Adherence of Drug Prescription to Guideline [179]
Lili Kamarah Darmowicraja, Iwan Dwiprahasto, Erna Kristin. (Indonesia)

136 Development of an Automated Pharmacovigilance System within the Military Healthcare System [180]
Trinka Coster, David Fram, Suji Xe, Karl Friedl, Paul Coratts. (United States)

137 Between and within Practice Variability among Practices within the Health Improvement Network [181]
Kevin Haynes, Warren B Bilker, Tom R TenHave, James D Lewis. (United States)

138 Signal Detection Biases Caused by the Use of Differentially Reported Non-Serious Events in the FDA AERS Database [182]
Keith L Altman. (United States)

139 A Demonstration of the Importance of Population Specification in Study Design [183]
Laura E Burleson. (United States)

140 Generation of Safety Data in Clinical Trials: What Are Participants’ Perspectives of Reporting? [184]
Elizabeth N Allen, Clare IR Chandler, Sarah G Staedke, Karen I Barnes. (South Africa)

141 How To Implement New Statistical Tools in Vaccine Safety? Hurdles Encountered [185]
Annette Köllner Doser, Katharina Hartmann, Grot Manika. (Switzerland)

142 Bias Is Worse Than Noise: Handling Missing Data for Confounders in Observational Studies [186]
Eric P Elkin, Dave P Miller. (United States)

143 Development of a Claims-Based Healthcare Safety Sentinel System Featuring Signal Strengthening during Sequential Monitoring [187]
Peter M Wahl, Sebastian Schneeweiss, Thomas E Wasser, Debra F Eisenberg, Keith Rodgers, Joshua J Gagné, Jeremy A Rassen, Jerry Avorn, Rhonda L Bahn. (United States)

144 Automated EMR Data Processing System for Post-Market Surveillance [188]
Dukyoung Yoon, Man Young Park, K’Young Lee, Rae Woong Park. (Republic of Korea)

145 Data-Driven Analysis of Comorbidities Associated with Systemic Lupus Erythematosus in MarketScan Claims Database [189]
Hans Petri, Debra Maldonato, Noah J Robinson. (United Kingdom)

146 Quality of Reporting of Harms in Randomized Controlled Trials: An Example Using Human Papillomavirus (HPV) Vaccines [191]
Leah M Smith, Jeevitha Senghantham, Karen KY Poon, Linda E Lévesque. (Canada)

147 Evaluating Adherence to Antihypertensive Medication Using Medication Event Monitoring System [192]
Peter Doros, Ria Benko, Aniko Czakó, Maria Matuz, Ferenc Thurzo, Gyongyver Soos. (Hungary)

Methods

125 A Combined Comorbidity Score for Predicting 1-Year Mortality in Elderly Patients Using Healthcare Claims Data [168]
Joshua Gagne, Robert Glynn, Jerry Avorn, Raisa Levin, Sebastian Schneeweiss. (United States)

126 National Estimates of Pediatric Inpatient Medication Use in the US in 2008 [169]
Tamar Lasky, Shirley V Wang, Frank R Ernst, Jay Greenspan, M Liliana Gonzalez. (United States)

127 Qualitative Evaluation of Medication Use in Two Different Geriatric Inpatient Populations of a University-Affiliated Hospital [170]
Jean Frederic Westphal, Cathy Nonnenmacher. (France)

128 Assessing the Effectiveness of Counter Matching as a Tool for Improving the Efficiency of the Nested Case Control Design in Pharmacoepidemiological Studies [171]
Victor A Kiri, Gilbert MacKenzie. (United Kingdom)

129 Room for Improvements in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs [172]
Grace Wangge, Olaf H Klungel, Kit CB Roos, Anthonia de Boer, Arno W Hoes, Mirjam J Kool. (Netherlands)

130 Validation of Claims-Based Diagnostic Codes for Severe Hypoglycemic Events (SHES) in a Commercially-Insured Population [173]
Debra F Eisenberg, Gregory W Daniel, Usha Subramanian, Tracy Breen, Rhonda L Bahn, Peter M Wahl, William H Herman. (United States)

131 Accuracy of Identifying Outpatient Neutropenia Diagnoses in Claims Data [174]
Seo Young Kim, Daniel H Solomon, Jun Liu, Gina Chang, Gregory W Daniel, Sebastian Schneeweiss. (United States)

132 Extracting Meaningful, Searchable and Discrete Data from Unstructured Medical Text [176]
Aaron WC Kamaus, Gerasimos Petratos, Anthony Amey, Peter Bechtel, Daniel Dine. (United States)

133 Comparison of Two Penalized Regression Methods for Signal Detection [177]
Marietta Rottenkolber. (Germany)

134 A Combined Statistical and Non-Statistical Approach to Assessing Whether Adverse Events Associated with Different Lots of Identical Drug Are Clinically and Statistically Relevant [178]
Dorian Villegas, Wendy Ye, Fred Schneeweiss, Mark Von Tress, Sam Yaran. (United States)

135 The Effect of Reimbursement System Versus Global Financial System on Drug Cost, Precentage of Branded Drug and Adherence of Drug Prescription to Guideline [179]
Lili Kamarah Darmowicraja, Iwan Dwiprahasto, Erna Kristin. (Indonesia)

136 Development of an Automated Pharmacovigilance System within the Military Healthcare System [180]
Trinka Coster, David Fram, Suji Xe, Karl Friedl, Paul Coratts. (United States)

137 Between and within Practice Variability among Practices within the Health Improvement Network [181]
Kevin Haynes, Warren B Bilker, Tom R TenHave, James D Lewis. (United States)
148 Development of a Comorbidity Score To Predict Disability in Older Adults from Prescription Claims Data [193]
Marie-France Dubois, Edeletrut Kröger, Nicole Dubuc, Ronald Girard, Réjean Hébert. (Netherlands)

149 The Relationship between Bisphosphonate Adherence and Fracture: Is It the Behavior or the Medication? Results from the Placebo Arm of the Fracture Intervention Trial [194]
Jeffery R Curts, Elizabeth Delzell, Lang Chen, Suzanne Judd, Dennis Block, Kristine Ensrud, Lisa Palermo, Monika Safford, Ann Schwartz, Doug Bauer. (United States)

150 Linking UK Death Certificate Data to UK Primary Care Data (GPRD) To Obtain Cause of Death [195]
Efronii Setakis, Arlene Gallagher, Tim J Williams, Tjejped EvStour. (United Kingdom)

151 Nephrogenic Systemic Fibrosis (NSF) and Gadolinium-Based Contrast Agents (GBCA's). A Statistical Simulation Study [196]
Alexander Michel, Tilo Blenk. (Germany)

152 Prediction Equations for Adjusting Reporting Error in Self-Reported BMI [197]
Lina Titievsky, Andrew G Rundle. (United States)

153 Tools and Methods for Sample Size Calculation Using Person-Time Data [198]
X Zhou, R E Sobel, A Bate. (United States)

154 SALOME: A Pilot Study To Test Causality Assessment of Drug-Exposed Acute Liver Failure Cases Using Different Scales [199]
Ezgi Gulum, Georges Pageaux, Dominique Larrey, Franco Bissoli, Yves Horsmans, Jacques Bernuau, Bruno Stricker, Douglas Thorburn, Patrick Bliin, Nicholas Moore. (France)

155 An Algorithm To Identify Practices Common to Both the GPRD and THIN Database [200]
Bing Cai, Weifeng Xu, Edward Bortnichak, Watson Douglas. (United States)

156 Applying Data-Mining Techniques to Paediatric Data within the WHO-UMC Database; the Impact of Vaccines [201]
S de Bie, KMC Verhamme, SMJM Strous, GW ‘t Jong, BHIC Stricker, MGJM Sturkenboom. (Netherlands)

157 Nimesulide Suspension in Acute Upper Respiratory Infection in Asian Indian Paediatric Population: Results from Post Authorization Safety Study [202]
Manoj Sharma, Arani Chatterjee. (India)

158 Educating a Pharmacoepidemiology Researcher on Selecting Optimal Healthcare Databases for Research [203]

159 Drug Prescription Monitoring System To Estimate Incidence and Prevalence of Type 1 Diabetes [204]
Marina Maggini, Roberto Da Cas, Carlotta Lunghi, Flavia Pricci. (Italy)

160 Missing Data in Primary Care Databases; Problems and a Possible Solution [205]
Louise Marston, James Carpenter, Kate Walters, Richard Morris, Irwin Nazareth, Irene Petersen. (United Kingdom)

161 Sequential Analysis for Safety Surveillance [206]
Alexander M Walker, Martin Kulldorff. (United States)

162 A Real Time Opioid Class REMS: User Acceptance Pilot [175]
Edgar Adams, Nat Katz, Kevin Flynn, Robin Kinard, Rick Sage. (United States)

163 A Real Time Opioid Class REMS: Technical Feasibility [207]
Edgar Adams, Nat Katz, Kevin Flynn, Robin Kinard, Rick Sage. (United States)

164 The RCT Participant Cohort Study [208]
Daniel O Koralek, Nicolle M Gatto. (United States)

165 Evaluation of US Package Inserts Following the Physician Labeling Rule [209]
James Buchanan, Sally Van Doren. (United States)

166 Suitable Study Designs for Pharmaco-genetic Research [210]
F H van der Baoon, O H Klungelan, D E Grobbe, A CG Eggbert, M J Kno. (Netherlands)

167 Evaluation of Death Information in Claims Database [211]
Shuko Nojiri, Tsugumichi Sato, Kyoshi Kubota. (Japan)

168 Persistency and Concurrency Analysis of Leflunomide Therapy [212]
Sigal Kaplan, Esther Zhou. (United States)

169 Effectiveness of Osteoporosis Drugs in Preventing Secondary Fracture in Taiwan [213]
Tzu-Chein Lin, Yea-Huei Kao Yang, Chyuy-Yu Yang. (Taiwan)

170 Nonsteroidal Anti-inflammatory Drug Use and Risk of Venous Thromboembolism: A Population-Based Case-Control Study [214]
Morten Schmidt, Christian F Christiansen, Erzebet Horvath-Puhó, Henrik Toft Sørensen. (Denmark)

171 Influence of Socioeconomic Factors on the Persistence of Alendronate Use. A Nationwide Prescription Database Study in Norway [215]
Helene Devald, Kari Furu, Svetlana Skurtvest, Aage Tverdal, Jan A Falch, Anne Johanne Sogaard. (Norway)

172 Effects of Cox-2 Selectivity NSAID Groupings in UGIB and MI ADR Detection Using Bayesian Hierarchical Modeling: EU-ADR Project [216]
D Prieto, M Molokhia, S Evans, M Schuemie, R Herings, J van der Lei, M Sturkenboom. (United Kingdom)

173 Abstract Withdrawn by Author [217]

174 Incidence Rates of Edema in Solid Tumor Cancer Patients in the THIN Database [218]
Víctor Gastanaga, Chuck Wentworth, Vanantha Ganesh, Gail Hughes, Fei Xue, Mukes Verma, Isaiah Dimery, Sean Zhao. (United States)

175 Pharmacoepidemiological Study of Antiretrovirals in Lagos University Teaching Hospital South West Nigeria [219]
Ibrahim Adenkele Oreagba, Sikiru Olanujji Usman, Sulaiman Akamnu, Oluranti Opanuga. (Nigeria)

176 To Study the Extent of Off-Label Drug Use in Paediatric Population and Occurrence of Fatal ADRs: A 03 Months Study in a Large Mutispeciality Hospital in India [220]
Pradeep Kumar, Arun K Biswas, Pipasha N Biswas. (India)
177 To Study the Extent of Off-Label Drug Use in an Adult Population and Occurrence of Fatal ADRs: A 03 Month Study in a Large Multispeciality Hospital in India [221]
Pradeep Kumar, Arun K Biswas, Rpasha N Biswas. (India)

178 Active Monitoring of Antiviral Medications in Korea [222]
Hye Jin Park, JaYoung Kim, Junghoon Jang, Myung Jung Kim, Young Hoan Kim, Ji-Hye Ha. (Korea)

179 Sex-Related Differences in Hospital Admissions Due to Adverse Drug Reactions in the Netherlands [223]
Eline M Rodenburg, Bruno HCh Stricker, Loes E Visser. (Netherlands)

180 Adverse Events with Fatal Outcome, a Ten Year Survey of Iranian Spontaneous Reports Database [224]
Shadi Yousefian, Gloria Shalviri. (Islamic Republic of Iran)

181 Drug Dictionaries Information on the Risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Discrepancies with Pharmacoepidemiology Studies [225]
Cynthia Haddad, Alexis Sidoroff, Sylvia Kardaun, Maja Mockenhaupt, Daniel Creamer, Jean Claude Roujeau. The RegiS-CAR Study Group. (France)

182 Prescription Combination Medicines Significantly Contribute to Acetaminophen Exposure in the U.S. [226]
Gregory E Powell, Julie I Papay, Ed N Patti, Christine M Hunt. (United States)

183 Patient Reporting of Adverse Drug Reactions in the UK: Potential Signals Generated by Patients Compared to Healthcare Professionals [227]
Lorna Hazell, Victoria Cornelius, Saad Shakir, Anthony Avery. (United Kingdom)

184 Glaucoma Management in the Patient with Airways Disease: Are We Helping or Harming? [228]
Andrew L Gilbert, Elizabeth E Roughhead. (Australia)

185 Medication Errors Made by Nurses – A Result of Interrelated Human and System Factors [229]
Monica Bergqvist, Eva Andersén Karlsson, Karin Sparring Björksten, Carolin Modigh, Lina Benson, Johanna Ulflarsson. (Sweden)

186 An Environmental Scan of Risk Minimisation Interventions [230]
Lenhang Nkeng, Anne-Marie Cloutier, Camille Craig, Jacques Leloirie, Yola Moride. (Canada)

187 Evaluation of Medication Safety in Neurological Inpatients Using the Clinical Decision Support Software MediQ [231]
Markus Guzek, Martin Huber, Stefan Russmann. (Switzerland)

188 Abstract Withdrawn by Author [232]

189 In-Hospital Therapeutic Risk Management Following a Fall in the Geriatric Population: Taking the Evidence to the Bedside [233]
Sarah Gabrielle Béland, Antoine Pariente, Marie-Jeanne Kerogot, Judith Latour, Yola Moride. (Canada)

190 Characterization of Current Risk Evaluation and Mitigation Strategies (REMS) [234]
Alicia W Gilsenan, Elizabeth B Andrews, Kelly A Hollis. (United States)

Michelle Putzeist, Aukje M Mantel-Teeuwisse, Christine C Gispen-De Wied, Arno W Hoes, Hubert G Leufkens. (Netherlands)

192 Characteristics of Patients Prescribed Sitagliptin and Other Oral Antihyperglycemic Agents in a Large U.S. Claims Database [236]
Bing Cai, Leonid Katz, Charles M Alexander, Deborah Williams-Heriman, Cynthia J Girman. (United States)

193 Automated Robust Mapping GPRD Medical Diagnosis Read Codes to SNOMED CT for OMOP Project [248]
Hoa Y Le, Kathleen J Beach. (United States)

194 Effect of Different Trimming Methods for Propensity Score Distribution on Risk Estimates [249]
Hoa Y Le, Kathleen J Beach. (United States)

195 Association between Bilirubin and Oxidative Stress Mediated Disease [604]
Laura Horsfall, Greta Rait, Kate Walters, Dallas M Swallow, Stephen P Pereira, Irene Petersen. (United Kingdom)
Need Evidence?

Patient Registries  Comparative Effectiveness
Safety / Surveillance  Phase IIIB Expanded Access
Risk Management  Quality Measurement
Health Outcomes  Quality Improvement
Phase IV Studies  Health Interventions
Quality of Life  Observational Studies

Talk to the Leader in Real-World Research.
Visit Outcome booth #20 at the ICPE Annual Meeting!

www.outcome.com  evidence@outcome.com  617-621-1600  +41 (0) 21 321 3560
**Anti-Infectives**

1. Evaluating the Effects of a FDA Boxed Warning on Adverse Event Reporting: Is There a Difference in the Rate of Reporting of Tendon-Related Adverse Events Associated with the Use of Fluoroquinolones after a FDA Boxed Warning? [316]
   Axel Olsen, Mary Mease, John R Hall, Eric Gemmen, William Garvert. (United Kingdom)

2. Adverse Events Induced by Ceftriaxone: A Ten Years Review of Reported Cases to Iranian Pharmacovigilance Centre [317]
   Gloria Shalviri, Shadi Yousefian, Kheirollah Gholami. (Islamic Republic of Iran)

3. The Study of Adverse Drug Reaction of Telbivudine in Chronic Hepatitis B Virus Infection at Siriraj Hospital [318]
   Promate Trugpliankit, Naruemon Dhana, Tawesak Tanwandee, Nithiphot Phumjyn, Ploylarp Lertvipapath. (Thailand)

4. Comparison of Systemic Antimicrobials (AM) Consumption and Costs in Different Wards of Multi-Profile Hospital [319]
   Ljubov I Kachushova, Svetlana A Ratchina, Alexander A FoKin, Elena V Korneva, Vladimir M Mischenko, Roman A Pavlukov. (Russian Federation)

5. Signal Detection Research of Oseltamivir Using Administrative Data for Public Insurance [320]
   Suhyun Lee, Chumgang Choi, Wan Gyoow Shin. (Korea)

6. Factors Influencing Antimicrobial (AM) Prescribing to Adult Patients with Acute Rhinosinusitis (ARS) [321]
   E Shal, S Ratchina, V Mischenko, L Kachushova, S Palyutin, O Reshetko, S Suleymanov, I Coulomb, Antoine Pariente. (France)

7. A Drug Utilization Study of Posaconazole in French Hospitals [322]
   Helen Huang, Zhiping Huang, Sandrine Coulomb, Antoine Lafuma, Alejandro Arana. (United States)

8. TdP Liability of Fluoroquinolones: Integrated Approach Based on FDA Spontaneous Reports and Literature Data [323]
   Emanuele Rasci, Elisabetta Poluzzi, Ugo Moretti, Fabrizio De Ponti. (Italy)

9. Abstract Withdrawn by Author [324]

10. Detection of Fluoroquinolone-Induced Tendon Disorders Using a Hospital Database [325]
    Katsushiito Hori, Kasumi Yamakawa, Naoko Yoshida, Kazunori Ohnishi, Junichi Kawakami. (Japan)

11. Trends in Consumption Antimicrobials for Six Years (2003-2008) in Clinical Centre University of Sarajevo [326]
    Begler Begovic, Lejla Begovic, Anra Cabaravdic. (Bosnia and Herzegovina)

12. Exposure to Co-Trimoxazole and the Risk of Cardiac Dysrhythmia [327]
    William A Blumentals, Steven E Elkin, Miriam Adamcova. (United States)

13. Abstract Withdrawn by Author [328]

14. Concomitant Use of Drugs That Prolong the QT Interval during Methadone Maintenance Treatment [349]
    Klaus Romere, Rowan Frost, Mary Brown, Raymond L Woesley. (United States)

**Cardiovascular**

15. Antihypertensive Drug Use and Risk of Depression: A Nested Case-Control Study from the Paner@mica Database [329]
    F Salvo, F Bazin, P Noize, A Fourrier-Réglat, V Arcoraci, D U Tari, S Moretti, A P Caputi, A Pariente. (France)

16. Interim Results of a Modified Prescription Event Monitoring Study on Ivabradine: Case Series of Utilisation in Patients under the Age of Forty Years [330]
    C Doe, C Fogg, D Loyton, Saad AW Shakir. (United Kingdom)

17. Management of Acute Myocardial Infarction in France: Results from the EOLE Cohort [331]

    Cristina Varas-Lorenzo, Brian Calingaert, Nuria Riera-Guardia, Jordi Castellsague, Francesca Salvo, Federica Nicotra, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)

    Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Jordi Castellsague, Francesca Salvo, Federica Nicotra, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)

20. Effects of Phytosterol-/Stanol-Enriched Margarines on Effectiveness of Statins and Adherence to Therapy [334]
    Simone Eussen, Nynke de Jong, Cathy Rompelberg, Johan Garssen, Monique Verschuren, Olaf Klungel. (Netherlands)

21. Drug Utilization Evaluation on the Combination of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Taiwan [335]
    Wen-Yi Chang, Li-Chia Chen, Li-Jen Cheng. (Taiwan)

22. Past Adherence as a Predictor of Future Adherence to Preventive Drug Treatments [336]
    Colin Dormuth, Amanda Patrick, Sutherland Jenny, Alan Brookhart. (Canada)

23. Identifying the Predictors for Adverse Drug Reaction Due to Angiotensin Converting Enzyme Inhibitors in Indian Hospitalized Patients [337]
    Thiayagu Rajakannan, Laxmanarayana K Bairy, Padma GM Rao, Dipesh Patel, Padmakumar Ramachandran. (India)

24. Abstract Withdrawn by Author [338]

    Willemijn M Meijer, Jetty A Overbeek, Maurice A Brokhart, Kimberly Woodruff, Joseph Jackson, Fernie JA Penning-van Beest. Ron MC Herings. (Netherlands)

26. The Effect of Rosuvastatin on Hemoglobin Levels in Patients with Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial [340]
    Maurice A Brokhart, Daniel H Solomon, Robert J Glynn, Paul M Ridker. (United States)

27. Angioedema and ACE Inhibitors or Angiotensin II Receptor Blockers, Revisited [341]
    Rachel L Jones, Genevieve M Gabb. (Australia)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
</table>
| 28   | Statin Use and the Prevalence of Autoantibodies in the Doetinchem Cohort [342]  
HJ de Jong, JW Cahen Tervaert, OH Klungel, PC Souverein, RJ Vandebriel, J Dammareaux, H van Loveren, WMM Verschuren. (Netherlands) |
| 29   | Patient’s Medication Adherence in Primary Hypertension [343]  
Josip Cuhil, Marcel Leppee, Jelena Boskovic. (Croatia) |
| 30   | The Impact of Prescribing Guidelines on Physician Selection of Drug Therapy for Newly Diagnosed Patients with Hypertension in the UK [344]  
Brian Serumaga, Anthony Avery, Rachel Elliott. (United States) |
| 31   | Association between the Use of Statins and Systemic Lupus Erythematosus [346]  
SRF Saldi, HJ de Jong, PC Souverein, RHB Meyboom, RJ Vandebriel, JW Cohen Tervaert, H van Loveren, OH Klungel. (Netherlands) |
| 32   | Sibutramine Adverse Drug Reactions [347]  
Pakawadee Sriphiromya. (Thailand) |
| 34   | Signal Detection of Adverse Drug Reactions of Clopidogrel Using Administrative Data for Korean Public Insurance [350]  
Jinhyung Kim, Chungam Choi, Wan Gyoon Shin. (Korea) |
| 35   | Applied Epidemiology throughout the Lifecycle of Drugs: Two Case Studies [351]  
Ouwei Ataher, Anna Greenacre. (United States) |
| 36   | Drug Use and the Risk of Road Traffic Crashes: Preliminary Results from the French CESIR-U Study [352]  
S Blażejowski, P Philip, R Ribeyreau-Gayon, E Lagarde, PO Girodet, A Parente, P Noize, JL Maunoir, I Merle, D Orsoni, D Lauque, N Moore. (France) |
| 37   | Education and Use of Prescribed Drugs [353]  
Aage Tverdal, Solveig Sakshaug, Hege S Blix, Randi Selmer. (Norway) |
| 38   | The Association of Aggression and Medication Use with Treatment Outcome of Hospitalized Psychiatric Patients [354]  
Laurette E Goedhard, Joost J Stolker, Henk L Nijman, Toine C Egberts, Eibert R Heerdink. (Netherlands) |
| 39   | Actual State of Cancer Pain Management [355]  
Hwa J Kim, Joongyub Lee, Moo-song Lee, Byung-joop Park. (Korea) |
| 40   | The Influence of Using Methylphenidate on the Coming up of Psychiatric Disorders in Children with ADHD [356]  
Chun-Shiouh Gau, Chih-Fu Chen, Susan Shur-Fen Gau. (Taiwan) |
| 41   | Trials Assessing Pharmacotherapeutical Management of Aggression in Psychiatric Patients: Comparability with Clinical Practice [357]  
Laurette E Goedhard, Joost J Stolker, Henk L Nijman, Toine C Egberts, Eibert R Heerdink. (Netherlands) |
| 42   | Complementary and Alternative Medicine for Attention Deficit/Hyperactivity Disorder in the Eastern Cape, South Africa [358]  
Samman Snyman, Ilse Truter. (South Africa) |
| 43   | Validation of a Monte-Carlo Markov Model for Schizophrenia [359]  
Alice Dragomir, Jean-Francois Angers, Jean-Eric Tarride, Ridha Joober, Sylvie Perreault. (Canada) |
| 44   | The Association of Early Discontinuation of Antidepressants to Pharmaceutical Market or System Policies [360]  
Anna B Almardottir, Ingunn Björnsdóttir, Atli Sigurjónsson. (Iceland) |
| 45   | Abstract Withdrawn by Author [361] |
| 46   | Risk of Overuse When Taking Benzo-diazepines [649]  
Tom J Lindquist, Ivar A Aursnes, Trine Bjerner, Ingunn F Tveite. (Norway) |
| 47   | Phelophepa Health Care Train: An Epidemiological Overview of the Western Cape in 2009 [362]  
Ilse Truter. (South Africa) |
| 48   | Factors Associated with Adverse Drug Events in an Intensive Care Unit [363]  
Adriano M Reis, Silvia Helena De B Cassiani. (Brazil) |
| 49   | Effect of the Universal Health Care Scheme on Prescribing Patterns across Thailand [364]  
Sak silent Srira, Christine Bond, Corri Black. (United Kingdom) |
| 50   | UK/USA Differences in Marketing Claim [365]  
Stephen R Chapman, Nicholas Thayer, Bernard Naughton. (United Kingdom) |
| 51   | The Use of Antimicrobial Drugs in the Treatment of Diabetic Patients: Analysis of ‘Real World Data’ from Electronic Health Records [366]  
Svetlana Sergeeva, Darya Dolotova, Nikolay Matveev, Gagik Galstyan. (Russian Federation) |
| 52   | Prevalence of Adverse Drug Effects/Adverse Drug Reactions in the 200 Most Commonly Prescribed Medications in the United States Corrected for Prescription Volume [367]  
Mary Kiersma, Alda Hess, Kristin Villa, Brian Sheppler, Matthew Murawski. (United States) |
| 53   | Characteristics and LDL-C Therapeutic Objectives of Patients Receiving Unusual Lipid-Modifying Therapy Regimens [368]  
Goelle Desamericq, Laurent Laforest, Marie-Sophie Schwalm, Alison Bourke, Melanie Bouquet, Eric Van Ganse, Philippe Moulin. (France) |
| 54   | Drug Utilization Physician Survey of Intron A® in Europe [369]  
Jamie T Laudati, Shirin Ahmed, Eu Jong Jo, Alejandro Arana. (United States) |
| 55   | Access to Drugs Via the Judiciary Power in Brazil: Obstacles for the Rational Use of Medicines [370]  
Marina Machado, Francisco Acuarc, Cristina Brandão, Daniel Faleiros, Augusto Guerra Jr, Mariângela Cherchiglia, Eli Iola Andrade. (Brazil) |
56 Socioeconomic Inequalities in Prescription Medicines Use [371]
Claudia Furtado, João Pereira. (Portugal)

57 Abstract Withdrawn by Author [372]

58 Services for Which Pharmacists May Levy a Fee: Primary Care Drug Therapy (PCDT) [373]
Ilse Truter, Research and Development Task Team South African Pharmacy Council. (South Africa)

59 Effects of an Educational Intervention on the Prescribing of Antimalarials in a Nigerian Teaching Hospital [374]
Obehi Akoria, Peter Akhideno, Stephen Ayinbuomwan, Abimbola Olowofela, Aghogho Akpojemew. (Nigeria)

60 Utilization and Expenditures Trends of Potentiated Penicillins J01 in the Czech Republic in 1997-2008 [375]
Vladimíra Vojtová, Karel Urbánek, Dominika Hajdú, Petra Langerová. (Czech Republic)

61 Drug Consumption in Old-Elderlies Admitted to Hospital between 1994 and 2004 [376]
ML Laroche, T Pelou, S Crépin, JP Charmes, L Merle. (France)

62 Determinants of Compliance with Oral Hypoglycaemic Agent in Korean Type 2 Diabetic Patients [377]
Young Sik Kim, Kyung-Mi Park, Sung Sunwoo, Yun Jun Yang, Young Sung Suh. (Korea)

63 Prescribing in Compliance with Patient Formularies Increases Primary Adherence in Patients Receiving Electronic Prescriptions [378]
Michael A Fischer, Niteesh K Choudhry, Jerry Avorn, Sebastian Schneeweiss, William H Shrank. (United States)

64 Comparison of Prescribing Patterns for Asthma in Five European Countries [379]
Laurent Laforest, Marie-Sophie Schwalm, Marion Dufour, Mélanie Broquet, Alison Bourke, Eric Van Gasse. (France)

65 Could Adverse Reactions of Antibiotic Drugs in Children Be Detected in a Prescription Database? [380]
Josta de Jong, Jens HJ Bos, Tjalling V de Vries, Lakkie TW de Jong - van den Berg. (Netherlands)

66 Drug Utilization Patterns of Antiplatelet Therapies among the Older Adults in Taiwan [381]
Hsiang-Wen Lin, I-Wen Yu. (Taiwan)

67 Correlates of Intentional Interruption of Inhaled Corticosteroids and Spontaneous Changes in Doses by Asthma Patients: Results from a Pharmacy-Based Study [382]
Laurent Laforest, Eric Van Gasse, Mélanie Broquet, Cécile Ritteng, Gilles Devouassoux, Geneviève Charbon, French Council of Pharmacists. (France)

68 Long-Term Trends in Immunosuppressants Utilization the Czech Republic [383]
Karel Urbanek, Jan Strachil, Vladimir Vojtova, Petra Langerova. (Czech Republic)

69 Uncontrolled Type 2 Diabetes Treated with Oral Hypoglycaemic Agents (OHM) in Monotherapy: Therapeutic Behaviour in Primary Care in France [384]
B Balkau, S Halimi, JF Blicke, E Tocque, E Amelineau, S Bouée. (France)

70 Hepatic Risk among Patients with Chronic Pain: A Retrospective Cohort Study [385]
Yingkai Cheng, Dale Marmaduke, Antonio Crucitti, Sharon Hoog, Indiana Stromborn. (United States)

71 Antivertigo and Antiemetic Prescribing to Children and Adolescents [386]
Ilse Truter. (South Africa)

72 Factors Associated with the Initiation of Proton Pump Inhibitors in New Corticosteroid Users [387]
Jeffrey C Munson, Peter M Wahl, Gregory Daniel, Stephen E Kimmel, Sean Hennessy. (United States)

73 Treatment of Rare Diseases in Brazil [388]
Cristina Mariano Ruas Brandao, Marina Amaral Avila Machado, Anderson Lourenço da Silva, Francisco de Assis Acuciro. (Brazil)

74 Final Results from a Retrospective Cohort Study of the Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators [389]
David D Dore, Gary L Bloomgren, Made Wenten, Rebecca A Noel, Daniel K Braun, John D Seeger. (United States)

75 Use of Serotonergic Drugs and the Risk of Bleeding [390]
Bertha Maria Verdel, Patrick C Souverein, Eibert R Heerink, Hubert GM Leufkens, Toine CG Egberts. (Netherlands)

76 Antidiabetic Utilization and Prescribing Patterns in Outpatients of Diabetic Pay-for-Performance Program [391]
Ju-Hui Tseng, Li-Chia Chen. (Taiwan)

77 Pulmonary and Cardiovascular Safety of Inhaled Insulin in a Real-World Setting: The Exubera Large Simple Trial (VOLUME) [392]
Nicole M Gatto, Francesca M Kalitsopoulos, Richard J Riese, William T Duggan, Neville C Jackson. (United States)

78 Long-Term Patterns of Statin Therapy in Patients with Type 2 Diabetes Mellitus Compared to Long-Term Oral Antidiabetic Medication Patterns [393]
Egbert Lamberts, Giel Nijpels, Jacqueline Dekker, Laura Welschen, Marcel Bouy, Patrick Souverein, Jacqueline Hugtenburg. (Netherlands)

79 Abstract Withdrawn by Author [394]

80 DPP-4 Inhibitors and the Occurrence of Infections: A Nested Case-Control Study [395]
Marjolein J Willemen, Aukje K Mantel-Teeuwisse, Sabine M Straus, Toine C Egberts, Hubert G Leufkens. (Netherlands)

81 Factors Associated with Short-Term Adherence to Dietary and Lifestyle Guidelines in Secondary Prevention of Acute Myocardial Infarction in Real Life Practice in France (EOLE Cohort) [396]

82 Japan Statin Study (JSS), a Prospective Case-Cohort Study for Monitoring Multiple Adverse Events: Rationale, Design and Characteristics of Study Subjects [397]
Shigeru Kageyama, Masaki Kitamura, Akira Kokan, Kyoshi Kubota, Kenichi Matsui, Nobuhiro Ooba, Takao Oni, Tsugumichi Sato, Yoshihiro Shimodozono, Hiromi Uehara, Mitsunori Yamaguchi. (Japan)

83 Is There an Association between Selective Serotonin Reuptake Inhibitor Use and Uncomplicated Peptic Ulcers? – A Population-Based Case-Control Study [398]
Michael Dell, Ove B Schaffalitzky de Muckadell, Annamarie Touborg Lassen, Jesper Hallas. (Denmark)
84 Does the Omega-3 Prescription Change the Post-MI Lifestyle Adjustment? Results from the EOLE Cohort [399]
C Dureau, C Droz, D Thomas, N Danchin, J Tricoire, J Bénichou, F Puillard, P Ducimetière, S Hercberg, H Maizi, E Guiard, M-A Bernard, P Blin, N Moore. (France)

Methods

85 Challenges of Measuring Medicine Compliance: The Australian Context [400]
Louise Bartlett, Maxine Robinson. (Australia)

86 Abstract Withdrawn by Author [401]

87 Research Working Groups on Drug Utilization across Europe [402]
L Ibáñez, H Petri, P Solari, E Ballarin, M Sabaté, J Hasfard, S Yebao, K L Goh, JR Laporte, J Fortune, R Schienger. (Spain)

88 Use of NSAIDs in France: Analysis from Reimbursement (CNAM-TS) Database [403]
Manoj Sharma, Ezgi Gulmez, Regis Lassalle, Nicholas Moore. (India)

89 How Can the Economic Impact of Drug-Related Morbidity Be Measured? A Systematic Literature Review [404]
Hanna Gyllensten, Anna K Jönsson, Clas Ibáñez, Anders Carlsten. (Sweden)

90 A Tool for Facilitating Comparability in Prospective Observational Studies [405]
Victor A Ki, Martin Lang, Gary Coward. (United Kingdom)

91 Drug Safety Data Mining with a Tree-Based Scan Statistical [406]
Martin Kulldorff, Inna Dashevsky, Taliser Avery, Arnold K Chan, Robert L Davis, David Graham, Susan E Andrede, Denise Boureau, Margaret J Gunter, Lisa Herrinton, Pam Pawloski, Marsha A Raebel, Douglas Roblin, Richard Platt, Jeffrey S Brown. (United States)

92 Development of Hospital Based Computerized Drug Safety Database [407]
Thiyagues Rajakannan, SuriulivelRajan Malayasamy, Rajesh Vilakkthala, Padma GM Rao, Laxminarayanaka K Bairy. (India)

93 Joinpoint Regression To Examine the Impact of Drug Safety Warnings on Drug Utilization Trends When Interrupted Time-Series Analysis Is Not Feasible [408]
CY Chen, Almut Winterstein. (United States)

94 Is There a Need for Better Communication of Benefit Risk of Medicines to Patients and Prescribers? [409]
Deborah Szafir, Philip Watson, Simon Ingate, Francois Lucas, Swapu Banerjee, Philippe Van der Auwera. (United Kingdom)

95 Developing an Indicator-Based Performance Tool for Pharmacovigilance Systems [410]
Jude I Nwokike, Mohan P Joshi, Andy Stergachis, Shabir Banoo. (United States)

Muscles and Bones

96 Characteristics of Exposure to Non-Steroid Anti-Inflammatory Drugs in European Databases [411]
Frank de Vries, Helle Kieler, Liset van Dijk, Tobias Svensson, Tjeerd van Sta. (United Kingdom)

97 Assessing the Risk of Osteonecrosis of the Jaws (ONJ) Due to Bisphosphonates Therapy: A Nested Case-Control Study [412]
Francesco Lapi, Achille Caputi, Giovanni Corrao, Nicola Montanaro, Miriam Stirkenboom, Dario Gregori, Flavia Carle, Angelo Menna, Annarita Vestri, Giampiero Mazzaglia. (Italy)

98 Analysis of Strontium Ranelate Utilisation from Prescription-Event Monitoring (PEM): Focus on ‘Off Label’ and Special Populations Use in Support of Risk Management [413]
Vicki Osborne, Deborah Layton, Soad AW Shakir. (United Kingdom)

99 Prescribing of Fall-Risk Increasing and Fracture-Preventing Drugs in Older Hip Fracture Patients: Observational Study [414]
Christina Sjöberg, Linda Bladh, Lars Klintberg, Dan Mellström, Claes Ohlsson, Susanna M Wallerstedt. (Sweden)

100 Analysis of Patient Safety Exposure for Enbrel Using Insurance Claims Database [415]
Fei Xue, Jason Yuan, Victor Gastanaga, Scott Stryker, Gail Hughes, Peter McCraskery, Sean Zhao. (United States)

101 Maternal Use of Codeine and Other Analgesics in Sweden [416]
Anders Sandström, Fredrik Granath, Tobias Svensson, Helle Kieler. (Sweden)

102 Administrative Complexities for a European Observational Study [417]
Ezgi Gulmez, Séverine Lignot, Corinne de Vries, Miriam Stirkenboom, Patrick Blin, Nicholas Moore. (France)

103 The Mondriaan Project: The Dutch Healthcare Landscape as a Population Laboratory [418]
Olaf H Klungel, Marc C Rietveld, Mark CH de Groot, Ronald P Stolk, Maarten J Postma, Hubert GM Leufkens, Toine CG Egberts, Anke M Holvex, Lex van de Langenj, Willem de Brujin, Arno W Hoex, Diedrik E Grobbe. (Netherlands)

104 Adherence to Medication Safety Practices Recommendations in Developing Countries: Data from Saudi Arabia [419]
Hisham Aljadhey, Abdulaziz Alhusan, Khaled Alburaikhan, Mansour Adam, Mohammed Alsultan, Michael Murray, David Bates. (Saudi Arabia)

105 Assessment of the Representativity of In-Patient Hospital Diagnoses in the German Pharmacoepidemiological Research Database [420]
Tania Schink, Edeltraut Garbe. (Germany)

106 The Relative Value of EMRs and Claims Data in Health Services Research [421]
S L West, W G Johnson. (United States)

Pharmacovigilance

107 Multiple Drug Exposure and Severity of Adverse Drug Reactions [422]
Francisco Batel-Marques, Nuno Cerveiro, Ana Filipa-Macedo, Carlos Fonse-Ribeiro, Margarida Caroana, Tice Macedo. (Portugal)

108 Utilization of Medical Information Databases in Drug Safety Evaluation Process in PMDA [423]
Ayumi Endo, Chieko Ishiguro, Eiko Tada, Maki Noguchi, Kazuhira Matsui. (Japan)

109 Lifestyle Drugs and Psychiatric Adverse Events in Randomised Clinical Trials [424]
110 The Views of Reporters to the UK Yellow Card Scheme on the Importance of Direct Patient Reporting [425]
Janet Krska, Julia Taylor, Anthony J Avery. (United Kingdom)

111 Evaluation of Anaphylaxis Patients Using Commercially Available Japanese Claim Data [426]
Ayumi Endo, Chieko Ishiguro, Maki Noguchi, Eiko Tada, Kazuhiro Matsumi. (Japan)

112 Preventability of Reported Adverse Drug Reactions to the Swedish Medical Products Agency [427]
Anna K Jönsson, Henrik Lövborg, Ingela Jacobsson, Thomas Bradley, Staffan Hägg. (Sweden)

113 Monitoring the FDA AERS Database To Identify Safety Issues: Does the Need Diminish as Product Time on the Market Increases? [428]
John Watson, Stephanie Reisinger, Jonathan Morris. (United States)

114 A Novel Approach To Review of Batch Related Adverse Event Reports [429]
Steven R Bailey, Peter Huber, Robert Maroko, Robert Azadian. (United States)

115 Abstract Withdrawn by Author [430]

116 An Evaluation of the Impact of REMS on Spontaneous Reporting for Marketed Products [431]
Reema Jain. (United States)

117 A Statistical Analysis Approach to Trend Analysis within a Company Safety Database [432]
Steven R Bailey, Peter Huber, Robert Azadian, Frank D’Angelo, Robert Maroko. (United States)

118 Documentation Grading To Assess Systematic Variability in the Quality of Individual Case Safety Reports [433]
Tomas Bergvall, Jessica Nilsson, Richard Hill, G Niklas Norén, Marie Lindquist. (Sweden)

119 Comparison of Quantitative Signal Detection Using Observational and Spontaneous Adverse Event Data [434]
Gregory E Powell, Patrick B Ryan, Edward N Pottishall. (United States)

120 Abstract Withdrawn by Author [435]

121 Critical Issues in Comparing the Use of Biologicals across Various European Countries: TNF Inhibitors as Case Study [436]
J M Hoebert, A K Mantel-Teeuwisse, L van Dijk, R O Laing, H GM Leufkens. (Netherlands)

122 Treatment Patterns in a Large U.S. Medical-Claims Based Cohort of Breast Cancer (BC) Patients Receiving HER2 Directed Therapy [437]
Lisa Wang, Laura Chu, Sam Agresta, Wei Dong. (United States)
123 Predictors of Tuberculosis Testing in Prescribers of Anti-Tumor Necrosis Factor (TNF) Agents in the European Union [438]
Meredith Y Smith, Brian Attig, Thomas Eagle. (United States)

Amy Steffey, Rhonda Lizewski, Andrea Sutherland, Jeff Roberts, Nancy Miller, Robert P Wise. (United States)

125 Effectiveness of Recruiting and Retention Strategies for Clinical Studies of Drugs, Medical Devices, and Biologics [440]
Ellen Pinnow, Mary E Ritchey, Andrea Tilley, Danica Marincac-Dabic. (United States)

126 Acute Hemolysis Consistent with Intravascular Hemolysis in Patients Receiving WinRho To Treat ITP [441]
Aileen Buckler, Nisha Jain, Basil Golding, Faith Barash, Robert Wise. (United States)

127 Trastuzumab (T) Treatment Outcomes According to Concomitant Chemotherapy Regimen: Overall Survival (OS) of HER2+ Metastatic Breast Cancer (MBC) Patients [442]
Sallie-Anne Pearson, Preepyporn Srasuebkul, Carole Harris, Robyn Ward, Timothy Dobbins. (Australia)

128 Updated Post-Licensure Safety Surveillance for Recombinant Human Coagulation Factor VIIa [443]
Alan C Ou, Nisha Jain, Charles W Maplethorpe, Robert P Wise. (United States)

129 The Use of Observed vs Expected Analyses in Real-Time Vaccine Safety Surveillance in the UK during the H1N1 Pandemic [444]
Suzie Seabrove, Philip Bryan, Lesley Wise. (United Kingdom)

130 Risk of Cardiovascular Events among 3,865 Elderly Diffuse Large B-Cell Lymphoma Patients Treated with Doxorubicin-Based Chemotherapy +/- Rituximab: A Population-Based Study [445]
Huei-Ting Tsai, Ruth Pfeiffer, C Ola Landgren. (United States)

131 Proactive Pharmacovigilance of the Human Papillomavirus (HPV) Vaccine [446]
Jenny Wong, Suzie Seabrove, Saira Mahmood, Philip Bryan. (United Kingdom)

132 Comparative Safety of Antipsychotic Medications in Elderly Medicaid-Eligible Nursing Home Patients [447]
Sebastian Schneeweiss, Krista Huybrechts, Tobias Gerhard, Mark Olso, Jeremy A Rassen, Raisa Levin, Judith Lucas, Stephen Schneeweiss. (United States)

133 Population-Based Study: Adherence Impact of Antihypertensive Agents on Vascular Events among Patients with Ischemic Stroke [449]
Sylvie Perreault, Robert Cote, Alice Drago. (Canada)

134 Prioritizing Comparative Effectiveness Research [450]
A M Walker, A R Patrick, M S Lauer, C T Laurencin, M G Marin, R Platt, P Stang, S Schneeweiss. (United States)

135 Tiotropium and Severe COPD Exacerbations – Comparisons with Long-Acting 2-Mimetics [451]
Ana Anforo, Katia MC Verhamme, Charlotte van Noord, Mendel Haag, Guy GO Brusselle, Miriam CJM Sturkenboom. (Netherlands)

136 Delayed Progression to Insulin in Patients with Type 2 Diabetes Mellitus Treated with Thiazolidinediones: A Population-Based Cohort Study [452]
Colin R Dormouth, Greg Carney, Jenny Sutherland. (Canada)

137 Current and Potential Uses of Clinical Registries for Comparative Effectiveness Research [453]
Richard Gliklich, Michelle B Leavy, Christina D Mack, Laura Whiteside, Dan Campion, Barbara Bartman. (United States)

138 Abstract Withdrawn by Author [454]

139 Examination of Effects of Regression to the Mean and Medication Adherence on HbA1C Levels among New Users of Oral Antidiabetic Drugs [455]
Carlos Grijalva, Robert Greevy, Mary Huizinga, Christianne Roumie, Harvey Murff, Shirley Liu, Adriana Hung, Marie Griffin. (United States)

140 The Standard Care Versus Celecoxib Outcome Trial (SCOT): A Large Streamlined Safety Study [457]
Isla S Mackenzie, Daniel Rutherford, Evelyn A Findlay, Chris H Hawkey, Ian Ford, Thomas M MacDonald. (United Kingdom)

141 Effectiveness of Zanamivir (RELENZA) Prophylaxis for Influenza [458]
Kandace Amend, Yani Vannappagari, Maria Wood-Armany, Rob Gately, John D Seeger. (United States)

142 Chronic Heart Failure Treated with Loop-Diuretics Is Associated with Increased Risk of Hospitalization with Pneumonia: A Population-Based Case-Control Study [459]
Sinna P Ulrichsen, Reimar W Thomsen. (Denmark)

143 Validation of Psoriasis and Its Prevalence, Treatment, and Severity in the Health Improvement Network (THIN) [460]
N M Seminara, K Abuabara, D B Shin, S E Kimmel, D Margolis, A Truel, J M Gelbard. (United States)

144 Linking Primary Care Data (UK GPRD) to Hospital Records (HES) [461]
Susan C Eaton, Efrosini Setakis, Tim Williams, Tjeerd Van Staa. (United Kingdom)

145 Abstract Withdrawn by Author [462]

146 Validation of a Claims-Based Diagnostic Code for Stevens-Johnson Syndrome (SJS) in a Commercially-Insured Population [463]
Gregory W Daniel, Debra F Eisenberg, Judith K Jones, Earl L Goehrung, Peter Winters, Jay Levin, Peter M Wahl, Rhonda L Bohn. (United States)

147 Lipid Levels among Antiretroviral (ARV) Naive HIV-Infected Individuals in Routine Care [465]
H M Crane, J AC Delaney, E Brown, J W Willig, M Mugavero, P W Hunt, B Rodriguez, W C Matthews, M Saag, M M Kitaahata. (United States)

148 The Incidence of Pancreatic and Thyroid Cancers in Patients with Type 2 Diabetes Mellitus Compared to Nondiabetics in a Managed Care Population [466]
Kwame Appenteng, Rebecca Noel, Dale Marmoducke, John Roberts, Stephen Motsko. (United States)

149 Exposure Classification for Case-Control Studies When Variables Are Both Confounders and Intermediaries [468]
Andrea Gruneir, Connie Marras, Hadas Fischer, Xuesong Wang, Suben Gill, Paula Rochon, Geoffrey Anderson. (Canada)
150 Primary Care Prescribing of Anti-Osteoporotic Type Medications Following Hospitalisation for Fractures [469]
Bernie McGowan, Minam C Casey, Joe Marry, Kathleen Bennett, (Ireland)

151 Adherence to Osteoporosis Drugs and Fracture Prevention: No Evidence of Healthy Adherer Bias in a Frail Cohort of Seniors [470]
Suzanne M Cadarette, Daniel H Solomon, Jeffrey N Katz, Amanda R Patrick, M Alan Brookhart. (Canada)

152 Utilisation of Non-Steroidal Anti-Inflammatory Drugs in Quebec, Canada: Is There a Change in the Patient Risk Profile after the Withdrawal of Rofecoxib? [471]
Elham Rahme, Jean-Philippe Lafortune, Jean-Pascal Roussy, Suzanne Morin. (Canada)

153 Clopidogrel Use and Mortality after Peptic Ulcer Bleeding: A Population-Based Cohort Study [472]
Morten Schmidt, Anders Riis, Christian F Christiansen, Timothy L Lash, Henrik Toft Sørensen. (Denmark)

154 Persistence and Compliance of Deferoxamine (DFX) Versus Deferasirox in Medicaid Patients with Sickle-Cell Disease (SCD) [473]
L B Jordan, F Vekeman, A Sengupta, M Carol, A Guo, M S Duh. (United States)

155 Why Do Hospital Patients Experience Adverse Drug Events? [474]
A Dequito, P Mol, J van Doornmaal, R Zeal, P van den Berst, F Hoaier-Ruskamp, J Kosterink. (Netherlands)

156 Effectiveness of Cardioprotective Drugs in Elderly Individuals with Type 2 Diabetes [475]
Caroline Sirois, Joceylne Moisan, Jean-Pierre Grégoire. (Canada)

157 Trends in Use of Gastroprotective Strategies with NSAID Treatment in the United Kingdom, Italy, and the Netherlands [476]
V Valkhoff, E van Soest, J Dieleman, R Schade, G Mazzaghia, M Molokhia, E Kuipers, M Sturkenboom. (Netherlands)

158 Timing of Prophylaxis Relative to Respiratory Syncytional Virus Seasons [477]
Christian Hampp, Almut G Winterstein. (United States)

159 For What Diagnoses Are Psychotropic Medications Being Prescribed? Implications for Understanding Off-Label Prescribing [478]
Tami L Mark. (United States)

160 Association between HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients Using Antipsychotics: A Replication Study [479]
Anne Risselada, Jelle Vehof, Richard Brugge- man, Bob Wiffert, Dan Cohen, Asmar Al Hadithy, Johan Arends, Hans Mulder. (Netherlands)

161 Association between the ADRA2A 1291 C/G Polymorphism and the Metabolic Syndrome [480]
Anne Risselada, Jelle Vehof, Richard Bruggerman, Bob Wiffert, Dan Cohen, Asmar F Al Hadithy, Johan Arends, Hans Mulder. (Netherlands)

162 Dosing Algorithm for Phenprocoumon: Using Patient Characteristics and Genotype Information To Calculate the Optimal Monitoring Dose [481]
Rianne MF van Schie, Saskia le Cessie, Frits R Rosendaal, Anke-Hilse Maitland-van der Zee. The EU-PACT Study Group. (Netherlands)

163 Validation of Warfarin Pharmacogenetic Algorithms in Real Clinical Practice [482]
Melina Marin-Leblanc, Sylvie Perreault, Marie-Pierre Dubé. (Canada)

164 Prognostic Value of Chronic Kidney Disease in Patients with Coronary Heart Disease: Role of GFR Estimating Equations [483]
Qu-Li Zhang, Hermann Brenner, Wolfgang Koening, Dietrich Rothenbacher. (Germany)

165 Candidate Genes Associated with Phenprocoumon Maintenance Dosage [484]
Martina Teichert, Mark Eijgelshelm, Loes E Visser, Bruno HC Stricker. (Netherlands)

Daniel Renouf, Linda Coate, Rihong Zhai, Matthew Kulke, Rebecca S Heist, Penelope Bradbury, Wei Xu, Zhengfei Chen, Kofi Asomaning, John Wain, Li Su, Geoffrey Liu, David C Christiani. (Canada)

167 Change in Drug Utilization Patterns in Statin Users with Increased Creatine Phosphokinase (CPK) Levels [486]
Frank de Vries, Efrosos Setakis, Tjeerd van Staa. (United Kingdom)

168 Prognostic Role of Genetic Polymorphisms in Head and Neck Cancer (HNC) Survival [487]
Abul K Azad, Geoffrey Liu, Wei Xu, Dangxiao Cheng, Elodie Samson, Maryam Mirshams, Zhuo Chen, Svetap Savas, John Waldron, Isabelle Bairati, Meyer Francois. (Canada)

169 The Effect of Daily Aspirin on Ovarian Cancer Serum Biomarkers in Healthy Postmenopausal Women [488]
Kimberly Lowe, Robin Forest, Jason Thorn, Lindsay Bergan, CY Wang, Anne McTiernan, Nicole Urban. (United States)

170 Genetic Polymorphisms as Prognostic/Predictive Biomarkers of Single-Agent Erlotinib Therapy in NCIC-CTG BR.21 Non-Small Cell Lung Cancer (NSCLC) Trial [489]
Geoffrey Liu, Dangxiao Cheng, Aurelie Le Maitre, Ni Liu, Zhuo Chen, Lesley Seymour, Keyue Ding, Frances Shepherd, Ming Tsoa. (Canada)
<table>
<thead>
<tr>
<th>Poster Walk Pregnancy SIG</th>
</tr>
</thead>
</table>
| **171** The Safety of Citalopram Exposure during Pregnancy – Maternal Characteristics, Birth Outcomes and Early Hospital Admissions for 1157 Children [490]  
Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia) |  
| **172** Exposure to Anti-Infective Drugs during Pregnancy and the Risk of Small-for-Gestational-Age Newborns [491]  
Fabiano Santos, Odile Sheehy, Sylvie Perreault, Ema Ferreira, Anick Bérard. (Canada) |  
| **173** SSRI Drug Use during Pregnancy and Perinatal Outcome [492]  
Heli Malm, Miia Artama, Mika Gissler, Annukka Ritvanen. (Finland) |  
| **174** Drug Use during Pregnancy in South-western France [493]  
Anne-Laure Voisin, Philippe Latry, Claude Peter, Karin Martin-Latry. (France, Metropolitan) |  
| **175** EFEMERIS, the French Prescription Database in Pregnant Women: A 4 Year-Follow Up [494]  
Christine Damase-Michel, Isabelle Lacroix, Caroline Hurault, Sylvie Kessler, Claudine Guittard, Sabine Vidal, Jean Louis Mantastruc. (France) |  
| **176** Oral Antibiotic Prescribing in Pregnancy in United Kingdom [495]  
I Petersen, R Gilbert, A Rudolfi, S Evans, I Nazareth. (United Kingdom) |  
| **177** Elevated Risk of Preeclampsia in Pregnant Women with Depression: Disease vs. Antidepressants [496]  
Kristin Palmsten, Soko Setoguchi, Andrea V Margulis, Amanda R Patrick, Sonia Hernández-Díaz. (United States) |  
| **178** SSRI and Risk of Congenital Cardiac Abnormalities [497]  
Irene Petersen, R Gilbert, S Evans, L Marston, I Nazareth. (United Kingdom) |  
| **179** Pregnancy Loss in Patients with Type 1 or Type 2 Diabetes during Pregnancy [498]  
Anita McGrogan, Julia Snowball, Corinne de Vries. (United Kingdom) |  
| **180** Birth Outcomes among Women Exposed to Oseltamivir (Tamiflu) During Pregnancy [499]  
Tobias Svensson, Fredrik Granath, Olof Stephansson, Helle Kieler. (Sweden) |  

---

**THE DEGGE GROUP, LTD.**  
*Drug Safety Research and Information*

**Risk Management:** Risk Evaluation & Mitigation Strategies, Program Evaluation, Registries;  
**Pharmacoepidemiology:** Natural History of Disease, Phase IV Studies, and Literature Reviews;  
**Pharmacovigilance:** Spontaneous Reports, AERS, and Safety & SOP Audits;  
Scientific Advisory Panel / Endpoint Adjudication Management, and CRO Oversight

*Visit our Booth to see how we can help you,*  
or visit: [www.deggegroup.com](http://www.deggegroup.com)

**22 years of Consulting and Research in Drug Safety and Pharmacoepidemiology**  
*Bridging Scientific Expertise with Real World Data*

*80+ database profiles in 17 countries: Asia* (China, India, Korea, Taiwan),  
*Europe* (Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom),  
*New Zealand, Australia, and North America* (Canada, USA)

[www.bridgetodata.org](http://www.bridgetodata.org)  
*Your connection to healthcare databases worldwide®*

1616 N. Fort Myer Drive, Suite 1430, Arlington, VA 22209, USA  
Tel: +1 703 894-0804  
Fax: +1 703 894-0803
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Exposure to Quinolones during Pregnancy: Lack of Association with an Increased Risk for Birth Defects and Other Adverse Pregnancy Outcomes [578]</td>
</tr>
<tr>
<td>2</td>
<td>Systemic Antibiotic Use among Children in Germany. An Analysis of Outpatient Dispensations Based on Claims Data of German Statutory Health Insurances [579]</td>
</tr>
<tr>
<td>3</td>
<td>Adverse Events Associated with Antibiotic Use [580]</td>
</tr>
<tr>
<td>5</td>
<td>Risk Factors for Non-Tuberculous Mycobacterial Infections Post-Transplantation [582]</td>
</tr>
<tr>
<td>6</td>
<td>Vancomycin Use in Children Hospitalized in the United States in 2008 [583]</td>
</tr>
<tr>
<td>7</td>
<td>The Rate of Adherence to an Antibiotic Treatment Guideline [584]</td>
</tr>
<tr>
<td>9</td>
<td>A Prospective Study of Asthma and Subsequent Use of Hypnotics [586]</td>
</tr>
<tr>
<td>10</td>
<td>Cataract Is a Frequent Adverse Effect of Widely Used Drugs [587]</td>
</tr>
<tr>
<td>11</td>
<td>Treatment and Characteristics of Thrombotic Thrombocytopenic Purpura in a Managed Care Population [588]</td>
</tr>
<tr>
<td>12</td>
<td>Regional Variations in Gaucher Disease Presentation: Data from the ICGG Gaucher Registry [589]</td>
</tr>
<tr>
<td>13</td>
<td>Behavioral Risk Factors among Hispanic and Non-Hispanic White Adults in the United States [590]</td>
</tr>
<tr>
<td>14</td>
<td>Characterization of Acetaminophen Overdose-Related Emergency Department Visits and Hospitalizations in the United States [591]</td>
</tr>
<tr>
<td>15</td>
<td>Abstract Withdrawn by Author [592]</td>
</tr>
<tr>
<td>16</td>
<td>Prevalence and Incidence of Diabetes Mellitus in Ireland from Prescription Database [593]</td>
</tr>
<tr>
<td>17</td>
<td>Incidence of Diabetic Retinopathy and Diabetic Macular Edema in Newly Diagnosed Type 1 and Type 2 Diabetic Patients [594]</td>
</tr>
<tr>
<td>19</td>
<td>Comorbidity Profile of Viral Hepatitis B in a Claims Database [596]</td>
</tr>
<tr>
<td>20</td>
<td>Comorbidity Profile of Viral Hepatitis C in a Claims Database [597]</td>
</tr>
<tr>
<td>21</td>
<td>Prevalence of Depression in Patients with Parkinson’s Disease [598]</td>
</tr>
<tr>
<td>22</td>
<td>Impact of Comorbidities on the Burden for Patients with Parkinson’s Disease [599]</td>
</tr>
<tr>
<td>23</td>
<td>Elevated Risk for Acute Pancreatitis in Type 2 Diabetes Patients Compared to Those without Diabetes [600]</td>
</tr>
<tr>
<td>25</td>
<td>Down’s Syndrome (DS) in Children, Adolescents and Adults in the UK General Practice Research Database (GPRD): Prevalence and Comorbidities [602]</td>
</tr>
<tr>
<td>26</td>
<td>High Levels of Dispensed Short-Acting beta Agonists in Asthma Patients: Results from the L777 Observational Study [603]</td>
</tr>
</tbody>
</table>

**Moved to Poster Session A**

<p>| 27 | Association between Bilirubin and Oxidative Stress Mediated Disease [604]                                                              | Laura Horsfall, Greta Rait, Kate Walters, Dallas M Swallow, Stephen P Pereira, Irene Petersen. (United Kingdom)                       |</p>
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Location or Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Incidence and Prevalence of Endometriosis: Administrative Health</td>
<td>Marie-Josée Martel, Nabil Ackad, Jean Lachaine. (Canada)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Databases Study from Quebec [605]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Rare Diseases, Orphan Drugs, and the Legislation in China [607]</td>
<td>Yanjun Zhang, Yan-De Zhang, Jing-Bo Wang, Jeff J Guo. (United States)</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>A Study of Comorbidities in Multiple Sclerosis [608]</td>
<td>Cheryl Enger, Michael Doherty, Yvonne Geissbühler, William Collins, John Seeger. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Setting: The VESUVE Cohort Study [609]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Incidence of Brain Metastases and Hemorrhage among Lung Cancer</td>
<td>Sonia S Maruti, E Dawn Flick, Leanne Houwelling, Myrthe PP van Herk-Sukel, Wei Dong. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patients: A Systematic Review [610]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Incidence of Thyroid Hormone Therapy in Patients Treated with</td>
<td>Katrin Schuessel, Sandra Feldt, Renate Quinzer, Sittah Czech, Alexandra Franzmann, Wolf-Dieter Ludwig, Martin Schulz. (Germany)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sorafenib or Sunitinib [611]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Resection of Colorectal Cancer (CRC) Metastasis after Bevacizumab</td>
<td>A Fournier-Reglat, M Rouyer, J Benichou, A Balestra, R Lassalle, A Grelaud, D Smith, A Ravaud, N Moore, and the ETNA Group. (France)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(BV) Treatment for 1st-Line Therapy: The ETNA Cohort Study [613]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Safety of Two Forms of L-Asparaginase in a Children Cohort with Acute</td>
<td>Heliani K Szajtjman, Martine Munzer, Marion T Lefaurie, Frédéric Burde, Thierry P Trenque. (France)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lymphoblastic Leukemia [614]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Comorbidity Among Hormone Resistant Prostate Cancer Patients in the</td>
<td>Claudia Cabrera, Ceri Hirst, Cortney Hayfinger, Linda Koo. (Sweden)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>US [615]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Bone Marrow Reticulin and Collagen Content in Patients with Adult</td>
<td>Mette Nærgaard, Marianne Schmidt Ettrup, Sean Zhao, Preben Johansen, Henrik Toft Sørensen. (Denmark)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic Idiopathic Thrombocytopenic Purpura (cITP): A Danish Nationwide</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study [616]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Analysis of Patient Exposure to Vectibix Based on the IntrinsicQ</td>
<td>Fei Xue, Daniel Bloney, Julie Moloney, Victor Gastanago, Jason Yuan, Scott Stryker, Gail Hughes, Deborah Arrindell, Sean Zhao. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Database [617]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Use and Costs of Oral Anticancer Drugs (ATC L01) in the Netherlands</td>
<td>Lonneke Timmers, Jan-Jacob Beckeringh, Myrthe PP van Herk-Sukel, Epie Boven, Jaqueline G Hugtenburg. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>from 2000 to 2008 [618]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>Colorectal Cancer Incidence on the GPRD [619]</td>
<td>Rachel Charlton, Julia Snowball, Corinne de Vries. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>Survival by Anatomic Site, Histologic Type and Tumor Stage in Stomach</td>
<td>Lisa Wang, Laura Chu, Mona Shing, Wei Dong. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer Patients from the U.S. SEER Cancer Registry [620]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Abstract Withdrawn by Author [621]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Statin-Associated Total Cholesterol Concentration Change and Outcome</td>
<td>Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>of Cardiovascular Event among Chronic Kidney Disease Patients: A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Population-Based Cohort Study [622]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Dual Antiplatelet Therapy Benefited the Patients Received Percutaneous</td>
<td>Chia-Hsien Chang, Yea-Huei Kao Yang. (Taiwan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coronary Intervention in Taiwan [623]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Abstract Withdrawn by Author [624]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Drug Utilization Review of Anthypertensive Therapy among Patients</td>
<td>Obinna Ikechukwu Ekweunife, Chukwuemeka Micheal Ubaka. (Nigeria)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>with Compelling Indications in Two Hospitals in South-Eastern Nigeria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Hypertension Management Is Suppressed by the Start of Diabetes</td>
<td>Jaco Voorham, Flora M Hooijer-Ruskamp, Bruce H Wolfenbuttel, Ronald P Stolk, Petra Denig. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drugs [626]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Incidence of Hospitalized Rhabdomyolysis with Statin and Fibrate Use</td>
<td>Kandace L Amend, Joan Landon, Steve J Niemcryk, Andrew McAfee. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in an Insured US Population [627]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Statins in the Primary and Secondary Prevention of Cardiovascular</td>
<td>Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disease among Patients with Rheumatoid Arthritis: A Population-Based</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cohort Study [628]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>The Impact of Statins on Total Cholesterol Concentration and Risk of</td>
<td>Kimberly Forde, Kevin Haynes, James Lewis, Vincent Lo Re. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiovascular Disease among Patients with COPD: A Population-Based</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cohort Study [629]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>Risk of Myocardial Infarction in UK Primary Care Patients with</td>
<td>Laura K Chu, Winfried Werther. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis C Virus Infection [630]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>Concomitant Use of Diuretics and Risk of Digoxin Intoxication among</td>
<td>Chul Woo Rhee, Dong Yoon Kang, So Young Park, Byung Joo Park. (Republic of Korea)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Elderly Heart Failure Patients [631]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>Myocardial Infarction and Cerebrovascular Accident in Patients with</td>
<td>Laura K Chu, Winfried Werther. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Retinal Vein Occlusion [632]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Pharmacoepidemiology Safety Study of Statin, Fibrate, or Statin-Fibrate</td>
<td>Cheryl Enger, Robert Gately, Steve J Niemcryk, Eileen E Ming, Andrew T McAfee. (United States)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Combination Therapy [633]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Title</td>
<td>Authors</td>
<td>Location</td>
</tr>
<tr>
<td>-----</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>56</td>
<td>Hyperprolactinemia and Risk of Valvular Heart Disease: A Danish Nationwide Population-Based Cohort Study [634]</td>
<td>Merete L Dybdal, Jens Otto L Jørgensen, Henrik T Sørensen. (Denmark)</td>
<td>(Denmark)</td>
</tr>
<tr>
<td>57</td>
<td>Prevalence of Atrial Fibrillation (AF) in the US [635]</td>
<td>Kathy L Schulman, Stephen S Johnston, Jay Lin, Daniel M Huse. (United States)</td>
<td>(United States)</td>
</tr>
<tr>
<td>58</td>
<td>Incidence Rates of Retinal Artery Thrombosis in Solid Tumor Cancer Patients in the THIN Database [636]</td>
<td>Victor Gastanaga, Chuck Wentworth, Gail Hughes, Fei Xue, Vanitha Ganesh, Mukesh Verma, Isaiah Dimery, Sean Zhao. (United States)</td>
<td>(United States)</td>
</tr>
<tr>
<td>59</td>
<td>Parameterizing Risk-Benefit Models from Primary Care Data: Recurrence and Exacerbation [637]</td>
<td>Andrew Maguire, Betina Blak, Kevin Haynes. (United Kingdom)</td>
<td>(United Kingdom)</td>
</tr>
<tr>
<td>60</td>
<td>Use of Propranolol in Liver Cirrhosis Patient To Prevent Esophageal Varix Bleeding [638]</td>
<td>Joongyub Lee, Nam-Kyong Choi, Ye-Jee Kim, Ju-young Shin, Byung-Joo Park. (Korea)</td>
<td>(Korea)</td>
</tr>
<tr>
<td>61</td>
<td>Cardiovascular Events in Statin Recipients: A 3-Year Record-Linkage Study on Prescription and Hospital Discharge Databases [639]</td>
<td>Elisabetta Poluzzi, Carlo Piccinni, Paolo Carta, Aurora Puccini, Monica Lanzoni, Domenico Motola, Alberto Vaccheri, Fabrizio De Ponti, Nicola Montanaro. (Italy)</td>
<td>(Italy)</td>
</tr>
<tr>
<td>63</td>
<td>Hospitalizations Associated with Acetaminophen Poisoning in the United States [641]</td>
<td>Syed Rizwanuddin Ahmad, Anne Elixhauser. (United States)</td>
<td>(United States)</td>
</tr>
<tr>
<td>64</td>
<td>Characteristics of Patients Receiving Varenicline Treatment for Smoking Cessation in UK Primary Care – A THIN Database Study [642]</td>
<td>Betina T Blak, Koo Wilson, Michael Metcalfe, Michelle Hard, Andrew Maguire, Victoria Gieno. (United Kingdom)</td>
<td>(United Kingdom)</td>
</tr>
<tr>
<td>65</td>
<td>Transitions from General Practitioner to Psychiatrist Care (Or Vice Versa) during a First Antidepressant Treatment Episode [643]</td>
<td>Helga Gardarsdottir, Toine CG Egberts, Eibert R Heerdink. (Netherlands)</td>
<td>(Netherlands)</td>
</tr>
<tr>
<td>66</td>
<td>Drug Utilization of Transdermal Fentanyl in Germany [644]</td>
<td>Ulrike Schmid, Kathrin Jobski, Edeltraut Garbe. (Germany)</td>
<td>(Germany)</td>
</tr>
</tbody>
</table>
67 Changes in Antidepressant Use Following Regulatory Agency Advisories [645]
Amanda R Patrick, Colin R Darmouth, Sebastian Schneeweiss. (United States)

68 Pattern of Triptan Use in a Sample of the Italian General Population [646]
Chiara Biagi, Elisabetta Polazzi, Domenico Matola, Giuseppe Roberto, Aurora Puccini, Alberto Vaccheri, Roberto D’Alessandra, Nicola Montanaro. (Italy)

69 Composite Data-Mining Index for Signal Detection Using Healthcare Claims Database: Methylphenidate Safety as an Example [647]
Jong-Mi Seong, Nam-Kyong Choi, Yunhee Choi, Ye-Jee Kim, Joongyub Lee, Jin Ho Lee, Byung-Joo Park. (Republic of Korea)

70 Factors Associated with the Schizophrenia Specific States: A Population-Based Study [648]
Alice Dragomir, Ridha Joober, Jean-Francois Angers, Jean-Eric Tarride, Sylvie Perreault. (Canada)

71 Risk of Cardiac Valve Regurgitation with Dopamine Agonist Use in Parkinson’s Disease and Hyperprolactinemia [650]
G Trifirò, M Mokhles, J Dieleman, E van Soest, G Mazzaglia, R Herings, C de Luise, D Ross, G Brusselle, A Colao, W Haverkamp, R Schade, G van Camp, R Zanetti, M Sturkenboom. (Netherlands)

72 Abstract Withdrawn by Author [651]

73 Antipsychotics and Diabetes: Does Effect Differ by Dose? [652]

74 Cause of Death in Patients with Multiple Sclerosis and Controls: The General Practice Research Database [653]
Arief Lalamohamed, Marloes T Bazelier, Tjeerd P van Staa, Frank de Vries. (Netherlands)

75 Association of Handgrip Strength with Dementia in a Korean Elderly Population [654]
Hee-Young Shin, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoon. (Korea)

76 Prevalence of Alcohol Related Disorders in German Patients Treated with High-Potency Opioids [655]
Ulrike Schmid, Sigrid Behr, Kathrin Jobski, Frank Andersohn, Edeltraut Garbe. (Germany)

77 The Prevalence of Depressive Symptoms and the Effects of Antidepressants in Patients with Psychotic Disorders in Routine Clinical Practice [656]
Katja Taxis, Irene Lako, Richard Bruggeman, Rikus Kneegtering, Dirk Wiersma, Cees Slooff. (Netherlands)

78 Association between LEP- and LEPRGene Polymorphisms and Dyslipidemia in Patients Using Atypical Antipsychotic Medication [657]
Jochem G Gregoor, Jan van der Weide, Harriet M Loovers, Harold J van Megen, Toine C Egberts, Eibert R Heerdink. (Netherlands)

79 Abstract Withdrawn by Author [658]

80 A Descriptive Analysis of Acetaminophen Poisoning in the U.S. Military Health Care System [659]
Lockwood Taylor, Suji Xie, Paula Doulaveris, Trinka Coster. (United States)

81 Can a Drug Have Better Results in the ‘Real World’? A Case Study of Cholinesterase Inhibitors in Australia [660]
Maxine Robinson, Kerry Atkins, Ann Leventor. (Australia)

82 Prevalence Rates of Comorbidities in Patients with Multiple Sclerosis [661]
Wendy J Carman, Andrew T McAfee, Julia LaGuerre, Shuhua Su, Darryl Chiu. (United States)

83 Observational Assessment of Safety in Seroquel XL (OASIS) Study: Design and Rationale of a Non-Randomised Observational Safety Study [662]
Deborah Layton, Vanessa Marshall, Sarah Clarke, Soad Shakir, Tony Hale. (United Kingdom)

84 Prescription Patterns among Children with Attention Deficit Hyperactivity Disorder (ADHD) in the United Kingdom (UK) [663]
Sudha R Raman, Stephen W Marshall, Til Stürmer. (United States)

85 Patient Reports of Antipsychotic-Induced Depressive Symptoms – A Cross Sectional Study in Patients with Psychotic Disorders [664]
Irene M Lako, Huib Burger, Rikus Kneegtering, Richard Bruggeman, Katja Taxis. (Netherlands)

86 Age Related Differences in Antidepressant Prescribing [665]
Thibaut Sanglier, Dominique Milea, Delphine Saragosse, Jean-Paul Auray, Marie Tournier, RJ Valuck. (France)

87 Prescribing Behaviour of Smoking Cessation Products in the UK – A THIN Database Study [666]
Betina T Blak, Michelle Hards, Hassy Dattani, Mary Thompson. (United Kingdom)

88 Antidiabetic Treatment in Japanese Psychotic Inpatients [667]
Ataru Inagaki, Toshiaki Itoh, Kazumi Tsukada. (Japan)

Grace P Chai, Hina Mehta, Laura Gournelle. (United States)

90 The Feasibility of Monitoring Paediatric Adverse Drug Reactions (ADRs) Via Specialist Clinics [669]
Mansour Tobaqiq, Derek Stewart, Peter J Helms, James McLay. (United Kingdom)

91 Frequency and Predictors of Anti-Epileptic Drug Regimen Change in an Incident Epilepsy Cohort [670]
Marianne C Cunnington, David J Webb, Ranjani Munjath. (United Kingdom)

92 Effect of Selective Serotonin Reuptake Inhibitors on Myocardial Infarction: A Systematic Review [671]
Ye-Jee Kim, Nam-Kyong Choi, Joongyub Lee, Chul Woo Rhee, So Young Park, Byung-Joo Park. (Republic of Korea)

93 Evaluation of Cardiovascular Diseases (CVDs) Risk for Patients with Fibromyalgia Syndrome in the United States [672]
P J Mease, M S Duh, F Vekeman, P Lefebvre, F Laliberté, M Boerstoel-Streefland, W Jiang, P J Zimetbaum. (United States)

94 Prevalence Rate Ratios of Comorbidities and Symptoms in Patients with MS Compared to the General Population, Stratified by Treatment Group [673]
Wendy J Carman, Andrew T McAfee, Julia LaGuerre, Shuhua Su, Darryl Chiu. (United States)

95 Changes in Prevalence of Comorbidities and Symptoms among MS Patients by Treatment Group [674]
Wendy J Carman, Andrew T McAfee, Julia LaGuerre, Shuhua Su, Darryl Chiu. (United States)

96 Selected Opioid Use in Medicare Part D and Medicaid Elderly [675]
Rita Ouellet-Hellstrom, Fatmatta Kuyateh, Farzana Ali, Emily Singer, Thomas E McCarthy, David J Graham. (United States)
97 Methylphenidate Treatment in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD): A Drug Utilization Study in a US Database [676]
Yvonne Geissbühler, Estel Plana, Catherine Tuvblad. (Switzerland)

98 Potentially Inappropriate Medication (PIM) Prescribing in Elderly Outpatients: An Evaluation of Claims Data Based on the Beers Criteria [677]
Martin Huber, Gerd A Kullak-Ublick, Majda Azermai, Robert Vanderstichele, Adriano Max M Reis, Silvia Helena De B Brauchli, Stephan Krahnenbühl, Susan S Jick, Christoph R Meier. (Switzerland)

99 Chronic Consumption of Antipsychotic Drugs in Belgian Nursing Home Residents [678]
Magda Azermai, Robert Vander Stichele, Monique Elseviers, Mirko Petrovic, Luc Van Bertel. (Belgium)

100 Factors Associated with Potential Drug Interactions in an Intensive Care Unit [679]
Adriano Max M Reis, Silvia Helena De B Cassiani. (Brazil)

101 When Inappropriate Medications Are Medically Justified in the Elderly [680]
ML Laroche, S Crépin, S Allouetteau, JP Charmes, L Merle. (France)

102 Generic Switching Does Not Influence Patients’ Concerns about Medicines: A Prescription Database and Questionnaire Study [681]
Morten Andersen, Karen Elberg, Annette Foged, Dorte G Hansen, Jesper Hållas, Jens Søndergaard. (Denmark)

103 The Pattern of Use of Anti-Depressant Drugs [682]
Sandra López-León, Joan Fortuny, Estel Plana, Elena Rivero. (Spain)

104 The Impact of Withdrawal Rofecoxib on NSAIDs Utilization [683]
J A nthohbari, C Boersma, S T Visser, M J Postma, L TW de Jong-van den Berg. (Indonesia)

105 Abstract Withdrawn by Author [684]

106 Chronic Benzodiazepine Consumption in Belgian Nursing Home Residents [685]
Magda Azermai, Robert Vanderstichele, Monique Elseviers, Mirko Petrovic, Luc Van Bertel. (Belgium)

107 Economic Burden of Drug Interactions Among Hospitalized Patients [686]
Cristiano S Mouro, Praçicio L Guimarães, Jéssica O Bonfini, Francisco A Acacio. (Brazil)

108 GP’s Opinions of the Hospital Discharge Notes – A Survey among GPs [687]
Anne K Eek, Hège S Blix, Kirsten K Viktå, Trond Møger, Aasmund Reikvam. (Norway)

Yan-Jun Zhang, Jing-Bo Wang, Jeff J Guo, Christina ML Kelton, Teresa Cavanaugh. (United States)

110 Does a National Medicines Policy Improve Medicines Access and Utilisation? [689]
Lisa G Pont, Anna Kemp, Elizabeth E Roughhead. (Australia)

111 Disease-Specific Healthcare Utilization Following Implementation of a Therapeutic Interchange Program [690]
Thomas K Hazlet, Srikanth Kadiyala, Stanley Gu, Elizabeth B James. (United States)

112 Is There an Underconsumption of Antidepressants in Nursing Home Residents? [691]
Magda Azermai, Robert Vander Stichele, Monique Elseviers, Mirko Petrovic, Luc Van Bertel. (Belgium)

113 Increase in Use of Hypnotic Drugs among Children and Adolescents Aged 0-17 Years – A Nationwide Prescription Database Study [692]
Ingemar Hertz, Kari Faru, Brittid Trond, Svetlana Skurtveit. (Norway)

114 Association between Prescribing Procedure and Rate of Revaluation [693]
Christina Sjöberg, Susanna M Wallerstedt. (Sweden)

115 Abstract Withdrawn by Author [694]

116 Representativity of Dispensations of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the German Pharmacoepidemiological Research Database [695]
Tania Schink, Edeltraut Garbe. (Germany)

117 The Effects of E-Prescribing on Generic Drug Utilization and Drugs Costs in the Ambulatory Care Setting: A Quasi Experimental Study [696]
J A nthohbari, E B Sulistiyanto. (Indonesia)

118 Metformin Associated Lactacidosis – An Increasing Problem? [697]
Steinar Madsen, Tanja Holstad. (Norway)

119 Reflux Disease, Gastrointestinal Ulcer or Weight Loss in Patients with COPD [698]
Cornelia Schneider, Susan S Jick, Ulrich Bothner, Christoph R Meier. (Switzerland)

120 Diabetes Mellitus and Risk of Gallstone Disease Followed by Cholecystectomy [699]
Patrick Imfeld, Michael Bodner, Yolanda B Brauchli, Stephan Krahnenbühl, Susan S Jick, Christoph R Meier. (Switzerland)

121 Analysis of Suspected Adverse Reactions to Antidiabetic Drugs Spain, 2008 [700]
Maria-Isabel Jimenez-Serrania, Ramona Mateos-Campos. (Spain)

122 Assessing Non-Serious Adverse Drug Events in Observational Studies among Type 2 Diabetes Mellitus Patients: A Review of Methods Used [701]
L Hakobyan, FM Haaijer-Ruskamp, D Dobre, D de Zeeuw, P Denig. (Netherlands)

123 Utilization Study of Antidiabetic Drugs in Spain, 2008 [702]
Maria-Isabel Jimenez-Serrania, Ramona Mateos-Campos. (Spain)

124 Drug-Related Upper Gastrointestinal Bleeding: Comparison of Signal Detection Results between Spontaneous Reporting and Longitudinal Health-Care Databases [703]
Vaishali Patadia, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Johan van der Lei, Miriam Sturkenboom, Gienluca Trifirò. (United States)

125 Strategies for Analyzing Multiple Gestations and Sequential Pregnancies in Pregnancy Registries [704]
Deborah Covington, Amanda Golembesky, Carl de Moor. (United States)

126 Impact Evaluation of Intermittent Preventive Treatment Implementation for Malaria during Pregnancy in Omdurman-Sudan IDP Camp 2006 [705]
Ahmed Eisa Saeed. (Sudan)
127 Medication Exposure in Pregnancy Risk Evaluation Program [706]
Susan Andrade, Pamela Scott, Craig Cheetham, William Cooper, Robert Davis, De-Kun Li, Sascha Dublin, Pamela Pawlaski, Marsha Raebel, Darren Toh. (United States)

128 Methodological Challenges in Evaluating Long-Term Safety of Quinacrine Non-Surgical Sterilization [707]
Jie Li, Judith K Jones, Arlene Tave, John C Pezzullo. (United States)

129 Global Prevalence of Pregnancy Outcomes [708]
Melissa Whipple Neibauer, Matthew Reynolds, Shannon L Michels, Jenna Collins. (United States)

130 A Claims-Based Algorithm To Estimate the Date of the Last Menstrual Period [709]
Andrea V Margulis, Soko Setoguchi, Sonia Hernández-Diaz. (United States)

131 A Preliminary Assessment of Health Care Databases Potentially Available for the Drug Safety Research in Pregnancy [710]
Wendy Camacho-Castillo, Irini-Alexia Terzakis, Susan S Roberts. (United States)

132 Prevalence and Predictors of Complementary and Alternative Medicine Products Use Among Pregnant Women in New Mexico [711]
Ludmila N Bakhireva, Preeyaporn Sarangarm, Sizhu Liu, Bannie N Young, Anne Davis, Jean T Cox, Sharon T Phelan, William F Reyburn. (United States)

133 A Database-Driven Adverse Drug Reactions Detection Method – A Pilot Test with Three Illustrative Cases [712]
Man Young Park, Dukyong Yoon, KIYoung Lee, Rae Woong Park. (Republic of Korea)

134 Trends of the Medical Consumption of Benzodiazepines during Years 2003 to 2007 in Taiwan and Preliminary Cross-National Comparisons [713]
Ching-Hsing Chang, Jin-Shion Lai, Chun-Sheng Chien, Jaw-Jou Kang. (Taiwan)

135 Innovative Signal Detection: Optimization of Empirica Signal – A Case Study [714]
Conny Berlin, Carles Blanch, David Lewis, Michel Petrin, Dionigi Maladorno, Severine Sarp, Christiane Michel, Philippe Close. (Spain)

136 Can Data Mining Spontaneously Reported Adverse Events Be Used To Assess Drug Abuse Potential [715]
Cynthia Arons, Eric Hung, Sian Ratcliffe, Doug Feltner, Manfred Hauben. (United Kingdom)

137 Identification and Characterization of Cancer Patients Using Health Insurance Database [716]
Fei Xue, Jason Yuan, Deborah Arrindell, Sean Zhao. (United States)

We discover the value within.

IMS helps you realize the potential of your products.
Combining commercial insight with scientific evidence is required to maximize market access. That's why IMS has built a global team of more than 300 experts in Pricing, Local Market Access, and Health Economics and Outcomes Research and the world's most extensive databases.

Our team combines rigorous scientific research — evidenced by more than 350 publications since 2008 — with commercially savvy consulting to help determine, demonstrate, communicate and realize product value.

We have unparalleled claims, medical, hospital and patient-centered pharmaceutical databases. Our HEOR experts use them to create an Evidence-Based Consulting™ powerhouse.

So the next time you’re thinking about product value, find out what we’re thinking.

Contact our consulting team at +1.703.286.2900 or visit www.imshealth.com/heor

INTELLIGENCE.
APPLIED.

© 2010 IMS Health Incorporated or its affiliates. All rights reserved.
138 Use of a Ranking Statistic To Assess Pharmacovigilance Data Mining Algorithms [717]
Stephanie Reisinger, Manfred Hauben, Alan Hochberg, Ronald K Pearson.
(United States)

139 Identifying Early Presentation of Multiple Sclerosis: A Challenge Using Insurance Claims Data [718]
Suellen M Curkendall, Cheng Wang, Barbara H Johnson, Ronald Prebleck, Amelio Torres, Volker Knappertz, Kathleen Gondek.
(United States)

140 Prospective, Active Surveillance for Medication Safety in Population-Based Health Networks: A Pilot Study [719]
Talise R Avery, Yury Vilk, Martin Kuilidoff, Lingling Li, T Craig Cheetham, Sascha Dublin, John Hsu, Robert L Davis, Liyan Liu, Richard Platt, Jeffrey S Brown.
(United States)

141 Potentially Inappropriate Drug Prescriptions in the Elderly in France: Results from the EGB Database [720]
ML Laroche, B Bongué, S Gutton, L Merle, A Calvez. (France)

142 Automated Method for Detecting Temporal Changes in Spontaneous AE Data [721]
Nancy Yuen, Nassrin Payvandi, Wendy Booth, June Almenoff, David Fram, William DuMouchel.
(United States)

143 Abstract Withdrawn by Author [722]

144 Drug Purchases during Pregnancy in Finland, 1996-2006: Focus on Antidepressants [723]
Miia Artama, Heli Malm, Mika Gissler, Annukka Rovaniemi, Drugs and Pregnancy Group. (Finland)

145 Establishing Drug-Era Persistence Window for Active Surveillance [724]
Abraham Hartzema, Patrick Ryan, Paul Stang, Judy Racossin, Marc Overhage.
(United States)

146 Completeness of Laboratory Data in a U.S. Claims Database [725]
Laura N Horne, Charles Doyle, Krista M Schildweiler, Eileen E Ming. (United States)

147 A Sorting and Classification Method for Interactive Visualization of Drug/Event Patterns across Many Patient Timelines [726]
Sigríður Gold, Suji Xie, Lockwood Taylor, Ana Szarfman, Trinka Coster. (United States)

148 Chiral Pharmacovigilence: Spontaneous Reporting Profiles of Racemates vs. Enantiomers [727]
Manfred Hauben, Meg Richards. (United States)

149 Development of Prediction Model for Severity of Adverse Drug Reactions in Hospitalized Patients [728]
Thiyagu Rajakannan, Laxminarayana K Bairy, Padma GM Rao, Yasudeva Guddattu, SurulivelRajan Mallayasamy. (India)

150 Guiding Antibiotic Selection: Differences in Methicillin-Resistant Staphylococcus aureus (MRSA) Rates among Hospitalized and Primary Care Patients [729]
Jessina C McGregor, David T Bearden, John M Townes, Dale F Kraemer, David H Smith.
(United States)

151 Users of Preserved Eye Drops: Who Switches to Preservative-Free Alternatives [730]
Jakob Petersen, Lesley Wise. (United Kingdom)

152 Methods for Assessing the Preventability of Adverse Drug Events – A Systematic Review [731]
Katja M Hakkarainen, Karolina Andersson, Max Petzold, Staffan Hägg. (Sweden)

153 An Algorithm for the Diagnosis of Suicide in the THIN Database [732]
Alejandro Arana, Felix M Arellano, Charles W Wentworth, Janet Price. (Spain)

154 Influence of Selection Criteria on Cohort Characteristics [733]
Suellen Curkendall, Tami Mark, Hufifang Liang, Helga Gardsdottir. (United States)

155 Linking UK Death Certificate Data to UK Primary Care Data (General Practice Research Database) [734]
Efrosini Setakis, Shivani Puri, Arlene Gallagher, Susan Eaton, Frank DeVries, Tim J Williams, Tjerd P VanStaa. (United Kingdom)

156 Lessons Learned from Mapping the THIN Database to the Observational Medical Outcome Partnership (OMOP) Common Data Model (CDM) [735]
X Zhou, S Murugesan, C Westworth, H Bhullar, A Bate. (United States)

157 Representiveness of Subset of the General Practice Research Database (GPRD) Linked to Other Data Sources [736]
Efrosini Setakis, Shivani Puri, Tim J Williams, Tjerd P VanStaa. (United Kingdom)

158 Vaccine Signal Detection: Comparative Results of Several Innovative Data Mining Approaches [737]
Steven R Bailey, Peter Huber, Robert Azadjanian. (United States)

159 Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on Blood Pressure in Patients with Hypertension [738]
Hisham Aljadhey, Michael Murray, D Craig Brater. (Saudi Arabia)

160 SALT-I (Study of Acute Liver Transplant): A Study of NSAID-Exposed Acute Liver Failure in European Transplant Centres [739]

161 A Review of RCTs on the Gastrointestinal and Cardiovascular Safety of NSAIDs in Children: The SOS Project [740]
M Balzarini, F Salvo, A Fourrier-Réglat, N Moore, M Haag, M Sturkenboom, F Zulian, C Giquinto, A Pariente. (France)

162 Multiple Myeloma and IV Bisphosphonate Are Risk Factors for Osteonecrosis of the Jaw [741]
Pat Tennis, Kenneth J Rothman, Rhonda Bahn, Hsiangku Tan, Mary Anthony, Athanasios Zavras, Brian Calingaert. (United States)

163 The SOS Project: Nonsteroidal Anti-Inflammatory Drugs and Upper Gastrointestinal Complications: Meta-Analysis of Epidemiological Studies [742]
Nuria Riera-Guardia, Jordi Castellsague, Brian Calingaert, Cristina Varas-Lorenzo, Annie Fourrier-Reglat, Federica Nicotra, Miriam STurkenboom, Susana Perez-Gutthann. (Spain)

164 The Utilization of Biological Agents in Rheumatoid Arthritis Patients in Southern Taiwan [743]
Hui-Chen Chang, Li-Chia Chen, Jin-Song Wu, Hui-Ling Tseng. (Taiwan)
165 Methodological Issues and Knowledge Gaps in RCTs Evaluating the Safety of NSAIDs in Adults: The SOS Project [744]
F Salvo, A Fourier-Reglat, M Balzarini, F Bazin, N Riera, M Haog, N Moore, M Sturkenboom, A Pariente. (France)

166 Prescribing Trends of Bisphosphonates in General Practice, UK 1995-2008 [745]
Jakob Petersen, Lesley Wise. (United Kingdom)

167 Chronic Use of Non-Steroidal Anti-Inflammatory Drugs and the Risk of Atrial Fibrillation [746]
Raffaele De Caterina, Ana Ruigómez, Luis Alberto Garcia Rodriguez. (Spain)

168 Chemoprevention of Breast Cancer with Bisphosphonates [747]
Sharon Hensley Afford, Christine Cole Johnson, Stephen B Gruber, Sofia D Merajver. (United States)

169 Pattern of Use of NSAIDs in Italian Population and Frequency of Risk Factors for Gastrointestinal Injury [748]
Chiara Sacripanti, Elisabetta Poluzzi, Alessandra Berti, Elisa Rossi, Marisa De Rosa, Nicola Montanaro. (Italy)

170 Factors Associated with Methodological Quality of RCTs Evaluating the Safety of NSAIDs: The SOS Project [749]
F Salvo, A Fourrier-Reglat, F Bazin, M Balzarini, M Haog, N Moore, M Sturkenboom, A Pariente. (France)

171 Trends in Reporting of Adverse Drug Reactions to HIV Medicines [750]
Paul L Barrow, Catherine A King, Jane A Woolley. (United Kingdom)

172 Characteristics of Paediatric Individual Case Safety Reports within the WHO-UMC Database [751]
S de Bie, KMC Verhamme, SMJM Straus, GW ’t Jong, BCH Stricker, MCJM Sturkenboom. (Netherlands)

173 Differences in Causality Assessments of Adverse Drug Reactions According to the Reports from Different Professional Groups [752]
Nuno Craveiro, Carlos Alves, Francisco Batel-Marques. (Portugal)

174 Topical NSAIDs Adverse Drug Reaction Reports in ThaiVigibase [753]
Pakawadee Sripliriiyam, Sareeya Wechwathan. (Thailand)

175 The Pattern of Drug-Induced Rhabdomyolysis Reports in Taiwan [754]
Wei-Ming Ke, Wen-Wen Chen, Chum-Shiouh Gau. (Taiwan)

176 Multicentre Study on Adverse Drug and Vaccine Reactions in Children during A-H1N1 Virus Pandemic [755]
Francesca Menniti-Ippolito, Roberto Da Cas, Concita Rafaniello, Giuseppe Traversa, Multicenter Study Group on Safety of Drugs and Vaccines in Children. (Italy)

177 Detection of Late Effects of Drugs Children Using a Spontaneous Report ADR Database [756]
S de Bie, KMC Verhamme, SMJM Straus, GW ’t Jong, BCH Stricker, MCJM Sturkenboom. (Netherlands)

178 Patient Reporting of ADRs in the UK: How Do Patient Reports Affect Potential Signals Generated by Healthcare Professionals? [757]
L Hazell, V Cornelius, S Shakir, A Avery. (United Kingdom)

179 The Yellow Card Scheme: Experience of Patient Reporting of Adverse Drug Reactions 5 Years Since Launch [758]
Sarah L Cumber, Sarah J Heffer, Shelley Gandhi, Anthony J Avery. (United Kingdom)

180 Spontaneous Reports as a Source for Risk Assessment of Long Term Drug Use in Children [759]
S de Bie, KMC Verhamme, SMJM Straus, GW ’t Jong, BCH Stricker, MCJM Sturkenboom. (Netherlands)

181 Importance of Medical Record Review for Database Studies: Example of Febrile Convulsion (FC) [760]
Patricia Saddier, Trung Tran, Bradley Ackerson, Lina Sy, Janis Yao, Craig Cheetham, Steven Jacobsen. (United States)

182 Reactogenicity of the Bivalent Human Papillomavirus Vaccine [761]
Jeanet M Kammeren, Nolene A Van der Maas, Hester E de Melker. (Netherlands)

183 Risk of Incident Autoimmune Diseases after Hepatitis B Vaccination – A Large Cohort Study in the GPRD [762]
Marco Egbring, Gerd A Kullak-Ublick, Stefan Russmann. (Switzerland)

184 Pilot Swine Flu Vaccination Active Surveillance Study: Interim Results [763]
D Layton, D Rutherford, T M MacDonald, S AW Shakir, I S Mackenzie. (United Kingdom)

185 Adverse Events Following Bivalent Human Papillomavirus Vaccination Reported to the Enhanced Passive Surveillance System of the Netherlands [764]
Nicoline van der Maas, Corrie Wessello, Tieke Phaff, Patricia Vermeer-de Bondt, Bregje Oostvogels. (Netherlands)

186 Characteristics of H1N1 Vaccine Exposures in a Large, Commercially Insured Population [765]
Peter M Wahl, Tao Gu, Gregory W Daniel, Marcus Wilson. (United States)

187 Pilot Swine Flu Vaccination Active Surveillance Study: Design and Rationale [766]
D Layton, D Rutherford, T M MacDonald, S AW Shakir, I S Mackenzie. (United Kingdom)

188 Adverse Events of Special Interest (AESI): H1N1 Vaccines Versus Seasonal Influenza Vaccines [767]
A Hidalgo-Simon, A Segec, J Slattery, A Szmgiel, I Skibicka, J Durand, A Addis, X Kurz. (United Kingdom)

189 Interim Results Should Be Taken with Caution: Example of a Vaccine Safety Study [768]
Patricia Saddier, John Hansen, Michael Emery, Bruce Fireman, Trung Tran, Roger Baxter. (United States)

190 Safety of a Monovalent 2009 Influenza A (H1N1) Vaccine in Adult and Pediatric Clinical Trial Populations [769]
A Graves Jones, S Bassal, P Thomas, M Greenberg, G Hartel, D Washington. (Australia)

191 Postmarketing Safety Review for Rotarix®: Data from the Vaccine Adverse Event Reporting System (VAERS), April 2008-October 2009 [770]
Wei Hua, Rosemary Tiernan, Amy Steffey, David Martin, Robert Wise. (United States)

192 Risk of Guillain-Barré Syndrome and Vaccination Against Seasonal Flu [771]
Lamiae Grimald-Bensouda, Michel Rosignal, Laurent Magy, Anne Cosson, Lucien Abenhaim. (France)
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors/Investigators</th>
<th>Affiliation/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>194</td>
<td>Participation of General Practices in a Swine Flu Vaccination Study [773]</td>
<td>Isla S Mackenzie, Moira Dryburgh, Daniel Rutherford, Thomas M MacDonald, Saad AW Shakir, Deborah Layton. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>196</td>
<td>Safety of the Influenza A (H1N1) 2009 Monovalent Vaccine Among the Indian Health Service User Population [775]</td>
<td>Yandong Qiang, Amy Groom, John Redd, Dana Haberling, Robert Holman, Cheyenne Jim, Hector Izurieta, Andrea Sutherland, Larry Layne, Theresa Cullen, James Cheek. (United States)</td>
<td></td>
</tr>
<tr>
<td>197</td>
<td>Reactogenicity of a Combined dT-IPV and a MMR Vaccine in Healthy 9-Year Old Children [776]</td>
<td>Jeanet M Kemmeren, Nicoline AT van der Maas, Hester E de Melker. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>198</td>
<td>Immediate Occurring Adverse Events Following Bivalent Human Papilloma-virus Vaccination in the Netherlands [777]</td>
<td>Nicoline van der Maas, Irmgard Zonnenberg-Hoff, Jeanet Kemmeren, Hester de Melker. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>199</td>
<td>Effectiveness of Pandemic Influenza Vaccination in a Dutch Population [778]</td>
<td>Leonoor Wijnans, Jeannie Dieleman, Bettie Voordouw, Miriam Sturkenboom. (Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>
Who is Kantar Health?

Kantar Health, a global consultancy and marketing insights organization, delivers value to our clients in the life sciences industry through four globally integrated practice areas: Treatment Value, Commercial Development, Brand and Stakeholder Management, and Marketing Insights.

Formed in 2009 by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare, and Ziment, Kantar Health is the next-generation decision-support partner, delivering evidence-based guidance to accelerate clients’ global and local success.

Come by our booth – #25 – to learn more about our gold-standard databases: Epi Database, Epi Database BRIC, CancerMPact, National Health and Wellness Survey, and custom epidemiology and safety capabilities.
### ABSTRACT INDEX

#### Final Program

**Abstract #** | **Poster #** | **Presentation Time** | **Room** | **Format**
--- | --- | --- | --- | ---
1 |  | 9:00 AM | Clarence | Oral
2 |  | 9:15 AM | Clarence | Oral
3 |  | 9:30 AM | Clarence | Oral
4 |  | 9:45 AM | Clarence | Oral
5 |  | 10:00 AM | Clarence | Oral
6 |  | 10:15 AM | Clarence | Oral
7 |  | 9:00 AM | Dukes | Oral
8 |  | 9:15 AM | Dukes | Oral
9 |  | 9:30 AM | Dukes | Oral
10 |  | 9:45 AM | Dukes | Oral
11 |  | 10:00 AM | Dukes | Oral
12 |  | 10:15 AM | Dukes | Oral
13 |  | 9:00 AM | Hall 4 | Oral
14 |  | 9:15 AM | Hall 4 | Oral
15 |  | 9:30 AM | Hall 4 | Oral
16 |  | 9:45 AM | Hall 4 | Oral
17 |  | 10:00 AM | Hall 4 | Oral
18 |  | 10:15 AM | Hall 4 | Oral
19 |  | 9:00 AM | Buckingham | Oral
20 |  | 9:15 AM | Buckingham | Oral
21 |  | 9:30 AM | Buckingham | Oral
22 |  | 9:45 AM | Buckingham | Oral
23 |  | 10:00 AM | Buckingham | Oral
24 |  | 10:15 AM | Buckingham | Oral
25 |  | 9:00 AM | Balmoral | Oral
26 |  | 9:15 AM | Balmoral | Oral
27 |  | 9:30 AM | Balmoral | Oral
28 |  | 9:45 AM | Balmoral | Oral
29 |  | 10:00 AM | Balmoral | Oral
30 |  | 10:15 AM | Balmoral | Oral
31 |  | 9:00 AM | Cambridge | Oral
32 |  | 9:15 AM | Cambridge | Oral
33 |  | 9:30 AM | Cambridge | Oral
34 |  | 9:45 AM | Cambridge | Oral
35 |  | 10:00 AM | Cambridge | Oral
36 |  | 10:15 AM | Cambridge | Oral

**Methodological Challenges in Cross-National Comparisons of Drug Utilization (Drug Utilisation / Health Services Research SIG Symposium)**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>37</td>
<td></td>
<td>3:30 PM</td>
<td>Balmoral</td>
<td>Sypos.</td>
</tr>
</tbody>
</table>

**Methodological Controversies from Comparative Effectiveness (CE) Studies Using Claims vs. Electronic Health Record (EHR) Data**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td></td>
<td>3:30 PM</td>
<td>Cambridge</td>
<td>Sypos.</td>
</tr>
</tbody>
</table>

**Ascertaining the Use of Biologics (Biologics SIG Symposium)**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td></td>
<td>3:30 PM</td>
<td>Dukes</td>
<td>Sypos.</td>
</tr>
</tbody>
</table>

**Guidance Regarding the Identification, Development, Validation and Translation of Coding Algorithms in Electronic Healthcare (EH) Databases (Database SIG Symposium)**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td></td>
<td>3:30 PM</td>
<td>Hall 4</td>
<td>Sypos.</td>
</tr>
</tbody>
</table>

**Identifying the Genetic Basis of Serious Adverse Events: Will High-Profile Genome-Wide Association (GWA) Studies Improve Drug Safety in the Next Decade? (A Joint MEBPharmacogenomics-SIG & ISAEC Symposium)**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>41</td>
<td></td>
<td>3:30 PM</td>
<td>Buckingham</td>
<td>Sypos.</td>
</tr>
</tbody>
</table>

**Friday, August 20...continued**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>42</td>
<td></td>
<td>3:30 PM</td>
<td>Clarence</td>
<td>Sypos.</td>
</tr>
</tbody>
</table>

**The Public Health Burden of Acetaminophen Poisonings: Risk Management Efforts To Mitigate it**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>575</td>
<td></td>
<td>3:30 PM</td>
<td>Ambassador</td>
<td>Sypos.</td>
</tr>
</tbody>
</table>

#### Poster Session A

**Anti-infectives**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>43</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Blood**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Cancer and Immunity**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>57</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>61</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>62</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>63</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>64</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>65</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Cardiovascular**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>67</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>68</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>70</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>71</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>72</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>73</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>74</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>75</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>76</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>77</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>79</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>80</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>83</td>
<td></td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>
### Abstract Index

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
</table>

#### Classical Pharmacoepidemiology

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>91  49</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>92  50</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>93  51</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>94  52</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95  53</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>96  54</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97  55</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>98  56</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>99  57</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 58</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>101 59</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### CNS

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>102 60</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>103 61</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>104 62</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>105 63</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>106 64</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>107 65</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>108 66</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>109 67</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>110 68</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>111 69</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>112 70</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>113 71</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>114 72</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>115 73</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>116 74</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Drug Utilization Research/Health Services Research

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>118 75</td>
<td>Abstract Withdrawn by Author</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>119 76</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>120 77</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>121 78</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>122 79</td>
<td>Abstract Withdrawn by Author</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>123 80</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>124 81</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>125 82</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>126 83</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>127 84</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>128 85</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>129 86</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>130 87</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>131 88</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>132 89</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>133 90</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>134 91</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>135 92</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>136 93</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Gut

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>137 94</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>138 95</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>139 96</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>140 97</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>141 98</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>142 99</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>143 100</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>144 101</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>145 102</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>146 103</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Lungs

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>147 104</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>148 105</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>149 106</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>150 107</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>151 108</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>152 109</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>153 110</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>154 111</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Medications in Pregnancy

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>155 112</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>156 113</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>157 114</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>158 115</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>159 116</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>160 117</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>161 118</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>162 119</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>163 120</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>164 121</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>165 122</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>166 123</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>167 124</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Methods

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>168 125</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>169 126</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>170 127</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>171 128</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>172 129</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>173 130</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>174 131</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>175 132</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>176 133</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>177 134</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>178 135</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>179 136</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>180 137</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>181 138</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>182 139</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>183 140</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>184 141</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>185 142</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>186 143</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>187 144</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>188 145</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract #</td>
<td>Poster #</td>
<td>Presentation Time</td>
<td>Room</td>
<td>Format</td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
<td>-------------------</td>
<td>---------</td>
<td>--------</td>
</tr>
<tr>
<td>189</td>
<td>145</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>191</td>
<td>146</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>192</td>
<td>147</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>193</td>
<td>148</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>194</td>
<td>149</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>195</td>
<td>150</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>196</td>
<td>151</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>197</td>
<td>152</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>198</td>
<td>153</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>199</td>
<td>154</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>200</td>
<td>155</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>201</td>
<td>156</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>202</td>
<td>157</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>203</td>
<td>158</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>204</td>
<td>159</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>205</td>
<td>160</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>206</td>
<td>161</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>207</td>
<td>162</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>208</td>
<td>163</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>209</td>
<td>164</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>165</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>211</td>
<td>166</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Muscles and Bones**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>212</td>
<td>168</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>213</td>
<td>169</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>214</td>
<td>170</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>215</td>
<td>171</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>216</td>
<td>172</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Pharmacovigilance**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>217</td>
<td>173</td>
<td>Abstract Withdrawn by Author</td>
<td></td>
<td></td>
</tr>
<tr>
<td>218</td>
<td>174</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>219</td>
<td>175</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>220</td>
<td>176</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>221</td>
<td>177</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>222</td>
<td>178</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>223</td>
<td>179</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>224</td>
<td>180</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>225</td>
<td>181</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>226</td>
<td>182</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>227</td>
<td>183</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>228</td>
<td>184</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Risk Management / Communication**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>229</td>
<td>185</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>230</td>
<td>186</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>231</td>
<td>187</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>232</td>
<td>188</td>
<td>Abstract Withdrawn by Author</td>
<td></td>
<td></td>
</tr>
<tr>
<td>233</td>
<td>189</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>234</td>
<td>190</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>235</td>
<td>191</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>236</td>
<td>192</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Miscellaneous**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>248</td>
<td>193</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>249</td>
<td>194</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>605</td>
<td>195</td>
<td>7:30 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>Abstract #</td>
<td>Poster #</td>
<td>Presentation Time</td>
<td>Room</td>
<td>Format</td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
<td>-------------------</td>
<td>------</td>
<td>--------</td>
</tr>
<tr>
<td>295</td>
<td></td>
<td>11:30 AM</td>
<td>Balmoral</td>
<td>Oral</td>
</tr>
<tr>
<td>296</td>
<td></td>
<td>11:45 AM</td>
<td>Balmoral</td>
<td>Oral</td>
</tr>
<tr>
<td>297</td>
<td></td>
<td>10:30 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>298</td>
<td></td>
<td>10:45 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>299</td>
<td></td>
<td>11:00 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>300</td>
<td></td>
<td>11:15 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>301</td>
<td></td>
<td>11:30 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>302</td>
<td></td>
<td>11:45 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>303</td>
<td></td>
<td>10:30 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>304</td>
<td></td>
<td>10:45 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>305</td>
<td></td>
<td>11:00 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>306</td>
<td></td>
<td>11:15 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>307</td>
<td></td>
<td>11:30 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>308</td>
<td></td>
<td>11:45 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
</tbody>
</table>

**Saturday, August 21…continued**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>327</td>
<td>12</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>328</td>
<td>13</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>349</td>
<td>14</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Cardiovascular**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>329</td>
<td>15</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>330</td>
<td>16</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>331</td>
<td>17</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>332</td>
<td>18</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>333</td>
<td>19</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>334</td>
<td>20</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>335</td>
<td>21</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>336</td>
<td>22</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>337</td>
<td>23</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CNS**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>338</td>
<td>24</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>339</td>
<td>25</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>340</td>
<td>26</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>341</td>
<td>27</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>342</td>
<td>28</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>343</td>
<td>29</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>344</td>
<td>30</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>345</td>
<td>31</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>346</td>
<td>32</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>347</td>
<td>33</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>348</td>
<td>34</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Classical Pharmacoepidemiology**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>350</td>
<td>34</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>351</td>
<td>35</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>352</td>
<td>36</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>353</td>
<td>37</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>354</td>
<td>38</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Drug Utilization Research/Health Services Research**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>362</td>
<td>47</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>363</td>
<td>48</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>364</td>
<td>49</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>365</td>
<td>50</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>366</td>
<td>51</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>367</td>
<td>52</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>368</td>
<td>53</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>369</td>
<td>54</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>370</td>
<td>55</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>371</td>
<td>56</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>372</td>
<td>57</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>373</td>
<td>58</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>374</td>
<td>59</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>375</td>
<td>60</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>376</td>
<td>61</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>377</td>
<td>62</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>378</td>
<td>63</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>379</td>
<td>64</td>
<td>8:00 AM - 6:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract #</td>
<td>Poster #</td>
<td>Presentation Time</td>
<td>Room</td>
<td>Format</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>------------------</td>
<td>------</td>
<td>----------------------</td>
</tr>
<tr>
<td>380</td>
<td>65</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>381</td>
<td>66</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>382</td>
<td>67</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>383</td>
<td>68</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Gut**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>384</td>
<td>69</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>385</td>
<td>70</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>386</td>
<td>71</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>387</td>
<td>72</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>388</td>
<td>73</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>389</td>
<td>74</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>390</td>
<td>75</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>391</td>
<td>76</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>392</td>
<td>77</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>393</td>
<td>78</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>394</td>
<td>79</td>
<td>Abstract Withdrawn by Author</td>
<td></td>
<td></td>
</tr>
<tr>
<td>395</td>
<td>80</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>396</td>
<td>81</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>397</td>
<td>82</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>398</td>
<td>83</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>399</td>
<td>84</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Methods**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>400</td>
<td>85</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>401</td>
<td>86</td>
<td>Abstract Withdrawn by Author</td>
<td></td>
<td></td>
</tr>
<tr>
<td>402</td>
<td>87</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>403</td>
<td>88</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>404</td>
<td>89</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>405</td>
<td>90</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>406</td>
<td>91</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>407</td>
<td>92</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>408</td>
<td>93</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>409</td>
<td>94</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>410</td>
<td>95</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Muscles and Bones**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>411</td>
<td>96</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>412</td>
<td>97</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>413</td>
<td>98</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>414</td>
<td>99</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>415</td>
<td>100</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>416</td>
<td>101</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Other**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>417</td>
<td>102</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>418</td>
<td>103</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>419</td>
<td>104</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>420</td>
<td>105</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>421</td>
<td>106</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Pharmacovigilance**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>422</td>
<td>107</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>423</td>
<td>108</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>424</td>
<td>109</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>425</td>
<td>110</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>426</td>
<td>111</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>427</td>
<td>112</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>428</td>
<td>113</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>429</td>
<td>114</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>430</td>
<td>115</td>
<td>Abstract Withdrawn by Author</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Saturday, August 21...continued

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>484</td>
<td>165</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>485</td>
<td>166</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>486</td>
<td>167</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>487</td>
<td>168</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>488</td>
<td>169</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>489</td>
<td>170</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
</tbody>
</table>

**Poster Walk - Pregnancy SIG**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>490</td>
<td>171</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>491</td>
<td>172</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>492</td>
<td>173</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>493</td>
<td>174</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>494</td>
<td>175</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>495</td>
<td>176</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>496</td>
<td>177</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>497</td>
<td>178</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>498</td>
<td>179</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
<tr>
<td>499</td>
<td>180</td>
<td>8:00 AM - 6:00 PM</td>
<td>Poster Walk</td>
<td></td>
</tr>
</tbody>
</table>

### Sunday, August 22

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>500</td>
<td></td>
<td>8:30 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
<tr>
<td>501</td>
<td></td>
<td>8:45 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
<tr>
<td>502</td>
<td></td>
<td>9:00 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
<tr>
<td>503</td>
<td></td>
<td>9:15 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
<tr>
<td>504</td>
<td></td>
<td>9:30 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
<tr>
<td>456</td>
<td></td>
<td>9:45 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
<tr>
<td>506</td>
<td></td>
<td>8:30 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>507</td>
<td></td>
<td>8:45 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>508</td>
<td></td>
<td>9:00 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>509</td>
<td></td>
<td>9:15 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>510</td>
<td></td>
<td>9:30 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>511</td>
<td></td>
<td>9:45 AM</td>
<td>Buckingham</td>
<td>Oral</td>
</tr>
<tr>
<td>512</td>
<td></td>
<td>8:30 AM</td>
<td>Balmoral</td>
<td>Oral</td>
</tr>
<tr>
<td>513</td>
<td></td>
<td>8:45 AM</td>
<td>Balmoral</td>
<td>Oral</td>
</tr>
<tr>
<td>467</td>
<td></td>
<td>9:00 AM</td>
<td>Balmoral</td>
<td>Oral</td>
</tr>
<tr>
<td>515</td>
<td></td>
<td>9:15 AM</td>
<td>Balmoral</td>
<td>Oral</td>
</tr>
<tr>
<td>516</td>
<td></td>
<td>9:30 AM</td>
<td>Balmoral</td>
<td>Oral</td>
</tr>
<tr>
<td>517</td>
<td></td>
<td>9:45 AM</td>
<td>Balmoral</td>
<td>Oral</td>
</tr>
<tr>
<td>518</td>
<td></td>
<td>8:30 AM</td>
<td>Cambridge</td>
<td>Oral</td>
</tr>
<tr>
<td>519</td>
<td></td>
<td>8:45 AM</td>
<td>Cambridge</td>
<td>Oral</td>
</tr>
<tr>
<td>520</td>
<td></td>
<td>9:00 AM</td>
<td>Cambridge</td>
<td>Oral</td>
</tr>
<tr>
<td>521</td>
<td></td>
<td>9:15 AM</td>
<td>Cambridge</td>
<td>Oral</td>
</tr>
<tr>
<td>522</td>
<td></td>
<td>9:30 AM</td>
<td>Cambridge</td>
<td>Oral</td>
</tr>
<tr>
<td>523</td>
<td></td>
<td>9:45 AM</td>
<td>Cambridge</td>
<td>Oral</td>
</tr>
<tr>
<td>524</td>
<td></td>
<td>8:30 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>525</td>
<td></td>
<td>8:45 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>526</td>
<td></td>
<td>9:00 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>527</td>
<td></td>
<td>9:15 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>528</td>
<td></td>
<td>9:30 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>529</td>
<td></td>
<td>9:45 AM</td>
<td>Clarence</td>
<td>Oral</td>
</tr>
<tr>
<td>530</td>
<td></td>
<td>8:30 AM</td>
<td>Dukes</td>
<td>Oral</td>
</tr>
<tr>
<td>531</td>
<td></td>
<td>8:45 AM</td>
<td>Dukes</td>
<td>Oral</td>
</tr>
<tr>
<td>532</td>
<td></td>
<td>9:00 AM</td>
<td>Dukes</td>
<td>Oral</td>
</tr>
<tr>
<td>533</td>
<td></td>
<td>9:15 AM</td>
<td>Dukes</td>
<td>Oral</td>
</tr>
<tr>
<td>534</td>
<td></td>
<td>9:30 AM</td>
<td>Dukes</td>
<td>Oral</td>
</tr>
<tr>
<td>535</td>
<td></td>
<td>10:30 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
<tr>
<td>536</td>
<td></td>
<td>10:45 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
<tr>
<td>537</td>
<td></td>
<td>11:00 AM</td>
<td>Oxford</td>
<td>Oral</td>
</tr>
</tbody>
</table>

---

**Lessons Learned from Collaboration among EU Biologics Registries in Rheumatology**

572 1:30 PM Hall 4 Sypos.

**The Industry-Academic Nexus: Experiences, Perspectives, and Suggestions for Enhancing Research Relationships**

573 1:30 PM Cambridge Sypos.

**The Alternate Life of Regulators**

574 1:30 PM Oxford Sypos.

**Rare Diseases: Unmet Medical Needs, Epidemiology and Regulatory Considerations**

576 1:30 PM Dukes Sypos.

**Linking Administrative and Electronic Medical Record Databases Using Hybrid Probabilistic and Deterministic Techniques**

577 1:30 PM Balmoral Sypos.

**Challenges and Opportunities in Shaping Medical Device Epidemiology**

781 1:30 PM Buckingham Sypos.

**Observed vs Expected Methodologies in Vaccine Safety Surveillance**

782 1:30 PM Clarence Sypos.
<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>578</td>
<td>1</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>579</td>
<td>2</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>580</td>
<td>3</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>581</td>
<td>4</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>582</td>
<td>5</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>583</td>
<td>6</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>584</td>
<td>7</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Anti-infectives**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>585</td>
<td>8</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>586</td>
<td>9</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>587</td>
<td>10</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>588</td>
<td>11</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>589</td>
<td>12</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>590</td>
<td>13</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>591</td>
<td>14</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>592</td>
<td>15 Abstract Withdrawn by Author</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>593</td>
<td>16</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>594</td>
<td>17</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>595</td>
<td>18</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>596</td>
<td>19</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>597</td>
<td>20</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>598</td>
<td>21</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>599</td>
<td>22</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>600</td>
<td>23</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>601</td>
<td>24</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>602</td>
<td>25</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>603</td>
<td>26</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>604</td>
<td>27</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>605</td>
<td>28</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>606</td>
<td>29</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>607</td>
<td>30</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>608</td>
<td>31</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Burden of Disease/Epidemiology of Illness**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>609</td>
<td>32</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>610</td>
<td>33</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>611</td>
<td>34</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>613</td>
<td>35</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>614</td>
<td>36</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>615</td>
<td>37</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>616</td>
<td>38</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>617</td>
<td>39</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>618</td>
<td>40</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>619</td>
<td>41</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>620</td>
<td>42</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Cancer and Immunity**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>621</td>
<td>43 Abstract Withdrawn by Author</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>622</td>
<td>44</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>623</td>
<td>45</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>624</td>
<td>46 Abstract Withdrawn by Author</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>625</td>
<td>47</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>626</td>
<td>48</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>627</td>
<td>49</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>628</td>
<td>50</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>629</td>
<td>51</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>630</td>
<td>52</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Cardiovascular**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>676</td>
<td>97</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>677</td>
<td>98</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>678</td>
<td>99</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>679</td>
<td>100</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>680</td>
<td>101</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>681</td>
<td>102</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>682</td>
<td>103</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>683</td>
<td>104</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>684</td>
<td>105 Abstract Withdrawn by Author</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>685</td>
<td>106</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>686</td>
<td>107</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>687</td>
<td>108</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>Abstract #</td>
<td>Poster #</td>
<td>Presentation Time</td>
<td>Room</td>
<td>Format</td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
<td>-------------------</td>
<td>------</td>
<td>--------</td>
</tr>
<tr>
<td>688</td>
<td>109</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>689</td>
<td>110</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>690</td>
<td>111</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>691</td>
<td>112</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>692</td>
<td>113</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>693</td>
<td>114</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>694</td>
<td>115</td>
<td><strong>Abstract Withdrawn by Author</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>695</td>
<td>116</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>696</td>
<td>117</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>697</td>
<td>118</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>698</td>
<td>119</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>699</td>
<td>120</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>700</td>
<td>121</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>701</td>
<td>122</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>702</td>
<td>123</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>703</td>
<td>124</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Gut**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>697</td>
<td>118</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>698</td>
<td>119</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>699</td>
<td>120</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>700</td>
<td>121</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>701</td>
<td>122</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>702</td>
<td>123</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>703</td>
<td>124</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Muscles and Bones**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>738</td>
<td>159</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>739</td>
<td>160</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>740</td>
<td>161</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>741</td>
<td>162</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>742</td>
<td>163</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>743</td>
<td>164</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>744</td>
<td>165</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>745</td>
<td>166</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>746</td>
<td>167</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>747</td>
<td>168</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>748</td>
<td>169</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>749</td>
<td>170</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Pharmacovigilance**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>750</td>
<td>171</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>751</td>
<td>172</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>752</td>
<td>173</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>753</td>
<td>174</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>754</td>
<td>175</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>755</td>
<td>176</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>756</td>
<td>177</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>757</td>
<td>178</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>758</td>
<td>179</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>759</td>
<td>180</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>

**Vaccines**

<table>
<thead>
<tr>
<th>Abstract #</th>
<th>Poster #</th>
<th>Presentation Time</th>
<th>Room</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>760</td>
<td>181</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>761</td>
<td>182</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>762</td>
<td>183</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>763</td>
<td>184</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>764</td>
<td>185</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>765</td>
<td>186</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>766</td>
<td>187</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>767</td>
<td>188</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>768</td>
<td>189</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>769</td>
<td>190</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>770</td>
<td>191</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>771</td>
<td>192</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>772</td>
<td>193</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>773</td>
<td>194</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>774</td>
<td>195</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>775</td>
<td>196</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>776</td>
<td>197</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>777</td>
<td>198</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>778</td>
<td>199</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
<tr>
<td>779</td>
<td>200</td>
<td>8:00 AM - 1:45 PM</td>
<td>Poster</td>
<td></td>
</tr>
</tbody>
</table>
### Advertisers Index

Bayer/Schering .................33  
Boehringer Ingelheim ........41  
Celgene ..........................21  
Degge .............................59  
Eli Lilly ..........................27  
GSK ...............................32  
Healthcare.......................8  
i3 Drug Safety ..................56  
IMS ...............................65  
Kantar ............................69  
LA-SER ...........................44  
Outcome .........................51  
ParagonRx .......................62  
Pfizer .............................13  
Phase Forward .................15  
Pope Woodhead ...............17  
Prosanos .........................22  
Registrat-Mapi ..................25  
Roche ............................24  
RTI-HS ...........................37  
UBC ...............................31  
Wiley-Blackwell ..............IBC
A selection of the top-downloaded papers from the 2009 Volume (18)


For more information on these top papers and other journal features, please visit www.interscience.wiley.com/journal/pds

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2010 Volume: 19 • Frequency: Monthly
26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management